Page last updated: 2024-10-16

adenine and B-Cell Chronic Lymphocytic Leukemia

adenine has been researched along with B-Cell Chronic Lymphocytic Leukemia in 852 studies

Research Excerpts

ExcerptRelevanceReference
"Moving from the recognition that infection control represents an unmet need, the Italian Society of Hematology (SIE) convened a panel of experts who had published and/or expressed an interest in infection complications in CLL."6.61Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. ( Barosi, G; Gaidano, G; Girmenia, C; Marchetti, M; Pane, F; Rambaldi, A; Tura, S; Zinzani, PL, 2019)
" He was diagnosed as having fibrinoid syndrome and started on topical prednisolone, brimonidine, timolol-dorzolamide, and orally administered acetazolamide."4.98Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature. ( Hwang, CK; Kim, BJ; Kolomeyer, AM, 2018)
" He was diagnosed with type I cryoglobulinemia and treated with rituximab, plasmapheresis, methylprednisolone, and ibrutinib was restarted."3.91Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL). ( Field, J; George, G; Singavi, A; Voshtina, E; Wright, N, 2019)
" Ibrutinib use, age, hypertension, and previous use of ACE inhibitors, angiotensin receptor blocker use, β blocker use, and aspirin use were independently associated with incident arrhythmias."3.91Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. ( Armanious, M; Chavez, JC; Emole, J; Fradley, MG; Gliksman, M; Lee, DH; McLeod, H; Pinilla-Ibarz, J; Rhea, I; Schabath, MB; Shah, B; Viganego, F; Walko, C; Welter-Frost, A, 2019)
" Ibrutinib dosing was held (≥7 days) for 79 patients and reduced for 31 patients because of AEs; these AEs resolved or improved in 85% (67 of 79) and 90% (28 of 31) of patients, respectively."3.11Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. ( Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dearden, C; Ghia, P; Grosicki, S; Hillmen, P; Hsu, E; Kipps, TJ; Li, JY; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Szoke, A; Tedeschi, A; Zhou, C, 2022)
" Common nonhematologic adverse events were fatigue (56%), nausea (53%), anorexia (41%), and diarrhea (41%) and were mostly low grade."3.11Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. ( Baker, S; Bhat, S; Byrd, JC; Canfield, D; Cempre, CB; Fu, Q; Hu, B; Huang, Y; Jaglowski, SM; Lapalombella, R; Lockman, H; Rogers, KA; Ruppert, AS; Shah, H; Stephens, DM; Vadeboncoeur, R; Walker, JS; Woyach, JA, 2022)
" Ruxolitinib dosing was based on a previous phase I trial."3.01Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial. ( Gallagher, J; Luo, Y; Shi, Y; Spaner, DE; Tsui, H; Wang, G, 2021)
"Adverse events were generally mild, but one case of fatal suspected unexpected serious adverse reaction occurred."3.01Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. ( Akber, M; Aleman, S; Bergman, P; Blennow, O; Blixt, L; Bogdanovic, G; Buggert, M; Chen, MS; Chen, P; Friman, G; Gomez, AC; Hansson, L; Hober, S; Lindgren, G; Ljunggren, HG; Ljungman, P; Loré, K; Mielke, S; Muschiol, S; Nilsson, P; Nordlander, A; Norlin, AC; Nowak, P; Österborg, A; Smith, CIE; Söderdahl, G; Thalme, A; Valentini, D; Vesterbacka, J; Wahren-Borgström, E; Wullimann, D, 2021)
" Most common adverse events (AEs) leading to prior KI discontinuation were rash (27%), arthralgia (18%), and atrial fibrillation (16%)."3.01Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. ( Barr, PM; Barrientos, JC; Brander, DM; Cheson, BD; Dorsey, C; Flinn, IW; Fonseca, GA; Ghosh, N; Hamadeh, IS; Kambhampati, S; Lamanna, N; Lansigan, F; LaRatta, N; Luning Prak, ET; Mato, AR; Miskin, HP; Pagel, JM; Paskalis, D; Pu, JJ; Rai, KR; Reeves, JA; Roeker, L; Schuster, SJ; Sitlinger, A; Skarbnik, AP; Sportelli, P; Svoboda, J; Tsao, P; Weiss, MS; Weissbrot, H, 2021)
"Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) comparisons."3.01Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. ( Abramson, JS; Bartlett, NL; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Kuzma, CS; Larson, RA; Little, RF; Litzow, M; Mandrekar, SJ; Nattam, S; Owen, C; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA, 2021)
" Common grade ≥3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time."2.94Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. ( Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dai, S; Dean, JP; Devereux, S; Ghia, P; Grosicki, S; Hillmen, P; Kipps, TJ; Lal, I; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Simpson, D; Tedeschi, A, 2020)
"Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK."2.94ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. ( Brown, JR; Cohen, A; Eichhorst, BF; Hilger, J; Hillmen, P; Huang, J; Lamanna, N; O'Brien, SM; Qiu, L; Salmi, T; Tam, CS; Wu, K, 2020)
"Lymphocytosis is a common and predictable pharmacodynamic effect of ibrutinib treatment, and in the absence of other signs of progression, does not represent disease progression."2.90Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. ( Barrientos, JC; Burger, JA; Byrd, JC; Hillmen, P; James, DF; Kipps, TJ; Ninomoto, J; Zhou, C, 2019)
" The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily."2.90Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. ( Arnason, JE; Bazemore, J; Boruchov, AM; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hellman, JM; Jacobsen, ED; Jacobson, CA; Kim, HT; Maegawa, R; Miskin, HP; Nicotra, A; Rueter, J; Savell, A; Sportelli, P; Stampleman, L, 2019)
" The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%])."2.90Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. ( Alvarez, J; Avivi, I; Balasubramanian, S; Ben-Yehuda, D; Bosch, F; Brody, J; Buglio, D; Caballero Barrigón, MD; Carpio, C; Ceulemans, R; Cordoba, R; de Jong, J; Demirkan, F; Ferhanoglu, B; Fourneau, N; Hellmann, A; Hodkinson, BP; Horowitz, NA; Jurczak, W; Kuss, B; Lopez-Guillermo, A; Ma, DDF; Marlton, P; Nagler, A; Ozcan, M; Schaffer, M; Streit, M; Wang, SS; Wrobel, T; Yağci, M; Younes, A, 2019)
" Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab."2.90Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. ( Avigdor, A; Bartlett, N; Cramer, P; de Jong, J; De Nicolao, G; Demirkan, F; Dilhuydy, MS; Fraser, G; Ganguly, S; Goy, A; Howes, A; Lavezzi, SM; Loscertales, J; Mahler, M; Neyens, M; Poggesi, I; Rule, S; Salman, M; Samoilova, O, 2019)
" In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3)."2.90Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. ( Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R, 2019)
"The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax)."2.90Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. ( Bishop, R; Bloor, A; Boucher, R; Brock, K; Devereux, S; Fegan, C; Forconi, F; Fox, CP; Gribben, JG; Hillmen, P; MacDonald, D; McCaig, A; Munir, T; Muñoz-Vicente, S; Patten, PEM; Pettitt, A; Rawstron, AC; Schuh, A; Yates, FJ, 2019)
"After minimal residual disease-guided treatment (day 1 of month 16), 84 (62%, 90% CI 55-69) of 135 patients (ITT population) achieved a complete response with bone marrow minimal residual disease of less than 0·01%."2.90Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. ( Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Lévy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L, 2019)
" Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia."2.87Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. ( Barr, PM; Byrd, JC; Cheson, BD; Choi, M; Chyla, B; Coutre, S; Davids, MS; Furman, RR; Humerickhouse, RA; Jones, JA; Lamanna, N; Mato, AR; Potluri, J; Salem, AH; Verdugo, M; Wierda, WG; Woyach, J; Zhou, L, 2018)
"We conducted an integrated safety analysis to characterize the frequency, severity, natural history, and outcomes of adverse events (AEs) with ibrutinib versus comparators."2.87Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. ( Barr, PM; Burger, JA; Chang, S; Coutre, S; Cramer, P; Dilhuydy, MS; Fraser, G; Graef, T; Hess, G; Hillmen, P; Howes, A; James, DF; Liu, E; Moreno, C; O'Brien, S; Patel, K; Styles, L; Tedeschi, A; Valentino, R; Vermeulen, J, 2018)
" To test this postulate, a pilot study (NCT02801578) was designed to systematically reduce ibrutinib dosing within the same patient with CLL over the course of three 28-day cycles."2.87A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. ( Bose, P; Chen, LS; Cruz, ND; Feng, S; Gandhi, V; Huang, X; Jain, N; Jiang, Y; Keating, MJ; Kroll, MH; Qiao, W; Thompson, PA; Wierda, WG; Wu, Q, 2018)
"Conclusion Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance."2.84BTK ( Abruzzo, L; Andritsos, LA; Awan, FT; Blachly, JS; Blum, KA; Byrd, JC; Chase, W; Coleman, J; Davis, M; Doong, TJ; Flynn, JM; Gordon, A; Grever, MR; Guinn, D; Heerema, NA; Jaglowski, S; Johnson, AJ; Jones, D; Jones, JA; Lehman, A; Lozanski, A; Lozanski, G; Lucas, M; Maddocks, K; Mantel, R; McWhorter, S; Ny, F; Rogers, K; Ruppert, AS; Smith, LL; Woyach, JA; Zhao, W, 2017)
"Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially."2.84Ibrutinib treatment improves T cell number and function in CLL patients. ( Andritsos, LA; Awan, F; Beckwith, K; Byrd, JC; Caligiuri, MA; Cheney, C; Do, P; Flynn, JM; Fraietta, JA; Gordon, A; Johnson, AJ; Jones, JA; June, CH; Lehman, AM; Long, M; Maddocks, KJ; Maus, MV; Mundy, BL; Muthusamy, N; Woyach, JA, 2017)
"Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted agents."2.84The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. ( Bozic, I; Burger, JA; Cibulskis, C; Farooqui, MZH; Fein, J; Getz, G; Herman, SEM; Hoellenriegel, J; Landau, DA; Leshchiner, I; Liu, D; Livitz, D; Neuberg, DS; Ravichandran, S; Rosebrock, D; Sivina, M; Sun, C; Underbayev, C; Wiestner, A; Wu, CJ; Zhang, W; Zviran, A, 2017)
" Safety was consistent with prior experience for each drug, with infusion reactions the most prevalent adverse event."2.84Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. ( Brooks, HD; Burke, JM; Fanning, S; Farber, CM; Greenwald, DR; Klein, L; Kolibaba, KS; Mahadevan, D; Miskin, HP; Schreeder, MT; Sharman, JP; Sportelli, P; Weiss, MS, 2017)
"The increasing indications and addition of newer agents to clinical practice and emergence of BTK inhibitor-related cardiac adverse events have complicated the management decisions for utilization of this class of therapy."2.82Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. ( Awan, FT; Christensen, BW; Zaha, VG, 2022)
" We also synopsize and discuss the cardiovascular adverse effects related to other more selective BTK inhibitors, which may guide the selection of appropriate BTK inhibitors."2.82Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. ( Dong, R; Lin, N; Tan, B; Yan, Y; Zeng, X, 2022)
"Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group)."2.82Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. ( Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D, 2016)
"A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells."2.82Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. ( Barrett, DM; Beckwith, KA; Byrd, JC; Cogdill, AP; Cook, DR; Do, P; Fraietta, JA; Gill, S; Hulitt, J; Johnson, AJ; June, CH; Kudchodkar, SB; Lacey, SF; Levine, BL; Long, M; Maddocks, K; Maus, MV; McGettigan, SE; Melenhorst, JJ; Muthusamy, N; Patel, PR; Porter, DL; Ruella, M; Woyach, JA; Xu, J; Zhang, C; Zheng, Z, 2016)
" We developed a population pharmacokinetic (PK) model for ibrutinib in patients."2.80Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. ( Advani, R; Byrd, JC; de Jong, J; De Nicolao, G; de Trixhe, XW; Loury, D; Marostica, E; McGreivy, J; O'Brien, S; Poggesi, I; Sukbuntherng, J; Vermeulen, A, 2015)
" When corrected for repeated dosing, pharmacokinetic parameters in healthy participants and patients were comparable."2.80The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. ( Byrd, JC; Chauhan, V; de Jong, J; Hellemans, P; James, D; Jiao, J; Loury, DJ; Mannaert, E; Murphy, J; O'Brien, S; Skee, D; Sukbuntherng, J, 2015)
"Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclophosphamide, and rituximab (FCR) for up to 6 cycles with daily ibrutinib (420 mg) until progressive disease or unacceptable toxicity."2.80The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. ( Barr, PM; Barrientos, JC; Brown, JR; Burger, JA; Clow, F; Flinn, IW; Friedberg, JW; Graef, T; James, DF; O'Brien, S; Rai, K; Tran, A, 2015)
" The most frequent adverse events (any grade) were diarrhea (70%), infusion-related reaction (45%), and peripheral sensory neuropathy (44%)."2.80Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. ( Andritsos, LA; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Hall, N; Heerema, NA; Jaglowski, SM; James, DF; Johnson, AJ; Jones, JA; Lozanski, G; Maddocks, KJ; Munneke, B; Nagar, V; Neuenburg, JK; Ruppert, AS; Smucker, K; Stefanos, M; West, JS; Woyach, JA, 2015)
"Ibrutinib is associated with bleeding-related adverse events of grade ≤ 2 in severity, and infrequently with grade ≥ 3 events."2.80Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. ( Cullinane, AM; Farooqui, MZ; Herman, SE; Holland, SM; Lipsky, AH; Lozier, JN; Marti, G; Martyr, S; Nghiem, K; Niemann, CU; Saba, N; Soto, S; Sun, C; Tian, X; Uzel, G; Valdez, J; Wiestner, A, 2015)
"The kinetics and degree of the treatment-induced lymphocytosis was highly variable; interestingly, in patients with a high baseline ALC the relative increase was mild and resolution rapid."2.79Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. ( Aue, G; Calvo, KR; Farooqui, M; Geisler, CH; Gyamfi, JA; Herman, SE; Jones, J; Lipsky, A; Liu, D; Maric, I; Marti, GE; Martyr, S; Mustafa, RZ; Niemann, CU; Pedersen, LB; Saba, N; Soto, S; Valdez, J; Wiestner, A, 2014)
"The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions."2.78Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. ( Blum, KA; Buggy, JJ; Burger, JA; Byrd, JC; Chang, BY; Clow, F; Coleman, M; Coutre, SE; Flinn, IW; Furman, RR; Grant, B; Hedrick, E; Heerema, NA; James, DF; Johnson, AJ; Jones, JA; O'Brien, S; Sharman, JP; Sukbuntherng, J; Wierda, WG; Zhao, W, 2013)
" The pharmacokinetic and pharmacodynamic data of acalabrutinib were also discussed."2.72Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. ( Li, J; Miao, Y; Xu, W, 2021)
"Whether this affects infection susceptibility and vaccination efficacy requires further investigation."2.72BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. ( Mulder, TA; Österborg, A; Palma, M, 2021)
"The occurrence of adverse events was revealed as a major cause of ibrutinib failure in the real-world."2.72Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. ( Baek, DW; Cho, HJ; Kim, J; Lee, JM; Moon, JH; Sohn, SK, 2021)
" In vitro exposure of leukemia cells to CAde showed that it was eight times less toxic as compared to CdA."2.71Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. ( Albertioni, F; Juliusson, G; Larsson, R; Liliemark, J; Lindemalm, S, 2004)
"A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of ibrutinib, a first-in-class oral inhibitor of Bruton tyrosine kinase (BTK), for the treatment of relapsed/refractory (R/R) and/or TP53 mutated patients with CLL."2.66Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. ( Matutes, E; Molica, S; Polliack, A; Tam, C, 2020)
"Advances in the molecular biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and development of molecularly targeted therapies have resulted in treatment innovations."2.66Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? ( Suzumiya, J; Takizawa, J, 2020)
"Chronic lymphocytic leukemia is one of the most common lymphoid malignancies."2.66Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia. ( Hanna, KS, 2020)
"Here, we report a case of an elderly chronic lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating ibrutinib therapy."2.66Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review. ( Albattah, A; Alhijji, I; Alokka, R; Elazzazy, S; Ghasoub, R; Nemir, A; Taha, R, 2020)
"Chronic lymphocytic leukemia has a highly variable disease course across patients, thought to be driven by the vast inter- and intrapatient molecular heterogeneity described in several large-scale DNA-sequencing studies conducted over the past decade."2.61Clonal dynamics in chronic lymphocytic leukemia. ( Gutierrez, C; Wu, CJ, 2019)
"The management of chronic lymphocytic leukemia (CLL) has undergone dramatic changes over the previous 2 decades with the introduction of multiple new therapies and new combinations."2.61Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. ( Woyach, JA, 2019)
" Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas."2.61Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. ( Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019)
"Moving from the recognition that infection control represents an unmet need, the Italian Society of Hematology (SIE) convened a panel of experts who had published and/or expressed an interest in infection complications in CLL."2.61Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. ( Barosi, G; Gaidano, G; Girmenia, C; Marchetti, M; Pane, F; Rambaldi, A; Tura, S; Zinzani, PL, 2019)
"Waldenström's macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients."2.61Updates in prognostication and treatment of Waldenström's macroglobulinemia. ( Advani, P; Ailawadhi, S; Paulus, A, 2019)
"Discussion One patient with chronic lymphocytic leukemia/small lymphocytic lymphoma and one patient with mantle cell lymphoma developed laboratory and clinical tumor lysis syndrome following initiation of ibrutinib therapy."2.58Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. ( Brown, JN; Hammond, JM; Titus-Rains, KS, 2018)
"Those who develop disease progression on ibrutinib are a particularly high-risk population with poor outcomes."2.58Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. ( Ayed, AO; Parikh, SA, 2018)
"While opportunistic infections and viral reactivations occur with both ibrutinib and idelalisib, these complications are less common and less severe with ibrutinib, especially when used as monotherapy without additional immunosuppressive agents."2.58Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. ( Pleyer, C; Sun, C; Wiestner, A, 2018)
"The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years."2.58Selecting Frontline Therapy for CLL in 2018. ( Jain, N, 2018)
"Although the therapy of chronic lymphocytic leukemia (CLL) has changed rapidly over the last 5 years, the key considerations in selecting a therapy for a previously treated patient with CLL continue to include the nature of the prior therapy and the duration of prior remission to that therapy, the prognostic features of the disease, and the health and comorbidities of the patient in question."2.58Relapsed CLL: sequencing, combinations, and novel agents. ( Brown, JR, 2018)
" With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase."2.55Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. ( Kaur, V; Swami, A, 2017)
" Here, we review the available literature on the pharmacokinetic and pharmacodynamic properties of these novel agents to guide the reader in the appropriate use of ibrutinib, idelalisib, and venetoclax."2.55Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax. ( Hill, BT; Waldron, M; Winter, A, 2017)
"The therapy for chronic lymphocytic leukemia (CLL) is undergoing a major transformation."2.55Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future. ( Molica, S, 2017)
"Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy."2.55Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. ( Bence-Bruckler, I; Coutre, S; Delage, R; Owen, CJ; Shustik, C; Toze, CL, 2017)
"Patients with chronic lymphocytic leukemia (CLL) having a chromosomal loss on the short arm of chromosome 17 including the TP53 gene locus (17p deletion) and/or having mutations in TP53 have a short overall survival and, until recently, limited treatment options."2.55Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. ( Edelmann, J; Gribben, JG, 2017)
"Treatment options for chronic lymphocytic leukemia, the most common leukemia in the United States, have expanded rapidly in recent years."2.55Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. ( Marini, BL; Perissinotti, AJ; Samanas, L, 2017)
" In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420 mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs."2.53A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. ( Kim, SS; Lee, CS; Rattu, MA, 2016)
"The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor signaling and other survival mechanisms holds great promise."2.52BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. ( de Rooij, MF; Eldering, E; Kater, AP; Spaargaren, M, 2015)
"Idelalisib has shown efficacy in the relapsed setting and is currently approved by the FDA for use in combination with rituximab."2.52Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. ( Burger, JA; Keating, MJ; O'Brien, SM; Sanford, DS; Wierda, WG, 2015)
" Ibrutinib is an orally bioavailable and highly specific BTK inhibitor that was recently approved for treatment of patients with recurrent CLL and mantle cell lymphoma (MCL)."2.52Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. ( Lynn Wang, Y; Smith, SM; Zhang, SQ; Zhang, SY, 2015)
" Discontinuation of ibrutinib is rarely due to adverse events related to the drug."2.52The clinical safety of ibrutinib in chronic lymphocytic leukemia. ( Molica, S, 2015)
" Orally bioavailable inhibitors of spleen tyrosine kinase, Bruton's tyrosine kinase, or PI3Kδ, induce high rates of durable responses."2.52The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. ( Wiestner, A, 2015)
"The leukemic B cells from patients with chronic lymphocytic leukemia (CLL) require interactions with non-malignant cells and matrix in the tissue microenvironment to survive and grow."1.91Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia. ( Chen, SS; Chiorazzi, N, 2023)
"The "accelerated" chronic lymphocytic leukemia (aCLL) is a relatively rare form of CLL progression."1.72Atypical "accelerated" chronic lymphocytic leukemia with abnormal lymphocyte chromatin clumping, bone involvement, and exceptional response to Imbruvica. ( Yavorkovsky, LL, 2022)
"A 79-year-old female was diagnosed with chronic lymphocytic leukemia seven years prior."1.72[Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia]. ( Kumekawa, H; Mizuchi, D; Tamura, K; Watanabe, D, 2022)
"Blood was obtained from patients with chronic lymphocytic leukemia, mantle-cell lymphoma and Waldenström macroglobulinemia with and without ibrutinib treatment and perfused through a microfluidic channel with(out) 60% stenosis over Horm type I collagen or human atherosclerotic plaque homogenate."1.72The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. ( Claushuis, TAM; Cosemans, JMEM; D'Italia, G; Karel, MFA; Kuijpers, MJE; Lemmens, TP; Tullemans, BME, 2022)
"Primary myelofibrosis (PMF) is not commonly associated with CLL, with only a few cases reported in the literature, with little information regarding the clinico-biological features and the optimal management for these associated conditions."1.72Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases. ( Angotzi, F; Bertorelle, R; Binotto, G; Cellini, A; Dei Tos, AP; Pizzi, M; Scarmozzino, F; Trentin, L; Visentin, A, 2022)
"Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated with the Bcl-2 inhibitor venetoclax."1.72Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients. ( Ferrarini, I; Gandini, F; Rigo, A; Zapparoli, E, 2022)
"Certain genetic features in chronic lymphocytic leukemia (CLL) are associated with inferior outcomes after chemoimmunotherapy (CIT)."1.72Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status. ( Deering, KL; Harshaw, Q; Huang, Q; Leslie, LA, 2022)
" Adverse events occurred in 74."1.72Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance. ( Akizuki, R; Fujino, A; Nomura, F; Omi, A; Tsujioka, S, 2022)
" Toxic effects of the combination of ibrutinib and cetuximab have been reported in a patient with metastatic CRC."1.72Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia. ( Araz, M; Artaç, M; Çeneli, Ö; Karaağaç, M; Karakurt Eryilmaz, M; Korkmaz, M, 2022)
"BACKGROUND Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm and the most common leukemia in adults in Western countries."1.72An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation. ( Colaci, E; Giusti, D; Leonardi, G; Luppi, M; Maccaferri, M; Marasca, R; Pioli, V; Potenza, L; Pozzi, S, 2022)
"Among patients with CLL disease progression on ibrutinib, OS was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy (median not reached) or venetoclax-based treatment (median 29."1.72Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. ( Ailawadhi, S; Braggio, E; Call, TG; Chanan-Khan, AA; Ding, W; Hampel, PJ; Hanson, CA; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Parrondo, R; Rabe, KG; Schwager, SM; Sher, T; Shi, M; Slager, SL; Van Dyke, DL; Wang, Y, 2022)
"Chylothorax is an infrequent pleural effusion often caused by traumatic or nontraumatic injury to the thoracic duct."1.72Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report. ( Cheng, L; Huang, M; Jiang, L; Wei, J; Xu, H; Zhou, M, 2022)
"Ibrutinib reduces mortality in chronic lymphocytic leukemia (CLL)."1.62Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. ( Abdel-Qadir, H; Austin, PC; Calvillo-Argüelles, O; Lee, DS; Leong, D; Nanthakumar, K; Pang, A; Prica, A; Sabrie, N; Thavendiranathan, P, 2021)
"In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes."1.62Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? ( Baratè, C; Biagi, A; Borella, C; Cairoli, R; Cassin, R; Cavalloni, C; Chiarenza, A; Ciolli, S; Coscia, M; Del Poeta, G; Deodato, M; Di Raimondo, F; Fresa, A; Frustaci, AM; Greco, A; Ielo, C; Lapietra, G; Laurenti, L; Mauro, FR; Montillo, M; Morelli, F; Murru, R; Pelle, AC; Postorino, M; Reda, G; Rossi, V; Sportoletti, P; Tedeschi, A; Varettoni, M; Vitale, C; Zamprogna, G, 2021)
" Patient characteristics, ibrutinib use and adverse drug reactions (ADRs) were collected from medical records."1.62Patterns of use and safety of ibrutinib in real-life practice. ( Allouchery, M; Delaunay, P; Delwail, V; Guidez, S; Lafay-Chebassier, C; Pérault-Pochat, MC; Salvo, F; Tomowiak, C, 2021)
"ALK-positive histiocytosis is a recently described entity with few reported cases in literature."1.62ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib. ( Brousset, P; Evrard, SM; Kanoun, S; Laurent, C; Meggetto, F; Péricart, S; Syrykh, C; Ysebaert, L, 2021)
" Ibrutinib is currently not available in a liquid oral dosage form."1.62Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia. ( Arnall, JR; DiSogra, KY; Janes, A; Moore, DC; Park, SI; Tran, T, 2021)
"Opportunistic infections in chronic lymphocytic leukemia (CLL) have been described in clinical trials, single-center studies, and case reports."1.62A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. ( Aspelund, T; Björkholm, M; Gíslason, GK; Gottfreðsson, M; Kristinsson, SY; Landgren, O; Rögnvaldsson, S; Steingrímsson, V; Turesson, I; Þorsteinsdóttir, S, 2021)
"Recirculation of chronic lymphocytic leukemia (CLL) cells between the peripheral blood and lymphoid niches plays a critical role in disease pathophysiology, and inhibiting this process is one of the major mechanisms of action for B-cell receptor (BCR) inhibitors such as ibrutinib and idelalisib."1.62FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. ( Amruz Cerna, K; Benes, V; Borsky, M; Brychtova, Y; Doubek, M; Kostalova, L; Kren, L; Krivanek, J; Kudlickova Peskova, M; Liskova, K; Loja, T; Mayer, J; Mladonicka Pavlasova, G; Mraz, M; Musilova Litzmanova, K; Ondrisova, L; Oppelt, J; Panovska, A; Pospisilova, S; Seda, V; Sharma, S; Tan, Z; Verner, J; Vojackova, E; Zhang, S; Zicha, D, 2021)
" He was placed on intravenous immunoglobulin (IVIg) in combination with ibrutinib."1.62[Intravenous immunoglobulin in combination with ibrutinib for the treatment of IgM-type M protein associated peripheral neuropathy complicated with chronic lymphocytic leukemia]. ( Kawano, K; Kawano, Y; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Uchida, H, 2021)
"A 77-year-old man with underlying chronic lymphocytic leukemia (CLL) on ibrutinib treatment was admitted because of a superinfected mosquito bite on the left ear and multiple partially necrotic skin lesions disseminated all over the entire body five days after returning from a trip to Colombia."1.62An Eschar-like souvenir from a journey to Colombia: Ecthyma gangrenosum as a differential diagnosis of tropical diseases in immunocompromised patients - a case report. ( Einwächter, H; Konukiewitz, B; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Verbeek, M; Wiedemann, GM, 2021)
" While 176 adverse events (AEs) were reported in 74 (54."1.62Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data ( Akay, OM; Akdeniz, A; Akpınar, S; Aydoğdu, İ; Baştürk, A; Batur, DS; Berber, İ; Çekdemir, D; Çetin, G; Davulcu, EA; Demircioğlu, S; Deveci, B; Dinçyürek, HD; Doğu, MH; Durusoy, SS; Ertop, Ş; Ferhanoğlu, B; Güneş, AK; Gürkan, E; İlhan, G; Kaya, E; Kızıklı, A; Kurtoğlu, E; Mehtap, Ö; Okan, V; Okay, M; Özcan, MA; Özcan, Ö; Özet, G; Özkocamaz, V; Pepedil Tanrıkulu, F; Sahip, B; Saydam, G; Sayınalp, N; Seyhanlı, A; Sönmez, M; Terzi, H; Tombak, A; Turgut, B; Uçar, MA; Ümit, EG; Ünal, A; Yavaşoğlu, İ; Yıldırım, R; Yılmaz, M, 2021)
"NOTCH1 mutations in chronic lymphocytic leukemia (CLL) lead to accumulation of NOTCH1 intracellular domain (NICD) and prolong signaling."1.56Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. ( Allan, JN; Arruga, F; Bracciamà, V; Coscia, M; D'Arena, G; Deaglio, S; Forconi, F; Furman, RR; Gaidano, G; Gizzi, K; Packham, G; Vaisitti, T; Vitale, N; Yeomans, A, 2020)
"The case is here reported of a chronic lymphocytic leukemia patient with ibrutinib-induced polyneuropathy."1.56Ibrutinib-induced polyneuropathy: A case report. ( Albayrak, M; Cömert, P; Öztürk, HB; Reis Aras, M; Şahin, O; Yıldız, A, 2020)
"Tumor lysis syndrome is an oncologic emergency resulting from rapid and massive tumor cell death that may lead to serious clinical complications including acute kidney injury and cardiac arrest."1.56Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib. ( Brener, H; Brener, ZZ; Losev, A, 2020)
"Ibrutinib use in chronic lymphocytic leukemia (CLL) has previously been associated with CNS-A."1.56Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report. ( Barnes, M; Buttar, B; Gondal, K; Kaell, A; Kumar, V; Le, TH; Siddique, H, 2020)
" The aim of this work is to develop a population pharmacokinetic model for ibrutinib and its dihydrodiol metabolite to quantify pharmacokinetic inter- and intra-individual variability, to evaluate the impact of several covariates on ibrutinib pharmacokinetic parameters, and to examine the relationship between exposure and clinical outcome."1.56Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. ( Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020)
" The purpose of this study was to describe treatment patterns, adverse events (AEs), and economic burden among treated patients with CLL."1.56Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study. ( Burudpakdee, C; Kabadi, SM; Near, A; Wada, K, 2020)
"Lysosomes in chronic lymphocytic leukemia (CLL) cells have previously been identified as a promising target for therapeutic intervention in combination with targeted therapies."1.56Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells. ( Chanas-Larue, A; Gibson, SB; Henson, ES; Johnston, JB; Villalpando-Rodriguez, GE, 2020)
"Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor."1.56Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis. ( Boutoille, D; Brochard, J; Guimard, T; Le Pape, P; Leterrier, M; Mahe, B; Mahe, J; Morio, F; Morrier, M; Raffi, F, 2020)
"Novel agents have made the management of chronic lymphocytic leukemia (CLL) more promising and personalized."1.56Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia. ( Fan, L; Kong, YL; Li, JY; Liang, JH; Pan, BH; Wang, L; Wu, JZ; Xia, Y; Xu, W; Zhu, HY, 2020)
"Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common adult leukemia, accounting for ≈ 37% of all leukemias in the United States."1.56Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis. ( Borra, S; Huang, Q; Janjan, N; Li, J; Shrestha, S; Sundaram, M; Wang, L, 2020)
"Approximately 25% of patients with chronic lymphocytic leukemia (CLL) experience a flare of disease following ibrutinib discontinuation."1.56Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. ( Braggio, E; Call, TG; Ding, W; Fonder, AL; Hampel, PJ; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Rabe, KG; Schwager, SM; Slager, SL; Van Dyke, DL; Wang, Y; Witzig, TE, 2020)
"The clinical course of chronic lymphocytic leukemia (CLL) is often complicated by autoimmune cytopenia (AIC)."1.51[Improvement of autoimmune cytopenia with ibrutinib in a chronic lymphocytic leukemia patient complicated by monoclonal immunoglobulin deposition disease]. ( Hara, S; Ishikawa, T; Nakamura, M; Yamashita, D; Yoshioka, S, 2019)
" Submaximal ibrutinib dosing will have to be further systematically evaluated."1.51Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre. ( Banerji, V; Brown, K; Bucher, O; Dawe, DE; Dhaliwal, DH; Geirnaert, M; Hibbert, I; Johnston, JB; Uminski, K, 2019)
"After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials with two real-world databases."1.51Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. ( Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R, 2019)
"The median times to disease progression and RT were 33."1.51Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. ( Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W, 2019)
"These CLL-like cells show genome instability and dysregulation of multiple CLL-associated cellular processes, including deregulated B cell receptor signaling, which we also identified in human CLL cases."1.51A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. ( Brooks, AN; Campagna, DR; Carrasco, RD; Cartun, ZJ; Cibulskis, CL; DeCaprio, JA; Ebert, BL; Fan, J; Fleming, MD; Gambe, RG; Getz, G; Ghia, EM; Herman, SEM; Kipps, TJ; Leshchiner, I; Martinez, AZ; Neuberg, D; Obeng, EA; Rassenti, LZ; Reed, R; Regis, FFD; Sun, J; Taylor-Weiner, A; Ten Hacken, E; Wan, Y; Wang, L; Wiestner, A; Wu, CJ; Yin, S, 2019)
" Emerging real-world-data shows similar response and survival, but higher discontinuation rates due to adverse events (AEs)."1.51Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. ( Angelopoulou, M; Bitsani, C; Dimou, M; Iliakis, T; Kalyva, S; Koudouna, A; Kyrtsonis, MC; Panayiotidis, P; Papaioannou, P; Pardalis, V; Tsaftaridis, P; Vassilakopoulos, TP, 2019)
"In primary chronic lymphocytic leukemia (CLL) lymphocytes, pharmacological interference with mitochondrial ATP synthesis or glucose metabolism affects BTK activity."1.51Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. ( Aloyz, R; Doyon, D; Paliouras, M; Sharif-Askari, B, 2019)
"Neutrophilic panniculitis is a relatively rare condition, characterized by predominantly neutrophilic inflammation in the subcutaneous fat."1.48Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis. ( Bayers, S; Stewart, J; Vandergriff, T, 2018)
" To elucidate on-target and pharmacodynamic effects of acalabrutinib, we evaluated several laboratory endpoints, including proteomic changes, chemokine modulation and impact on cell migration."1.48Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. ( Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG, 2018)
"Ibrutinib represents a revolution in chronic lymphocytic leukemia treatment scenario providing results never seen before and offering an effective therapy even in high-risk patients with really poor outcome after chemoimmunotherapy."1.48Ibrutinib and its use in the treatment of chronic lymphocytic leukemia. ( Cairoli, R; Deodato, M; Frustaci, AM; Mazzucchelli, M; Montillo, M; Tedeschi, A, 2018)
"Results from several recent studies in chronic lymphocytic leukemia (CLL) have demonstrated an association between ibrutinib exposure and the development of atrial fibrillation, estimated incidence of 11% with long-term follow up."1.48Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. ( Ali, N; Carver, J; Clasen, S; Gashonia, L; Hughes, M; Mato, AR; Nabhan, C; Pickens, P; Rhodes, J; Schuster, S; Svoboda, J, 2018)
"We conducted a retrospective analysis of chronic lymphocytic leukemia patients treated with ibrutinib either commercially or on clinical trials."1.48Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. ( Bachow, SH; Barr, P; Brander, DM; Cheson, BD; Claxton, D; Dorsey, C; Goy, A; Hill, B; Howlett, C; Isaac, K; Kennard, KH; Kiselev, P; Lamanna, N; Landsburg, D; Mato, AR; Nabhan, C; Nasta, SD; Pu, J; Schuster, SJ; Skarbnik, A; Svoboda, J; Thompson, MC; Timlin, C; Ujjani, CS; Winter, A; Zent, C, 2018)
"Invasive bacterial infections developed in 23 (53."1.48Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. ( Cohen, N; Hohl, TM; Palomba, ML; Redelman-Sidi, G; Seo, SK; Taur, Y; Varughese, T, 2018)
"Most patients with chronic lymphocytic leukemia (CLL) present with multiple comorbidities."1.48Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. ( Alqahtani, H; Amrock, SM; Choi, M; Churnetski, M; Cohen, JB; Danilov, AV; Gordon, MJ; Hoff, S; James, S; Kittai, A; Manda, S; Persky, D; Rivera, X; Spurgeon, SE, 2018)
"There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymphocytic leukemia (CLL) after the short-term and long-term administration of ibrutinib."1.48Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia. ( Gabcova, G; Gajdos, P; Kriegova, E; Manukyan, G; Mikulkova, Z; Papajik, T; Smotkova Kraiczova, V; Turcsanyi, P; Urbanova, R; Zehnalova, S, 2018)
" These findings suggest deterioration of the humoral immune system is associated with progressive CLL and altering the dosing of IgRT to achieve higher than conventional IgG target levels may have therapeutic activity."1.48Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia. ( Huang, J; Lazarus, A; Norris, P; Shi, Y; Spaner, DE; Venema, R; Wang, G, 2018)
"Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges."1.48Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. ( Achille, A; Deng, S; Fonseca, R; Jones, SS; Maharaj, K; Pabon-Saldana, M; Pinilla-Ibarz, J; Powers, JJ; Quayle, SN; Sahakian, E; Sotomayor, EM; Villagra, A, 2018)
"The established treatment algorithms for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are currently challenged by novel classes of drugs, with ibrutinib being one of the most effective."1.46Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related? ( Kalpadakis, C; Koulieris, E; Moschogiannis, M; Pangalis, GA; Rontogianni, D; Sachanas, S; Tsirkinidis, P; Yiakoumis, X, 2017)
"Rare cases of transformation to Hodgkin lymphoma (HL) have been reported in the literature with an estimated prevalence of 0."1.46Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. ( Catherwood, M; Glavey, S; Leader, M; Marafioti, T; McCartney, Y; McCloy, M; Murphy, P; Quinn, J; Sargent, J; Thornton, P, 2017)
"Fluorizoline induced apoptosis in chronic lymphocytic leukemia cells at concentrations in the low micromolar range."1.46The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax. ( Albericio, F; Cosialls, AM; de la Banda, E; Gil, J; González-Barca, EM; González-Gironès, DM; Iglesias-Serret, D; Lavilla, R; Núñez-Vázquez, S; Pomares, H; Pons, G; Preciado, S; Saura-Esteller, J, 2017)
"Richter syndrome (RS) is a rare event in chronic lymphocytic leukemia (CLL) that is influenced by biological factors and prior CLL treatments."1.46Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome. ( Albi, E; Ascani, S; Aureli, P; Baldoni, S; Del Papa, B; Di Ianni, M; Dorillo, E; Falzetti, F; Sportoletti, P, 2017)
"Here we show that treatment of chronic lymphocytic leukemia cells (CLL) with IT-901 effectively interrupts NF-κB transcriptional activity."1.46Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor. ( Allan, JN; Arruga, F; Deaglio, S; Furman, RR; Gaudino, F; Liou, HC; Moscvin, M; Ouk, S; Serra, S; Vaisitti, T; Vitale, N; Zakrzewski, JL, 2017)
"The lymph node (LN) is the site of chronic lymphocytic leukemia (CLL) cell activation and proliferation."1.46Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. ( Abdelghaffar, HA; Abousamra, NK; Anastas, V; Barber, E; Calvo, KR; Corrigan-Cummins, M; Elbaz, O; Farooqui, M; Herman, SE; Saba, NS; Saleh, LM; Sarasua, SM; Sun, C; Wang, W; Wiestner, A; Zhao, Z, 2017)
"Patients with chronic lymphocytic leukemia (CLL) that develop resistance to Bruton tyrosine kinase (BTK) inhibitors are typically positive for mutations in BTK or phospholipase c gamma 2 (PLCγ2)."1.46Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. ( Ahn, I; Albitar, A; Albitar, M; DeDios, I; Estella, J; Farooqui, M; Ma, W; Wiestner, A, 2017)
"A group of experts from the Spanish Chronic Lymphocytic Leukemia Group reviewed all published literature from January 2010 to January 2016, in order to provide recommendations based on clinical evidence."1.46Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. ( Abrisqueta, P; Bosch, F; Delgado, J; García-Marco, JA; Giraldo, P; González, M; Hernández-Rivas, JA; Jarque, I; Loscertales Pueyo, J; Martínez, R; Ramírez Payer, Á; Terol, MJ; Yáñez, L, 2017)
"The introduction of miR profiling of chronic lymphocytic leukemia (CLL) patients with different cytogenetic profiles and responses to therapy has allowed incorporation of important miR-mRNA interactions into the understanding of disease biology."1.46The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. ( Andritsos, LA; Byrd, JC; Fabian, C; Flynn, JM; Guinn, D; Jaglowski, SM; Johnson, AJ; Jones, JA; Lehman, A; Maddocks, K; Woyach, JA; Yu, L, 2017)
"Central nervous system involvement from chronic lymphocytic leukemia (CLL) occurs infrequently, and manifestations include cognitive and cerebellar dysfunction and cranial nerve palsies."1.43Optic Neuropathy Due to Chronic Lymphocytic Leukemia Proven With Optic Nerve Sheath Biopsy. ( Almarzouqi, SJ; Chevez-Barrios, P; Khan, K; Lee, AG; Malik, AI; Morgan, ML; Yalamanchili, S, 2016)
"Clinical responses to bendamustine in chronic lymphocytic leukemia (CLL) are highly heterogeneous and no specific markers to predict sensitivity to this drug have been reported."1.43CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. ( Arimany-Nardí, C; Aymerich, M; Cabezas, S; Campo, E; Clot, G; Colomer, D; Jiménez, L; Lee-Vergés, E; López-Guerra, M; López-Guillermo, A; Montraveta, A; Pastor-Anglada, M; Pérez-Galán, P; Pinyol, M; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S, 2016)
"A 70-year-old white man with stage C chronic lymphocytic leukemia who was being successfully treated with ibrutinib and rituximab developed bilateral, purpuric, painful cutaneous nodules."1.43Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal. ( Magro, CM; Mulvey, JJ; Nuovo, GJ, 2016)
"Ninety-five consecutive patients (93 chronic lymphocytic leukemia, 2 small lymphocytic leukemia) were included in the study between May 2014 and May 2015."1.43Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. ( Andersson, PO; Asklid, A; Hansson, L; Karlsson, C; Karlsson, K; Lauri, B; Lundin, J; Mattsson, M; Norin, S; Österborg, A; Sandstedt, A; Winqvist, M, 2016)
" Analysis of anti-CD20 mediated activation of natural killer cells isolated from patients on continued oral ibrutinib treatment suggested that repeated drug dosing inhibits these cells in vivo."1.42Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. ( Beurskens, FJ; Breij, EC; Da Roit, F; Engelberts, PJ; Golay, J; Gritti, G; Introna, M; Parren, PW; Rambaldi, A; Taylor, RP, 2015)
"Leukemic cells from Chronic Lymphocytic Leukemia (CLL) patients interact with stromal cells of the surrounding microenvironment."1.42Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. ( Ave, E; Castelli, M; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Giorgi, CA; Lessi, F; Martini, V; Piazza, F; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A; Zambello, R, 2015)
" Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL."1.40Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). ( Bojnik, E; Buggy, JJ; Byrd, JC; Chang, BY; Davis, ME; Dubovsky, JA; Efremov, DG; Gobessi, S; Goettl, VM; Harrington, BK; Johnson, AJ; Laurenti, L; MacMurray, J; Ruppert, AS; Smith, LL; Smucker, KA; Stefanovski, MR; Towns, WH; Woyach, JA, 2014)
"Thus, prolonged lymphocytosis is common following ibrutinib treatment, likely represents the persistence of a quiescent clone, and does not predict a subgroup of patients likely to relapse early."1.40Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. ( Byrd, JC; Clow, F; Flynn, J; Furman, RR; Ghia, E; James, DF; Johnson, AJ; Jones, J; Kipps, TJ; Lozanski, A; Lozanski, G; Lucas, D; Maddocks, K; Mantel, R; O'Brien, S; Rassenti, L; Ruppert, AS; Smith, LL; Smucker, K; Williams, K; Woyach, JA; Zhao, W; Zhong, Y, 2014)

Research

Studies (852)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (0.47)29.6817
2010's540 (63.38)24.3611
2020's308 (36.15)2.80

Authors

AuthorsStudies
Abdel-Qadir, H1
Sabrie, N1
Leong, D1
Pang, A1
Austin, PC1
Prica, A2
Nanthakumar, K1
Calvillo-Argüelles, O1
Lee, DS1
Thavendiranathan, P1
Abrisqueta, P2
Loscertales, J7
Terol, MJ3
Ramírez Payer, Á2
Ortiz, M1
Pérez, I1
Cuellar-García, C2
Fernández de la Mata, M1
Rodríguez, A1
Lario, A1
Delgado, J8
Godoy, A1
Arguiñano Pérez, JM1
Berruezo, MJ1
Oliveira, A1
Hernández-Rivas, JÁ3
García Malo, MD1
Medina, Á1
García Martin, P1
Osorio, S1
Baltasar, P1
Fernández-Zarzoso, M1
Marco, F1
Vidal Manceñido, MJ1
Smucler Simonovich, A1
López Rubio, M1
Jarque, I2
Suarez, A1
Fernández Álvarez, R1
Lancharro Anchel, A1
Ríos, E1
Losada Castillo, MDC1
Pérez Persona, E1
García Muñoz, R1
Ramos, R1
Yáñez, L2
Bello, JL1
Loriente, C1
Acha, D1
Villanueva, M1
Sivina, M12
Kim, E5
Wierda, WG40
Ferrajoli, A23
Jain, N23
Thompson, P7
Kantarjian, H12
Keating, M8
Burger, JA57
Tedeschi, A32
Frustaci, AM8
Mauro, FR22
Chiarenza, A12
Coscia, M16
Ciolli, S5
Reda, G17
Laurenti, L24
Varettoni, M6
Murru, R10
Baratè, C1
Sportoletti, P11
Greco, A1
Borella, C2
Rossi, V1
Deodato, M6
Biagi, A6
Zamprogna, G4
Pelle, AC1
Lapietra, G1
Vitale, C7
Morelli, F4
Cassin, R9
Fresa, A2
Cavalloni, C1
Postorino, M4
Ielo, C3
Cairoli, R5
Di Raimondo, F9
Montillo, M13
Del Poeta, G14
Yun, NK1
Alrifai, T1
Miller, IJ1
Larson, ML1
Kater, AP19
Slinger, E1
Cretenet, G1
Martens, AW1
Balasubramanian, S6
Leverson, JD1
Eldering, E6
Rigolin, GM14
Del Giudice, I9
Bardi, A2
Melandri, A1
García-Jacobo, RE1
Cura, F1
Raponi, S4
Ilari, C3
Cafforio, L3
Piciocchi, A6
Arena, V3
Albano, F2
Molica, S21
Trentin, L21
Marchetti, M7
Nanni, M1
Peragine, N5
Mariglia, P4
Vignetti, M3
Guarini, A6
Foà, R22
Cuneo, A20
Allan, JN10
Siddiqi, T8
Kipps, TJ29
Opat, S3
Badoux, XC1
Kuss, BJ3
Jackson, S2
Moreno, C21
Jacobs, R5
Pagel, JM9
Flinn, I1
Pak, Y1
Zhou, C11
Szafer-Glusman, E2
Ninomoto, J8
Dean, JP11
James, DF31
Ghia, P27
Tam, CS24
Akpinar, S2
Dogu, MH2
Celik, S1
Ekinci, O1
Hindilerden, IY1
Dal, MS2
Davulcu, EA2
Tekinalp, A1
Hindilerden, F1
Ozcan, BG1
Hacibekiroglu, T1
Erkurt, MA1
Bagci, M1
Namdaroglu, S1
Korkmaz, G1
Bilgir, O1
Cagliyan, GA1
Ozturk, HBA1
Serin, I1
Tiryaki, TO1
Ozatli, D1
Korkmaz, S1
Ulas, T1
Eser, B1
Turgut, B2
Altuntas, F2
Zimmerman, SM1
Peer, CJ1
Figg, WD1
O'Brien, SM15
Cappelli, LV1
Soscia, R1
De Propris, MS3
Steingrímsson, V2
Lund, SH1
Dickman, PW1
Weibull, CE1
Björkholm, M2
Landgren, O2
Kristinsson, SY2
Bloomquist, MS1
Curry, JL1
Krishnan, B1
Rivero, G1
Curry, CV1
Diwan, AH1
Teh, JSK1
Tam, PCK1
Badenoch, PR1
Adamson, PJ1
Brennan, C1
Marshman, G1
Gordon, DL1
Langerbeins, P7
Zhang, C3
Robrecht, S9
Cramer, P16
Fürstenau, M7
Al-Sawaf, O6
von Tresckow, J7
Fink, AM9
Kreuzer, KA5
Vehling-Kaiser, U2
Tausch, E8
Müller, L3
Eckart, MJ1
Schlag, R1
Freier, W1
Gaska, T1
Balser, C1
Reiser, M1
Stauch, M1
Wendtner, CM13
Fischer, K11
Stilgenbauer, S23
Eichhorst, B16
Hallek, M26
Spaner, DE6
Luo, Y1
Wang, G5
Gallagher, J1
Tsui, H3
Shi, Y6
Wang, H2
Tian, S2
Zhao, Q2
Blumenschein, W1
Yearley, JH1
Secreto, CR2
Sinha, S2
Call, TG16
Wang, Y8
Parikh, SA17
Kenderian, SS10
He, R2
Leis, JF16
Shi, M4
Van Dyke, DL6
Kay, NE22
Slager, SL14
Braggio, E10
Yan, H3
Ding, W18
Davis, JE1
Sharpe, C1
Mason, K1
Koldej, RM1
Ritchie, DS1
Bergman, P1
Blennow, O1
Hansson, L4
Mielke, S1
Nowak, P1
Chen, P2
Söderdahl, G1
Österborg, A11
Smith, CIE2
Wullimann, D1
Vesterbacka, J1
Lindgren, G1
Blixt, L1
Friman, G1
Wahren-Borgström, E1
Nordlander, A1
Gomez, AC1
Akber, M1
Valentini, D1
Norlin, AC1
Thalme, A1
Bogdanovic, G1
Muschiol, S1
Nilsson, P1
Hober, S1
Loré, K1
Chen, MS1
Buggert, M1
Ljunggren, HG1
Ljungman, P2
Aleman, S1
Shanafelt, T1
Wiestner, A36
Li, J8
Krigsfeld, G2
Ahn, IE10
Steele, L1
George, C1
Cerio, R1
O'Toole, EA1
Shah, HR1
Stephens, DM5
Visentin, A15
Cibien, F1
Pietrasanta, D5
Gentile, M15
Quaglia, FM4
Scarfò, L10
Pravato, S2
Piazza, F5
Naylor-Adamson, L1
Chacko, AR1
Booth, Z1
Caserta, S1
Jarvis, J1
Khan, S2
Hart, SP1
Rivero, F1
Allsup, DJ2
Arman, M1
Bories, P1
Ysebaert, L19
Aslan Candır, B1
Yiğenoğlu, TN1
Kızıl Çakar, M1
Purroy, N1
Tong, YE1
Lemvigh, CK1
Cieri, N1
Li, S2
Parry, EM1
Zhang, W3
Rassenti, LZ4
Lesnick, C1
Shanafelt, TD16
Livak, KJ2
Kharchenko, PV1
Neuberg, DS2
Olsen, LR1
Fan, J3
Gohil, SH2
Wu, CJ7
Greil, R4
Demirkan, F9
Anz, B4
Larratt, L3
Simkovic, M5
Novak, J2
Strugov, V3
Gill, D6
Gribben, JG9
Kwei, K1
Dai, S5
Hsu, E5
Flinn, IW14
Tahir, F1
Sy, J1
Reddel, S1
Trotman, J1
Yavorkovsky, LL1
Huber, H1
Edenhofer, S1
Schneider, C2
Bloehdorn, J2
Dreger, P5
Ritgen, M4
Illmer, T4
Illert, AL1
Dürig, J2
Böttcher, S5
Niemann, CU17
Kneba, M4
Döhner, H3
Kumekawa, H1
Watanabe, D1
Tamura, K1
Mizuchi, D1
Egyed, M1
Lueff, S1
Borbely, J1
Illes, A2
Giannarelli, D8
De Paoli, L4
Moia, R8
Levato, L8
Giordano, A1
Stelitano, C1
Noto, A3
Guarente, V1
Gaidano, G18
Foa', R1
Ma, XY1
Zhao, M1
Li, YD1
Chen, Y6
Wei, L1
Chen, ZS1
Barr, PM35
Bannerji, R2
Russell, K1
Wang, E1
Mi, X1
Thompson, MC4
Montoya, S1
Notti, RQ1
Afaghani, J1
Durham, BH1
Penson, A1
Witkowski, MT1
Lu, SX1
Bourcier, J1
Hogg, SJ1
Erickson, C1
Cui, D1
Cho, H1
Singer, M1
Totiger, TM1
Chaudhry, S1
Geyer, M1
Alencar, A1
Linley, AJ1
Palomba, ML3
Coombs, CC2
Park, JH3
Zelenetz, A1
Roeker, L3
Rosendahl, M1
Tsai, DE1
Ebata, K1
Brandhuber, B1
Hyman, DM1
Aifantis, I1
Mato, A10
Taylor, J1
Abdel-Wahab, O1
Innocenti, I10
Motta, M2
Pennese, E2
Rughini, A1
Di Sevo, D1
Tomasso, A1
Autore, F6
Pompili, M2
Coutre, S18
McKinney, M1
Rogers, K3
Mokatrin, A2
Valentino, R3
Szoke, A3
Deshpande, S1
Zhu, A1
Arango-Hisijara, I1
Osei-Bonsu, K1
Wang, M2
O'Brien, S46
Karel, MFA1
Tullemans, BME1
D'Italia, G1
Lemmens, TP1
Claushuis, TAM1
Kuijpers, MJE1
Cosemans, JMEM1
Collins, J1
Stump, SE1
Heiling, H1
Muir, M1
Deal, A1
Proco, D1
Nguyen, C1
Cozad, M1
Muluneh, B1
Sorin, B1
Vigneron, J1
Fadlallah, J1
Mondesir, J1
Fieschi, C1
Oksenhendler, E1
Galicier, L1
Malphettes, M4
Angotzi, F1
Scarmozzino, F1
Cellini, A1
Bertorelle, R1
Pizzi, M3
Binotto, G1
Dei Tos, AP1
Matutes, E2
Polliack, A13
Owen, C9
Robak, T15
Bairey, O6
Hillmen, P32
Coutre, SE16
Dearden, C5
Grosicki, S8
McCarthy, H4
Li, JY3
Offner, F3
Wang, XV3
Hanson, CA7
Paietta, EM2
Barrientos, J3
Jelinek, DF2
Zhang, CC3
Cashen, AF3
Mato, AR22
Singh, AK3
Mullane, MP3
Little, RF4
Erba, H5
Stone, RM4
Litzow, M4
Tallman, M2
Christensen, BW1
Zaha, VG1
Awan, FT10
Ferrarini, I3
Gandini, F1
Zapparoli, E1
Rigo, A2
Black, GS1
Huang, X10
Qiao, Y1
Tarapcsak, S1
Rogers, KA16
Misra, S2
Byrd, JC68
Marth, GT1
Woyach, JA47
Wang, W5
Zhang, Y1
Zhao, D1
Zhou, D2
AlHaj Issa, Z1
Altwijri, A1
Alfayez, M1
Huang, Q3
Deering, KL2
Harshaw, Q2
Leslie, LA2
Huang, Y6
Ruppert, AS18
Walker, JS1
Canfield, D1
Cempre, CB1
Fu, Q1
Baker, S1
Hu, B1
Shah, H1
Vadeboncoeur, R1
Bhat, S3
Jaglowski, SM9
Lockman, H1
Lapalombella, R4
Dhami, K1
Chakraborty, A1
Gururaja, TL1
Cheung, LW1
Sun, C13
DeAnda, F1
Chiodin, G5
Drennan, S2
Martino, EA4
Ondrisova, L3
Henderson, I1
Del Rio, L1
Tracy, I2
D'Avola, A2
Parker, H1
Bonfiglio, S2
Sutton, LA2
Strefford, JC1
Forster, J1
Brake, O1
Potter, KN1
Sale, B1
Lanham, S1
Mraz, M5
Stevenson, FK4
Forconi, F9
Levin, MD8
Dubois, J3
Kersting, S5
Enggaard, L3
Veldhuis, GJ2
Mous, R4
Mellink, CHM2
van der Kevie-Kersemaekers, AF1
Dobber, JA3
Poulsen, CB2
Frederiksen, H3
Janssens, A9
Schjødt, I2
Dompeling, EC2
Ranti, J3
Brieghel, C1
Mattsson, M5
Bellido, M2
Tran, HTT3
Nasserinejad, K4
Mulligan, SP12
Marlton, P2
Kuss, B2
Gerungan, P1
Puig, A1
McGeachie, M1
Dhopeshwarkar, N1
Yang, W1
Hennessy, S1
Rhodes, JM2
Cuker, A1
Leonard, CE1
Klaproth, H2
Eichhorst, BF3
Wu, Z1
Wang, L7
Fan, L2
Tang, H1
Zuo, X1
Gu, D1
Lu, X2
Li, Y3
Wu, J3
Qin, S1
Xia, Y2
Zhu, H2
Xu, W4
Jin, H1
Omi, A1
Nomura, F1
Tsujioka, S1
Fujino, A1
Akizuki, R1
Hampel, PJ6
Rabe, KG8
Muchtar, E8
Koehler, AB7
Parrondo, R2
Schwager, SM11
Sigmund, AM1
Maddocks, K7
Jaglowski, S6
Bhat, SA3
Kittai, AS3
Grever, MR5
Roeker, LE5
Feldman, TA1
Soumerai, JD2
Falco, V1
Panton, G1
Dorsey, C3
Zelenetz, AD2
Falchi, L1
Straus, DJ1
Pena Velasquez, C1
Lebowitz, S1
Fox, Y1
Battiato, K1
Laudati, C1
McCarthy, E1
Kdiry, S1
Martignetti, R1
Turpuseema, T1
Purdom, M1
Paskalis, D2
Miskin, HP6
Sportelli, P6
Li, A1
Ambruso, SL1
Oto, OA1
Barry, M1
Edelstein, CL1
Karvaly, GB1
Vincze, I1
Balogh, A1
Köllő, Z1
Bödör, C5
Vásárhelyi, B1
Intoppa, S2
Milani, ML2
Mattiello, V2
Neri, A4
Vallisa, D1
Grigg, AP1
Walker, P1
Korkmaz, M1
Karakurt Eryilmaz, M1
Karaağaç, M1
Araz, M1
Çeneli, Ö1
Artaç, M1
Perutelli, F2
Montalbano, MC2
Boccellato, E2
Pozzi, S1
Potenza, L6
Giusti, D1
Colaci, E1
Pioli, V1
Leonardi, G1
Maccaferri, M4
Luppi, M6
Marasca, R9
Chanan-Khan, AA11
Ailawadhi, S3
Sher, T2
Liu, Y2
Song, Y1
Yin, Q2
Dong, R1
Yan, Y1
Zeng, X1
Lin, N1
Tan, B1
Sundaram, M4
Trudeau, J1
Barrientos, JC18
Takács, F1
Kotmayer, L2
Czeti, Á1
Szalóki, G1
László, T1
Mikala, G1
Márk, Á1
Masszi, A1
Farkas, P3
Plander, M1
Weisinger, J1
Demeter, J2
Fekete, S1
Szerafin, L1
Deák, BM1
Szaleczky, E1
Sulák, A1
Borbényi, Z1
Barna, G2
Aqil, B1
Kaur, A1
Ramos, J1
Sukhanova, M2
Ma, S4
Gao, J3
Chen, YH1
Chen, Q2
Llull-Ramos, A1
Gracia-Darder, I1
Hernando, JDP1
Izquierdo-Herce, N1
Killock, D1
Choi, JH1
Hur, JY1
Won, YW1
Koba, Y1
Kawata, T1
Tamekane, A1
Watanabe, M1
Bomben, R9
Rossi, FM8
Vit, F1
Bittolo, T2
Zucchetto, A10
Papotti, R1
Tissino, E4
Pozzo, F3
Degan, M1
Polesel, J2
Bulian, P2
Olivieri, J3
Laureana, R1
Del Principe, MI2
Morabito, F6
Fronza, G4
Tafuri, A1
Zaja, F3
Gattei, V11
Esfandiari, N1
Bombardier, N1
Pierson, JC1
Chung, C2
Umoru, G1
Abboud, K1
Hobaugh, E1
Thompson, PA13
Keating, MJ30
Peterson, CB1
Garg, N7
Wang, SA2
Jorgensen, JL2
Kadia, TM1
Bose, P7
Pemmaraju, N4
Short, NJ2
DerSarkissian, M1
Ryan, K1
Duh, MS1
Wahlstrom, SK1
Hakre, S1
Yu, L4
Guo, H1
Chen, SS5
Chiorazzi, N5
Yang, S1
Li, N1
Zhu, R1
Feng, Y1
Zhuo, J1
Gale, RP1
Booth, E1
Backx, M1
Joshi, A1
Nizami, H1
Elmusharaf, N1
Nierengarten, MB1
Ambinder, AJ1
Hambley, B1
Shanbhag, S1
Merrill, SA1
Stirrups, R1
Simpson, D4
Stevens, D1
Lin, J2
Webb, T1
Fedorov, V1
Styles, L8
Zhou, Y1
Lu, H1
Yang, M1
Xu, C1
Romero, D3
Gandhi, V15
Wierda, W9
Fraser, G6
Brown, JR39
Dilhuydy, MS14
Jaeger, U10
Mahler, M6
Salman, M8
Eckert, K2
Solman, IG3
Cheng, M6
Londhe, A2
Howes, A10
Arruga, F2
Bracciamà, V1
Vitale, N2
Vaisitti, T2
Gizzi, K1
Yeomans, A2
D'Arena, G3
Furman, RR30
Packham, G3
Deaglio, S3
Carriles, C1
Ordóñez-Fernández, L1
Arias-Martínez, A1
Menárguez-Blanc, R1
Rosado-María, MC1
Wright, N1
Voshtina, E1
George, G1
Singavi, A1
Field, J1
Ye, CJ1
Xu, WB1
Yu, Q1
Wu, C2
Huang, L1
Li, JM1
Hofland, T2
de Weerdt, I4
Ter Burg, H1
de Boer, R1
Tannheimer, S1
Tonino, SH3
Munir, T6
Reddy, NM6
Ruchlemer, R2
Ben-Ami, R1
Bar-Meir, M1
Soussain, C1
Barzic, N1
Messina, JA1
Jain, P7
Cohen, R1
Hill, B3
Nijland, M1
Herishanu, Y7
Benjamini, O3
Tadmor, T2
Okamoto, K1
Arthurs, B1
Gottesman, B1
Talha, M1
Korem, M1
Bogot, N1
De Boer, F1
Rowe, JM1
Lachish, T1
Mascarella, MA1
Schweitzer, L1
Alreefi, M1
Silver, J1
Caglar, D1
Loo, VG1
Richardson, K1
Dufresne, P1
Lee, TC1
Sadeghi, N1
Williams, AM2
Baran, AM2
Schaffer, M2
Bushart, J1
Rich, L1
Moore, J1
Zent, CS6
Merli, M1
Passamonti, F1
Devereux, S9
Lal, I1
Thermos, G1
Tosios, KI1
Zi, F1
Shi, Q1
Tang, A1
Cheng, J1
Prezzo, A1
Cavaliere, FM1
Bilotta, C1
Pentimalli, TM1
Iacobini, M1
Cesini, L1
Quinti, I1
Emond, B2
Romdhani, H1
Lefebvre, P2
Wang, S4
Nakamura, M1
Yoshioka, S1
Yamashita, D1
Hara, S1
Ishikawa, T1
Fujinami, H1
Kusumoto, S1
Masaki, A1
Ohshima, Y1
Tachita, T1
Sasaki, H1
Marumo, Y1
Yoshida, T1
Narita, T1
Ito, A1
Ri, M1
Komatsu, H1
Inagaki, H1
Iida, S1
Maffei, R5
Arletti, L1
Fiorcari, S5
Benatti, S1
Michallet, M2
Sobh, M2
Koster, L1
Hoek, J1
Boumendil, A2
Scheid, C3
Fox, CP4
Wulf, G3
Krüger, W1
van Gelder, M4
Corradini, P1
Russo, D2
Passweg, J2
Schoemans, H2
Bethge, W2
Schaap, N1
Cornelissen, J2
Browne, P1
Durakovic, N2
Montoto, S2
Kroger, N2
Schetelig, J3
Uminski, K1
Brown, K1
Bucher, O1
Hibbert, I1
Dhaliwal, DH1
Johnston, JB3
Geirnaert, M1
Dawe, DE1
Banerji, V3
Petitdemange, A1
Martin, A1
Ruch, Y1
Chatron, E1
Karol, A1
Hansmann, Y1
Liu, Z2
Liu, J1
Zhang, T1
Chen, X2
Yu, J2
Tam, C10
Peri, AM2
Rossio, R1
Tafuri, F1
Benzecry, V1
Grancini, A1
Bandera, A2
Peyvandi, F1
Salles, G5
Bachy, E1
Smolej, L3
Baseggio, L3
Panovska, A2
Besson, H1
Healy, N2
Garside, J1
Iraqi, W2
Diels, J7
Pick-Lauer, C1
Spacek, M3
Urbanova, R2
Lysak, D1
Hermans, R1
Lundbom, J1
Callet-Bauchu, E2
Doubek, M7
Fakhri, B1
Andreadis, C1
Witzig, TE3
Fonder, AL4
Sarraf Yazdy, M1
Rhodes, J3
Goodfriend, J1
Narkhede, M1
Carver, J2
Gutierrez, C1
Printz, C1
Mhibik, M2
Shibayama, H1
Teshima, T1
Choi, I1
Hatake, K1
Sekiguchi, N1
Yoshinari, N1
Strati, P1
Schlette, EJ1
Solis Soto, LM1
Duenas, DE1
Estrov, Z17
Wistuba, II1
Baumann, T3
Montserrat, E7
Quijada-Álamo, M1
Hernández-Sánchez, M1
Alonso-Pérez, V1
Rodríguez-Vicente, AE1
García-Tuñón, I1
Martín-Izquierdo, M1
Hernández-Sánchez, JM1
Herrero, AB1
Bastida, JM1
San Segundo, L1
Gruber, M2
García, JL1
Yin, S2
Ten Hacken, E4
Benito, R1
Ordóñez, JL1
Hernández-Rivas, JM1
Gordon, MJ2
Sitlinger, A2
Salous, T1
Alqahtani, H2
Churnetski, M2
Rivera, X2
Wisniewski, P1
Cohen, J1
Patel, K5
Shadman, M5
Choi, M3
Stephens, D1
Persky, D2
Brander, D1
Danilov, AV8
Koehler, A1
van der Straten, L1
Visser, O1
Blijlevens, NMA1
Cornelissen, JJ1
Doorduijn, JK2
Dinmohamed, AG1
Rendeiro, AF2
Krausgruber, T2
Fortelny, N1
Zhao, F1
Penz, T1
Farlik, M1
Schuster, LC1
Nemc, A1
Tasnády, S2
Réti, M2
Mátrai, Z5
Alpár, D4
Schmidl, C2
Bock, C2
Benedetti, D2
Caldana, C1
Nanni, P1
Chivilò, H1
Cattarossi, I1
Zaina, E1
Norris, K1
Tripepi, G5
Santinelli, E2
Pozzato, G3
Rossi, D9
Pepper, C4
Hartmann, TN3
Cömert, P1
Albayrak, M1
Yıldız, A1
Şahin, O1
Öztürk, HB1
Reis Aras, M1
Brener, ZZ1
Brener, H1
Losev, A1
Boudny, M1
Trbusek, M2
Gauthier, J1
Hirayama, AV1
Purushe, J1
Hay, KA2
Lymp, J1
Li, DH2
Yeung, CCS1
Sheih, A1
Pender, BS1
Hawkins, RM1
Vakil, A1
Phi, TD1
Steinmetz, RN1
Riddell, SR1
Maloney, DG1
Turtle, CJ2
Le, TH1
Kumar, V1
Gondal, K1
Barnes, M1
Siddique, H1
Buttar, B1
Kaell, A1
Tresckow, JV1
Bahlo, J5
Pflug, N2
Heinz, WJ1
Hensel, M1
Sasse, S1
Huang, SJ1
Gerrie, AS1
Young, S1
Tucker, T1
Bruyere, H1
Hrynchak, M1
Galbraith, P1
Al Tourah, AJ1
Dueck, G1
Noble, MC1
Ramadan, KM1
Tsang, P1
Hardy, E1
Sehn, L1
Toze, CL2
Hanna, BS1
Yazdanparast, H1
Demerdash, Y1
Roessner, PM1
Schulz, R1
Lichter, P3
Seiffert, M1
Achenbach, SJ1
McCullough, KB2
Nedved, AN1
Smith, MD2
Finnes, HD3
Sica, A1
Sagnelli, C1
Papa, A1
Ciccozzi, M1
Sagnelli, E1
Calogero, A1
Martinelli, E1
Casale, B1
LoRe, VA1
Chong, EA2
Gerson, JN1
Barta, SK1
Landsburg, DJ2
Nasta, SD3
Svoboda, J8
Loren, AW1
Schuster, SJ13
Lamanna, N9
Qiu, L2
Salmi, T1
Hilger, J1
Wu, K1
Cohen, A1
Huang, J2
Blum, K2
Sharman, JP8
Zhao, W10
Heerema, NA14
Luan, Y2
Liu, EA1
Ozbagcivan, O1
Akarsu, S1
Nazli, EC1
Lebe, B1
Fetil, E1
Lucas, F1
Larkin, K2
Gregory, CT1
Orwick, S1
Doong, TJ3
Lozanski, A7
Lozanski, G13
Ngankeu, A1
Ozer, HG4
Sampath, D3
Thangavadivel, S2
Yilmaz, SA1
Blachly, JS5
Lin, VS1
Lew, TE2
Handunnetti, SM1
Blombery, P2
Nguyen, T1
Westerman, DA1
Roberts, AW1
Seymour, JF7
Anderson, MA1
İskender, G1
İskender, D1
Ertek, M1
Suzumiya, J1
Takizawa, J1
Recchia, AG1
Condoluci, A4
Loseto, G4
Consoli, U4
Scortechini, I5
Fraticelli, V1
Vigna, E4
Botta, C2
Arrigo, G1
Rago, A4
Angeletti, I4
Gallais, F2
Despas, F2
De Barros, S2
Dupré, L1
Quillet-Mary, A2
Protin, C4
Thomas, F1
Obéric, L3
Allal, B2
Chatelut, E2
White-Koning, M2
Davids, MS11
Melenhorst, JJ2
Lewis, T1
Corcoran, DB1
Thurston, DE1
Giles, PJ1
Ashelford, K1
Walsby, EJ2
Fegan, CD1
Pepper, AGS1
Miraz Rahman, K1
Kabadi, SM1
Near, A1
Wada, K1
Burudpakdee, C1
Allain, EP1
Rouleau, M1
Vanura, K1
Tremblay, S1
Vaillancourt, J1
Bat, V1
Caron, P1
Villeneuve, L1
Labriet, A1
Turcotte, V1
Le, T1
Shehata, M3
Schnabl, S2
Demirtas, D2
Hubmann, R2
Joly-Beauparlant, C1
Droit, A1
Jäger, U4
Staber, PB3
Lévesque, E1
Guillemette, C1
Thibaud, S1
Tremblay, D1
Bhalla, S1
Zimmerman, B1
Sigel, K1
Gabrilove, J2
Anastasopoulou, A1
DiPippo, AJ2
Kontoyiannis, DP2
Archibald, WJ1
Kabat, BF1
Herrmann, J1
Gianfelici, V1
Hardy-Abeloos, C1
Pinotti, R1
Dmitrieva, EA1
Nikitin, EA1
Ignatova, AA1
Vorobyev, VI1
Poletaev, AV1
Seregina, EA1
Voronin, KA1
Polokhov, DM1
Maschan, AA1
Novichkova, GA1
Panteleev, MA1
Ptushkin, VV1
Patel, KK1
Isufi, I2
Kothari, S1
Davidoff, AJ1
Gross, CP1
Huntington, SF1
Frei, M1
Aitken, SL1
Zhang, H3
Zhang, XH1
Li, BZ1
Lentini, M3
Zappalà, D1
Hochman, MJ1
Martin, DB1
Hu, EY1
Saygin, C1
Workman, SE1
Chiang, CL1
Coombes, KR1
Jones, D4
Muthusamy, N4
Allouchery, M1
Tomowiak, C3
Guidez, S1
Delwail, V1
Delaunay, P1
Lafay-Chebassier, C1
Salvo, F1
Pérault-Pochat, MC1
Baumann, TS1
Quinquenel, A5
Bijou, F1
Ferrant, E2
Michallet, AS9
De Silva, N1
Simon, F1
Hohloch, K2
Droogendijk, J1
van der Klift, M1
van der Spek, E2
Schöttker, B1
Gregor, M1
Haselager, MV1
Kielbassa, K1
Ter Burg, J1
Bax, DJC1
Fernandes, SM3
Borst, J1
Sibaud, V2
Beylot-Barry, M2
Vigarios, E2
Recher, C1
Lee, J2
Wang, YL8
Pula, B1
Iskierka-Jazdzewska, E7
Dlugosz-Danecka, M2
Szymczyk, A6
Hus, M7
Szeremet, A3
Drozd-Sokolowska, J1
Waszczuk-Gajda, A3
Zaucha, JM4
Holojda, J1
Piszczek, W4
Steckiewicz, P5
Wojciechowska, M4
Osowiecki, M3
Knopinska-Posluszny, W2
Dudzinski, M2
Zawirska, D2
Subocz, E3
Halka, J1
Pluta, A1
Wichary, R1
Kumiega, B2
Budziszewska, BK3
Jurczak, W5
Lech-Maranda, E3
Giannopoulos, K2
Jamroziak, K7
Chatzikonstantinou, T1
Quaresmini, G1
Garcia-Marco, JA3
Mirás, F1
Baile, M1
Marquet, J1
Gimeno, E1
Iyengar, S2
Ferrari, A1
Itchaki, G1
Lista, E2
Vandenberghe, E2
Wasik-Szczepanek, E1
Bron, D1
De Paolis, MR1
Farina, L3
Foglietta, M1
Herold, T1
Jaksic, O2
Malerba, L1
Orsucci, L2
Popov, VM1
Yassin, M1
Pocali, B1
Dos Santos, G1
Nikitin, E1
Andres, M1
Dimou, M2
Enrico, A1
Hakobyan, Y1
Kalashnikova, O1
Ortiz Pareja, M1
Papaioannou, M1
Shah, N1
Shrestha, A1
Stanca, O1
Stavroyianni, N3
Zdrenghea, M1
Stamatopoulos, K4
Rossi, G1
Rambaldi, A3
Puła, B4
Długosz-Danecka, M2
Salomon-Perzyński, A1
Rybka, J3
Gil, L2
Szukalski, Ł1
Sehn, LH1
Kuruvilla, P1
Christofides, A2
Stakiw, J1
Lama, TG1
Kyung, D1
Marcaillou, M1
Stéphanie, D1
Marion, B1
Julien, S1
Christophe, B1
Barnea Slonim, L1
Behdad, A1
Fan, F1
Yoo, HJ1
Stock, S1
Schubert, ML1
Neuber, B1
Hückelhoven-Krauss, A1
Gern, U1
Schmitt, A1
Müller-Tidow, C1
Schmitt, M1
Sellner, L1
Reynolds, G1
Slavin, M1
Teh, BW2
Chanas-Larue, A1
Villalpando-Rodriguez, GE1
Henson, ES1
Gibson, SB2
Tian, X8
de Fabritiis, P1
Bruno, A1
Cantonetti, M1
Aarup, K1
Rotbain, EC1
Pedersen, RS1
Bergmann, OJ1
Thomsen, RH1
Frederiksen, M1
Nielsen, T1
Christiansen, I1
Andersen, MA1
Fraser, GAM2
Chanan-Khan, A8
Santucci Silva, R1
Mayer, J8
Bartlett, NL6
Avigdor, A4
Rule, S6
Samoilova, O5
Pavlovsky, MA3
Goy, A9
Tamegnon, M1
Sun, S6
Connor, A1
Nottage, K1
Schuier, N1
Brochard, J1
Morio, F1
Mahe, J1
Le Pape, P2
Guimard, T1
Mahe, B3
Leterrier, M1
Morrier, M1
Raffi, F1
Boutoille, D1
Abruzzo, LV4
Andersen, BL2
Dean, A1
Lucas, M3
Banks, C1
Grantier, C1
Maddocks, KJ8
Valentine, TR1
Weiss, DM2
Jones, JA16
Pleyer, C2
Rampertaap, S1
Mu, R1
Soto, S8
Superata, J1
Gaglione, E1
Lotter, J1
Stetler-Stevenson, M5
Yuan, CM2
Maric, I6
Pittaluga, S4
Rosenzweig, S1
Fleisher, T1
Liu, W1
Xu, J2
Tang, Z1
Toruner, G1
Khanlari, M2
Medeiros, LJ2
Tang, G1
Cordoba, R3
Kong, YL1
Pan, BH1
Liang, JH1
Zhu, HY1
Wu, JZ1
Sheng, Z1
Song, S2
Yu, M1
Gao, A1
Gao, W1
Ran, X1
Huo, D1
Svanberg, R1
Ostrowski, SR1
Mattson, M1
Borra, S1
Shrestha, S1
Janjan, N1
Blum, LK2
Hoh, HY1
Lal, ID1
Mongan, A2
Lebas, D1
Preta, LH1
Leguern, A1
Modiano, P1
Wiart, T1
de Jong, J5
Mitselos, A1
Panizo, C1
Wrobel, T3
Jiao, J2
Sukbuntherng, J6
Ouellet, D1
Hellemans, P2
Cherng, HJ1
McPhail, ED1
Miranda, RN1
Lin, P1
Tawbi, HA1
Brander, DM9
Hill, BT6
Winter, A3
Lansigan, F4
Skarbnik, AP5
Pu, JJ5
Sehgal, AR3
Shah, NN2
Ujjani, CS5
Orlandi, EM2
Billio, A2
Ilariucci, F2
de la Serna, J2
Medina Perez, A1
Cimino, G1
Cavallari, M2
Cucci, R1
Vallerini, D1
Barozzi, P1
Marvyin, K1
Tjønnfjord, EB1
Breland, UM1
Tjønnfjord, GE3
Syrykh, C1
Péricart, S1
Evrard, SM1
Meggetto, F1
Kanoun, S1
Brousset, P1
Laurent, C1
Pulido-Pérez, A1
Bergón-Sendín, M1
Mateos-Mayo, A1
Parra-Blanco, V1
Suárez-Fernández, R1
Carretero-López, F1
Baldini, L1
Lafeuille, MH1
Gupta, D1
Kirar, S1
Gogia, A1
Gupta, R1
Mallick, S1
Soddu, S1
Thi Tuyet Tran, H1
Mousavi-Fatemi, K1
Mousavi, SA1
Khosravi, S1
Maleki, N1
Xia, M1
Luo, TY1
Harari, D1
Xiao, L2
Vaca, A1
DiSogra, KY1
Tran, T1
Arnall, JR1
Janes, A1
Moore, DC1
Park, SI1
Sora, F3
Chiusolo, P1
Giammarco, S1
Metafuni, E1
Bacigalupo, A1
Sica, S2
Kidoguchi, K1
Kubato, Y1
Nishimura, Y1
Kizuka-Sano, H1
Kimura, S1
Letestu, R2
Le Garff-Tavernier, M2
Aanei, C2
Ticchioni, M2
Subtil, F3
Rouille, V2
Laribi, K3
Villemagne, B2
Tournilhac, O7
Delmer, A6
Portois, C2
Pegourie, B2
Leblond, V6
De Guibert, S5
Orsini Piocelle, F1
Banos, A2
Carassou, P2
Cartron, G2
Fornecker, LM3
Dartigeas, C6
Truchan-Graczyk, M2
Vilque, JP3
Aurran, T3
Cymbalista, F12
Lepretre, S5
Levy, V5
Nguyen-Khac, F2
Feugier, P5
Messori, A1
Bartoli, L1
Sharma, S3
Pavlasova, GM1
Seda, V3
Cerna, KA1
Vojackova, E2
Filip, D1
Sandova, V1
Kostalova, L2
Zeni, PF1
Borsky, M3
Oppelt, J2
Liskova, K2
Kren, L2
Janikova, A1
Pospisilova, S5
Pacoureau, L1
De Menthon, M1
Boytchev, I1
Lazure, T1
Rocher, L1
Lambotte, O1
Noël, N1
Machnicki, MM1
Górniak, P1
Pępek, M1
Bluszcz, A1
Rydzanicz, M1
Płoski, R1
Makuch-Łasica, H1
Nowak, G1
Juszczyński, P1
Stokłosa, T1
Khountham, S1
Shindiapina, P1
Mo, X3
Lachowiez, C1
Wiczer, T1
Mousa, L1
Andritsos, LA10
Spurgeon, SE4
Gíslason, GK1
Þorsteinsdóttir, S1
Rögnvaldsson, S1
Gottfreðsson, M1
Aspelund, T1
Turesson, I1
Cavallini, C1
Galasso, M1
Pozza, ED1
Chignola, R1
Lovato, O1
Dando, I1
Romanelli, MG1
Krampera, M1
Pizzolo, G1
Donadelli, M1
Scupoli, MT1
Persky, DO1
Joseph, RE1
Amatya, N1
Fulton, DB1
Engen, JR1
Wales, TE1
Andreotti, A1
Ghosh, N2
Rai, KR1
Reeves, JA1
Cheson, BD9
Kambhampati, S2
Fonseca, GA1
Hamadeh, IS1
LaRatta, N1
Weissbrot, H1
Luning Prak, ET1
Tsao, P1
Weiss, MS4
Santoro, RC1
Falbo, M1
Iannaccaro, P1
Prejanò, S1
Nabergoj, S1
Markovič, T1
Avsec, D1
Gobec, M1
Podgornik, H1
Jakopin, Ž1
Mlinarič-Raščan, I1
Maharaj, D1
Srinivasan, G1
Abreu, MM1
Ko, MW1
Jewett, A1
Gouvea, J1
Bossio, S2
Al-Janazreh, H2
Mendicino, F2
D'Arrigo, G2
Galimberti, S3
Monti, P2
Menichini, P2
Cutrona, G3
Ferrarini, M3
Sieburth, RM1
Weaver, CD1
Kirzhner, M1
Shildkrot, Y1
Martín-Moro, F1
García-Cosío, M1
Marquet-Palomanes, J1
López-Gutiérrez, M1
Pian-Arias, H1
López-Jiménez, FJ1
Chandrashekar, N1
McKenney, R1
Saling, C1
Feller, F1
Vikram, HR1
Mehraban Far, P1
Rullo, J1
Farmer, J1
Urton, T1
Sato, N1
Yuda, J1
Yamauchi, N1
Kuzume, A1
Nakamura, H1
Chi, S1
Nagata, A1
Kaku, E1
Nishizawa, A1
Minami, Y1
Irwin, D1
Wilson, K1
Thompson, S1
Choudhry, A1
Caracciolo, D1
Durairaj, S1
Phumphukhieo, P1
Holding, S1
Allsup, D2
Lu, P7
Franzen, CA1
Venkataraman, G2
McClure, R1
Li, L3
Wu, W1
Niu, N1
Pei, J1
Baldwin, DA1
Nejati, R1
Wasik, MA1
Khan, N2
Tu, Y1
Larson, RA3
Chen, TL2
Harrington, B1
Truxall, J1
Wasmuth, R2
Prouty, A1
Sloan, S1
Lehman, AM4
Orlemans, E1
Baiocchi, RA1
Alinari, L1
Hertlein, E4
Burke, JM2
Schreeder, MT3
Lunin, SD1
Zweibach, A1
Shtivelband, M1
Travis, PM1
Chandler, JC1
Kolibaba, KS3
Salvetti, C1
Griggio, V1
Porrazzo, M1
Schiattone, L2
Vassallo, F1
Rivela, P1
Boccadoro, M1
Atene, CG2
Martinelli, S3
Ljungström, V1
Zucchini, P2
Forghieri, F1
Trenti, T1
Tagliafico, E1
Quinson, AM1
Maier, D1
Smith, D1
Debbia, G1
Chen, R1
Tsai, J1
Xiong, P1
Liu, C3
Burrows, F1
Plunkett, W5
Coleman, M8
Izumi, R6
Frigault, MM2
Quah, C1
Raman, RK1
Patel, P3
Wang, MH2
Beckmann, L1
Berg, V1
Dickhut, C1
Merkel, O1
Seifert, M1
da Palma Guerreiro, A1
Claasen, J1
Loroch, S1
Oliverio, M1
Underbayev, C3
Vaughn, L1
Thomalla, D1
Hülsemann, MF1
Sickmann, A1
Zahedi, RP1
Frenzel, LP1
Creuzet, E1
Nourrisson, C1
Chaleteix, C1
Poirier, P1
Moniot, M1
Loja, T1
Mladonicka Pavlasova, G1
Zicha, D1
Kudlickova Peskova, M1
Krivanek, J1
Benes, V1
Musilova Litzmanova, K1
Verner, J2
Brychtova, Y1
Tan, Z1
Zhang, S1
Amruz Cerna, K1
Phadke, NA1
Luk, SO1
Hochberg, EP1
Banerji, A1
Miller, CR1
Labanowska, J1
Grever, M1
Hertlein, EK1
Sakata, M1
Saburi, M1
Kawano, K1
Takata, H1
Miyazaki, Y1
Uchida, H1
Kawano, Y1
Ohtsuka, E1
Wiedemann, GM1
Schneider, J1
Verbeek, M1
Konukiewitz, B1
Spinner, CD1
Einwächter, H1
Schmid, RM1
Rothe, K1
Baptista, MJ2
Baskar, S1
Gaglione, EM2
Keyvanfar, K3
D Arrigo, G1
Koshiishi, M1
Odate, T1
Nakagawa, Y1
Suzuki, J1
Kumagai, T1
Kawashima, I1
Yamamoto, T1
Nakajima, K1
Tanaka, M1
Oishi, N1
Kondo, T1
Kirito, K1
Timofeeva, N1
Burger, J6
Takahashi, K3
Borthakur, G3
Kadia, T4
Sasaki, K3
Konopleva, M3
Jabbour, E3
Wang, X6
Kanagal-Shamanna, R5
Jorgensen, J4
Lopez, W1
Ayala, A3
Wang, Z1
Cheung, LWK1
Nguyen, AN1
Wimalachandra, M1
Basu, TN1
Salisbury, J1
Attard, N1
Calonje, E1
Patten, PEM3
Ronconi, G1
Dondi, L1
Calabria, S1
Piccinni, C1
Pedrini, A1
Esposito, I1
Martini, N1
Eik, D1
Kendall, EK1
Blackburn, A1
Qi, J1
Rader, C1
Giza, A1
Pelzer, BW1
Belliere, J1
Casemayou, A1
Colliou, E1
El Hachem, H1
Kounde, C1
Piedrafita, A1
Feuillet, G1
Schanstra, JP1
Faguer, S1
Krečak, I1
Čengić, M1
Skorić, I1
Nakić, M1
Gverić-Krečak, V1
Fowler, N2
Alvarado, Y2
Yilmaz, M3
DiNardo, C2
Ohanian, M3
Wei, C2
Cruz, N2
Ishdorj, G1
Nugent, Z1
Squires, M1
Kost, S1
Davidson, L1
Katyal, CS1
Marshall, A1
Shulman, K1
Kazarin, O1
Tannous, E1
Sofer, O1
Montresor, A1
Toffali, L1
Fumagalli, L1
Constantin, G1
Vinante, F1
Laudanna, C1
Lasica, M1
Tanigawa, T1
Sakurai, M1
Kato, J1
Mizuno, K1
Fujita, S1
Koda, Y1
Kikuchi, T1
Shimizu, T1
Okamoto, S1
Kataoka, K1
Sekiguchi, Y1
Iizuka, H1
Takizawa, H1
Mitsumori, T1
Tomita, S1
Izumi, H1
Okubo, M1
Miyake, K1
Osawa, T1
Sawada, T1
Yoshikawa, S1
Noguchi, M1
Booth, AM3
Nattam, S2
Kuzma, CS1
Abramson, JS2
Smith, SE2
Mandrekar, SJ4
Miao, Y1
Palma, M4
Mulder, TA1
Favini, C1
Ferri, V1
Forestieri, G1
Terzi Di Bergamo, L1
Schipani, M1
Sagiraju, S1
Andorno, A1
Rasi, S2
Adhinaveni, R1
Talotta, D1
Al Essa, W1
Margiotta Casaluci, G1
Patriarca, A1
Boldorini, RL1
Mateu-Albero, T1
Juárez-Sánchez, R1
Mol, W1
Terrón, F1
Muñoz-Calleja, C1
Cuesta-Mateos, C1
Smith, MR2
Cronin, JF1
Weiss, RF1
Yenerel, MN1
Kay, N1
Pinilla-Ibarz, J5
Rothbaum, W1
Hamdy, A6
Higgins, K1
Sohoni, S1
Miller, C1
Goldstein, D1
Beckwith, K2
Bond, DA2
Cheng, L1
Huang, M1
Wei, J1
Xu, H1
Zhou, M1
Jiang, L2
Gángó, A3
Kiss, R3
Hanna, E1
Deák, B1
Lévai, D1
Matolcsy, A3
Timár, B1
Cheung, MC1
Mittmann, N1
Abdel-Samad, N1
Lam, S1
Crump, M1
Sperlich, C1
van der Jagt, R1
Couban, S1
McDonald, G1
Shepherd, LE1
Yen, H1
Chen, BE1
Hay, AE1
Coppola, PE1
Broccoli, A1
Argnani, L1
Casadei, B1
Stefoni, V1
Bertuzzi, C1
Sabattini, E1
Zinzani, PL2
Cho, HJ1
Baek, DW1
Kim, J1
Lee, JM1
Moon, JH1
Sohn, SK1
Woyach, J5
Amaya-Chanaga, CI1
Holowka, T1
Cheung, H1
Malinis, M1
Gan, G1
Deng, Y1
Perreault, S1
Azar, MM1
Hassan, H1
Ammad Ud Din, M1
Jamshed, S1
Bress, J1
Mustafa, SS1
Solano de la Asunción, C1
Saus, A1
Olea, B1
Giménez, E1
Albert, E1
López-Jiménez, J1
Andreu, R1
García, D1
Fox, L1
Remigia, MJ1
Amat, P1
Solano, C1
Navarro, D1
Tschumper, RC1
Lesnick, CE1
Stone, R1
Litzow, MR1
Tallman, MS1
Aslan, B1
Kismali, G1
Chen, LS3
Iles, LR1
Mahendra, M1
Peoples, M1
Gagea, M1
Fowlkes, NW1
Zheng, X1
Wang, J3
Vellano, CP1
Marszalek, JR2
Bertilaccio, MTS1
Te Raa, D1
Visser, HPJ1
Hansenne, A1
Camboni, A1
Van Den Neste, E3
Bailly, S1
Tombak, A1
Pepedil Tanrıkulu, F1
Durusoy, SS1
Dinçyürek, HD1
Kaya, E1
Ümit, EG1
Yavaşoğlu, İ1
Mehtap, Ö1
Deveci, B1
Özcan, MA1
Terzi, H1
Okay, M1
Sayınalp, N1
Okan, V1
Kızıklı, A1
Özcan, Ö1
Çetin, G1
Demircioğlu, S1
Aydoğdu, İ1
Saydam, G1
İlhan, G1
Uçar, MA1
Özet, G1
Berber, İ1
Kurtoğlu, E1
Sönmez, M1
Batur, DS1
Yıldırım, R1
Özkocamaz, V1
Güneş, AK1
Sahip, B1
Ertop, Ş1
Akay, OM1
Baştürk, A1
Akdeniz, A1
Ünal, A1
Seyhanlı, A1
Gürkan, E1
Çekdemir, D1
Ferhanoğlu, B2
Hutchinson, L1
Kaur, V2
Swami, A1
Waldron, M1
Caruthers, S1
Tu, H1
Coleman, J2
Johnson, AJ24
Suzuki, S2
Cole, G2
Shustik, C1
Bence-Bruckler, I2
Delage, R1
Owen, CJ1
Andrasiak, I1
Podhorecka, M1
Goracy, A1
Kowal, M1
Ibanez, B1
Jankowska-Lecka, O1
Macheta, A1
Nowaczynska, A1
Drab-Urbanek, E1
Chocholska, S1
Jawniak, D1
Guinn, D6
Lehman, A6
Abruzzo, L2
Gordon, A4
Mantel, R6
Smith, LL6
McWhorter, S1
Davis, M2
Ny, F1
Chase, W1
Flynn, JM7
Blum, KA11
Martini, V4
Gattazzo, C2
Frezzato, F5
Trimarco, V3
Severin, F3
Scomazzon, E3
Guzzardo, V1
Saraggi, D1
Raggi, F2
Martinello, L1
Facco, M4
Brunati, AM1
Semenzato, G5
LaPlant, BR1
Le-Rademacher, J1
Feldman, AL1
Habermann, TM1
Wiseman, GA1
Lin, Y1
Asmus, E1
Nowakowski, GS2
Conte, MJ1
Bowen, DA2
Aitken, CN1
Greipp, PT1
Liu, X1
Wu, X3
Wellik, LE1
Micallef, I1
Viswanatha, DS1
Dong, H1
Ansell, SM1
Aurran-Schleinitz, T3
Dupuis, J6
Sinet, P1
Albrecht, C1
Howlett, C4
Kiselev, P3
Foon, K1
Lenhart, J1
Henick Bachow, S1
Winter, AM1
Cruz, AL1
Claxton, DF2
Daniel, C2
Isaac, K2
Kennard, KH2
Timlin, C3
Fanning, M1
Gashonia, L2
Yacur, M1
Nabhan, C8
Aw, A3
Agathanggelou, A2
Smith, E2
Davies, NJ1
Kwok, M2
Zlatanou, A1
Oldreive, CE1
Mao, J1
Da Costa, D1
Yadollahi, S1
Perry, T1
Kearns, P1
Skowronska, A1
Yates, E1
Parry, H2
Reverdy, C1
Delansorne, R1
Paneesha, S2
Pratt, G3
Moss, P2
Taylor, AMR1
Stewart, GS1
Stankovic, T2
Hellman, JM2
Birner, A1
Mazzucchelli, M2
Murthy, V1
Weaving, S1
Rafei, H1
Kharfan-Dabaja, MA3
Sachanas, S2
Pangalis, GA2
Moschogiannis, M2
Yiakoumis, X2
Koulieris, E2
Tsirkinidis, P1
Kalpadakis, C2
Rontogianni, D2
Baron, M2
Zini, JM1
Challan Belval, T1
Vignon, M2
Denis, B1
Alanio, A1
Glavey, S1
Quinn, J1
McCloy, M1
Sargent, J1
McCartney, Y1
Catherwood, M1
Marafioti, T1
Leader, M1
Murphy, P1
Thornton, P4
Van Sanden, S2
Baculea, S3
Cote, S3
Caligaris-Cappio, F2
DeVos, S1
Chung, D1
Gau, L1
Chang, B2
Edelmann, J1
Cosialls, AM1
Pomares, H1
Iglesias-Serret, D1
Saura-Esteller, J1
Núñez-Vázquez, S1
González-Gironès, DM1
de la Banda, E1
Preciado, S1
Albericio, F1
Lavilla, R1
Pons, G1
González-Barca, EM1
Gil, J1
Tran, PN1
Thorp, BC1
Badoux, X1
Douglas, AP1
Trubiano, JA1
Barr, I1
Leung, V1
Slavin, MA2
Winqvist, M3
Heimersson, K1
Mellstedt, H1
Lundin, J4
Fischer, A1
Bastian, S1
Cogliatti, S1
Mey, U1
Saub, J1
Schanz, U1
Padberg, B1
Meacham, PJ1
Feldman, MM1
Valencia, HE1
Newsom-Stewart, C1
Gupta, N1
Janelsins, MC1
Albi, E1
Baldoni, S1
Aureli, P1
Dorillo, E1
Del Papa, B1
Ascani, S1
Di Ianni, M1
Falzetti, F1
Skopelja-Gardner, S1
Jones, JD1
Hamilton, BJ1
Rigby, WFC1
Titus-Rains, KS1
Brown, JN1
Hammond, JM1
Long, M4
Do, P2
Mundy, BL1
Cheney, C2
Awan, F2
Fraietta, JA2
June, CH2
Maus, MV2
Caligiuri, MA1
Krämer, I1
Dietrich, S2
Zeis, M1
Stadler, M1
Bittenbring, J1
Uharek, L1
Hegenbart, U1
Ho, A1
Schmitz, N1
Singh, M1
Mealing, S1
Whelan, J1
England, JT1
Leitch, HA1
Dutton, D1
Roach, H1
Lowry, L1
Andrick, B1
Alwhaibi, A1
DeRemer, DL1
Quershi, S1
Khan, R1
Bryan, LJ1
Somanath, PR1
Pantin, J1
Skrabs, C4
Pickl, WF1
Perkmann, T1
Gessl, A1
Ali, N2
Malik, F1
Jafri, SIM1
Naglak, M1
Sundermeyer, M1
Pickens, PV2
Buchanan, J1
Wordsworth, S1
Clifford, R1
Robbe, P1
Taylor, JC1
Schuh, A7
Knight, SJL1
Asklid, A3
Eketorp-Sylvan, S1
Repits, J1
Søltoft, F1
Koopmans, SM1
Collett, L1
Howard, DR1
McParland, L1
Oughton, JB1
Rawstron, AC2
Hockaday, A1
Dimbleby, C1
Phillips, D1
McMahon, K1
Hulme, C1
Bloor, A3
Saluzzo, S1
Layer, F1
Stingl, G1
Stary, G1
Gaudino, F1
Ouk, S1
Moscvin, M1
Serra, S1
Zakrzewski, JL1
Liou, HC1
Tang, CPS1
McMullen, J1
Wolf, C1
Garding, A1
Filarsky, K1
Becker, N1
Zucknick, M1
Rouhi, A1
Weigel, A1
Claus, R1
Weichenhan, D1
Kuchenbauer, F1
Plass, C1
Mertens, D3
Stewart, J1
Bayers, S1
Vandergriff, T1
Kondo, K1
Shaim, H1
Harris, D1
Daher, M1
Basar, R1
Muftuoglu, M1
Imahashi, N1
Alsuliman, A1
Sobieski, C1
Gokdemir, E1
Liu, E2
Shpall, EJ1
Rezvani, K1
Saba, NS3
Wong, DH3
Tanios, G1
Iyer, JR2
Lobelle-Rich, P1
Dadashian, EL2
Liu, D6
Fontan, L1
Flemington, EK1
Nichols, CM1
Safah, H1
Melnick, A1
Herman, SEM6
Sato, R1
Jacob, J1
Gaballa, S1
Patel, VK1
Lamothe, B3
Ayres, ML1
Gay, J1
Cheung, JP1
Balakrishnan, K4
Ivan, C1
Morse, J1
Nelson, M1
Ayed, AO1
Godet, S2
Bastie, JN1
Herbaux, C2
Ghez, D5
Brion, A1
Shen, Y1
Best, OG1
Christopherson, RI1
Jiang, F1
Verma, P1
Xu, Y2
Fahrbach, K1
Dorman, E2
Sanden, SV1
Coulter, EM1
Pepper, A1
Mele, S1
Folarin, N1
Townsend, W1
Cuthill, K1
Phillips, EH1
Alberelli, MA1
De Candia, E1
Knopinska-Posłuszny, W2
Hołojda, J3
Hałaburda, K1
Warzocha, K4
Zhou, L1
Chyla, B1
Salem, AH1
Verdugo, M1
Humerickhouse, RA1
Potluri, J1
Robier, C1
Beham-Schmid, C1
Neubauer, M1
Landau, DA2
Rosebrock, D1
Fein, J1
Hoellenriegel, J3
Ravichandran, S1
Farooqui, MZH1
Cibulskis, C1
Zviran, A1
Livitz, D1
Bozic, I2
Leshchiner, I2
Getz, G3
Clasen, S1
Pickens, P1
Hughes, M1
Schuster, S1
Santucci-Silva, R1
Traina, S1
Chan, EKH1
Sengupta, N2
Chaffee, KG5
Dal Bo, M2
Bayer, E1
Härzschel, A1
Gutjahr, JC1
Ayed, A1
Chigaev, A2
Sklar, LA1
Janovska, P1
Kohoutek, J1
Bryjova, L1
Gregorova, M1
Dzimkova, M1
Skabrahova, H1
Radaszkiewicz, T1
Ovesna, P1
Vondalova Blanarova, O1
Nemcova, T1
Hoferova, Z1
Vasickova, K1
Smyckova, L1
Egle, A2
Pavlova, S1
Poppova, L1
Plevova, K1
Bryja, V1
Bosch, F3
Geisler, CH4
Patrussi, L1
Capitani, N1
Cattaneo, F1
Manganaro, N1
Gamberucci, A1
Pelicci, PG1
D'Elios, MM1
Baldari, CT1
Stankowicz, M1
Banaszynski, M1
Crawford, R1
Lampson, BL3
Christoforidou, A1
Kapsas, G1
Bezirgiannidou, Z1
Papamichos, S1
Kotsianidis, Ι1
Sinha, R1
Redekop, WK1
Gaye, E1
Le Bot, A1
Talarmin, JP1
Le Calloch, R2
Belaz, S1
Dupont, M2
Tattevin, P1
Skarbnik, A3
Zent, C1
Pu, J1
Claxton, D1
Landsburg, D1
Bachow, SH2
Barr, P1
Aschan, J1
Wildgust, M2
Bisi, L1
Cappelletti, A1
Colella, E1
Verga, L1
Foresti, S1
Migliorino, GM1
Gori, A1
Calleja, A1
Ledoux, MP1
Damaj, G1
Dreyfus, B1
Paul, F1
Souchet, L1
Delavigne, K1
Sharman, J3
Jones, J9
Chu, AD5
Rozovski, U2
Harris, DM1
Li, P1
Mirabelli, R2
El Halabi, L1
Cherif-Rebai, K1
Michot, JM1
Porpaczy, E3
Schwarzinger, I1
Augustin, D1
Thalhammer, R2
Boddy, CS1
Varughese, T1
Taur, Y1
Cohen, N1
Seo, SK1
Hohl, TM1
Redelman-Sidi, G1
Ito, Y1
Makita, S1
Maeshima, AM1
Hatta, S1
Suzuki, T3
Yuda, S1
Fukuhara, S1
Munakata, W1
Maruyama, D1
Izutsu, K1
Jin, J1
Hou, M1
Hu, J1
Hu, Y1
Ke, X1
Liang, Y1
Liu, T2
Lv, Y1
Ren, H1
Sun, A1
Zhao, C1
Wu, P1
Samp, JC1
Gauthier, G1
Terasawa, E1
Ujjani, C2
Trivedi, N1
Ramzi, P1
Maddy, LE1
O'Brien, DP1
Campbell, PJ1
Follows, G2
Perez, AM1
Musuraca, G1
Delgado, AR1
Galieni, P1
Visco, C1
Amendola, A1
Meneghini, V1
Re, F1
Gonzalez, M2
Cortelezzi, A3
Eyre, TA1
Kennedy, B1
Bowles, KM1
Kopacz, A1
Czyż, J1
Dasanu, CA1
Bosman, P1
Nagler, A2
Niederwieser, D2
Andersen, NS1
Finke, J1
Labussiere-Wallet, H1
Berg, T1
Bunjes, D1
Canepari, ME1
Schaap, M1
Goyal, NG1
Westbrook, TD1
Tomcsányi, J1
Nényei, Z1
Bózsik, B1
Ball, S1
Vutthikraivit, W1
Maiti, A1
Kittai, A2
Amrock, SM1
James, S1
Hoff, S1
Manda, S2
Cohen, JB2
Wanner, D1
Bohn, JP1
Rudzki, J1
Stockhammer, G1
Steurer, M1
Buhimschi, AD1
Armstrong, HA1
Toure, M1
Jaime-Figueroa, S1
Crews, CM1
Clow, F13
Fattizzo, B1
Tonella, T1
Massari, F1
Imbergamo, S1
Bonaldi, L1
Vio, S1
Gregianin, M1
Burei, M1
Harada, K1
Brooks, JP1
Lobo, FM1
Miyakoshi, S1
Nanba, A1
Uchiyama, T1
Kawamoto, K1
Aoki, S2
Reiff, SD1
Muhowski, EM2
Fabian, CA1
Smith, L1
Young, WB2
Johnson, AR2
Liu, L1
Aldana, G1
Jimenez, CA1
Moran, C1
Hsiehchen, D1
Arasaratnam, R1
Raj, K1
Froehlich, T1
Anderson, L1
Shaikh, H2
Khattab, A2
Faisal, MS2
Chilkulwar, A1
Albrethsen, M2
Sadashiv, S1
Fazal, S2
Hess, G1
Chang, S6
Vermeulen, J1
Graef, T4
Barnes, JI1
Divi, V1
Begaye, A1
Wong, R1
Owens, DK1
Goldhaber-Fiebert, JD1
Hoffman, C1
Moran, ME1
Reid, MA1
Whitlow, WT1
Larson, MC1
Kabat, B1
Bowen, D2
Boysen, J1
Krstic, A2
Peña Perez, L1
Berglöf, A2
Meinke, S2
Wang, Q2
Blomberg, KEM1
Kamali-Moghaddam, M1
Shen, Q1
Jaremko, G1
De Paepe, A1
Höglund, P1
Kimby, E4
Månsson, R2
Quach, H2
Maslyak, Z2
Stevens, DA3
Gill, DS1
Handunnetti, S2
Bhavsar, E1
Beach, DF1
Tuncer, HH1
Manukyan, G1
Turcsanyi, P1
Mikulkova, Z1
Gabcova, G1
Gajdos, P1
Smotkova Kraiczova, V1
Zehnalova, S1
Papajik, T1
Kriegova, E1
Konoplev, S2
Zuo, Z1
Venema, R1
Norris, P1
Lazarus, A1
Saenz-de-Viteri, M1
Cudrnak, T1
Lameris, R1
Endstra, S1
Jongejan, A1
Moerland, PD1
de Bruin, RCG1
Remmerswaal, EBM1
Ten Berge, IJM1
Liu, N2
van der Stelt, M1
Faber, LM1
de Gruijl, TD1
van der Vliet, HJ1
Cruz, ND1
Jiang, Y1
Wu, Q1
Feng, S1
Kroll, MH1
Qiao, W1
Nagy, N2
Eyupoglu, E2
Aczél, D2
Csomor, J1
Silva, RS2
Pristupa, A2
Pylypenko, H2
Villa, D2
Panagiotidis, P2
Karlsson, C4
Phelps, C2
Messina, M1
Marinelli, M1
Bonina, S1
Johnson, PW1
Steele, AJ2
Delgado Ramos, GM1
Almaddah, N1
Alsafwah, S1
Jegou, MH1
Maharaj, K1
Powers, JJ1
Achille, A1
Deng, S1
Fonseca, R1
Pabon-Saldana, M1
Quayle, SN1
Jones, SS1
Villagra, A1
Sotomayor, EM1
Sahakian, E1
Kolomeyer, AM1
Hwang, CK1
Kim, BJ1
Namn, Y1
Crawford, C1
McAuley, EM2
Shaffer, AL1
Young, RM2
Kruhlak, MJ1
Staudt, LM2
Hurria, A1
Major-Elechi, B1
Fruth, B1
Kuzma, C1
Patel, KP1
Routbort, M1
Bueso-Ramos, C1
Alhalouli, T1
Khoury, JD1
Luthra, R1
Kantarjian, HM2
Andersson, PO2
Karlsson, K2
Lauri, B2
Norin, S2
Sandstedt, A2
Rosenquist, R3
Späth, F1
Hermansen, JU1
Munthe, LA1
Taskén, K1
Skånland, SS1
Ben-Yehuda, D2
Lih, CJ1
Nogueras-Gonzalez, GM2
Andreeff, M1
Mathew, T1
Kim, HT1
Nicotra, A1
Savell, A1
Francoeur, K1
Bazemore, J1
Stampleman, L1
Maegawa, R1
Rueter, J1
Boruchov, AM1
Arnason, JE1
Jacobson, CA1
Jacobsen, ED2
Fisher, DC1
Estenfelder, S1
Fang, H2
Reichard, KK1
Smoley, SA1
Boudin, L1
Patient, M1
Tsitsi Nding Tsogou, P1
Roméo, E1
Bladé, JS1
de Jauréguiberry, JP1
Akhtar, OS1
Attwood, K1
Lund, I1
Hare, R1
Hernandez-Ilizaliturri, FJ1
Torka, P1
Gounari, M1
Ntoufa, S2
Gerousi, M1
Vilia, MG1
Moysiadis, T1
Kotta, K2
Papakonstantinou, N2
Agathangelidis, A1
Fonte, E1
Ranghetti, P1
Nenou, A1
Xochelli, A1
Muzio, M1
Tobinai, K1
Uchida, T1
Fukuhara, N1
Nishikawa, T1
Ho, AKH1
Koh, XQ1
Liau, MMQ1
Tan, KB1
Tan, CL1
Chui, W1
Worth, LJ1
Thursky, KA1
Younes, A1
Brody, J1
Carpio, C1
Lopez-Guillermo, A2
Ozcan, M1
Avivi, I1
Caballero Barrigón, MD1
Hellmann, A2
Ma, DDF1
Yağci, M1
Horowitz, NA1
Buglio, D1
Streit, M1
Hodkinson, BP1
Alvarez, J1
Ceulemans, R1
Wang, SS1
Fourneau, N1
Grossi, O1
Pineau, S1
Sadot-Lebouvier, S1
Hay, B1
Delaunay, J1
Miailhe, AF1
Bretonnière, C1
Jeddi, F1
Lavergne, RA1
Vladimer, GI1
Taubert, C1
Krall, N1
Pemovska, T1
Araghi, M1
Snijder, B1
Ringler, A1
Runggatscher, K1
de la Fuente, OL1
Hilgarth, M1
Hoermann, G2
Kubicek, S1
Superti-Furga, G1
McCaw, L2
Wang, C1
Bjarnason, G1
Pouvaret, A1
Guery, R1
Montillet, M1
Molina, TJ1
Duréault, A1
Bougnoux, ME1
Galliot, R1
Lanternier, F1
Delarue, R2
Lortholary, O1
Nastoupil, LJ1
Lunning, MA1
Vose, JM1
Flowers, CR1
Purdom, MA1
Fowler, NH2
Gambe, RG1
Sun, J2
Martinez, AZ1
Cartun, ZJ1
Regis, FFD1
Wan, Y3
Brooks, AN1
Taylor-Weiner, A2
Ghia, EM1
Obeng, EA1
Cibulskis, CL1
Neuberg, D2
Campagna, DR1
Fleming, MD1
Ebert, BL1
DeCaprio, JA1
Reed, R1
Carrasco, RD1
Corbingi, A2
Pasquale, R1
McWilliams, EM1
Lucas, CR1
Chen, T1
Harrington, BK2
Campbell, A2
Cheney, CM1
Carson, WE2
Butchar, J1
Tridandapani, S2
Castro, CE1
Lin, T1
Caldeira, D1
Alves, D1
Costa, J1
Ferreira, JJ1
Pinto, FJ1
Morande, PE1
Uriepero, A1
Seija, N1
Berca, C1
Fresia, P1
Landoni, AI1
Di Noia, JM1
Oppezzo, P1
Giovanni, B1
Ibatici, A2
Sola, S1
Brunasso, AMG1
Massone, C1
Vezan, R1
Naydenov, AV1
Taylor, LP1
Shah, A1
Goel, K1
Uchin, J1
Patibandla, SK1
Min, Z1
Bhanot, N1
Basumallik, N1
Geyer, MB1
Rivière, I1
Sénéchal, B1
Purdon, TJ1
Hsu, M1
Devlin, SM1
Halton, E1
Bernal, Y1
van Leeuwen, DG1
Sadelain, M1
Brentjens, RJ1
Manna, A1
Aulakh, S1
Jani, P1
Ahmed, S1
Akhtar, S1
Coignet, M1
Heckman, M1
Meghji, Z1
Bhatia, K1
Sharma, A2
Alegria, V1
Malavasi, F1
Chini, EN1
Paulus, A2
Man, S1
Henley, P1
Ohanyan, H1
Collignon, A1
Gilardin, L1
Dmytruk, N1
Durot, E2
Roos Weil, D1
Béné, MC1
Toussaint, E1
Merabet, F1
Evans, R1
Harasser, M1
El-Kholy, M1
Paredes-Moscosso, SR1
Della Peruta, M1
Nathwani, AC1
Ruan, Y1
Zuo, S1
Xing, Y1
Zhao, X1
Xia, S1
Bai, R1
Du, X1
Ma, CS1
Georgantopoulos, P2
Yang, H1
Norris, LB2
Bennett, CL2
Sollena, P1
Mannino, M1
De Simone, C1
Peris, K1
Fianchi, L1
Criscuolo, M1
Pagano, L1
Diker, O1
Sengar, M1
Gogtay, N1
Jain, H1
Mercier, T1
Maertens, J1
Lavezzi, SM1
Neyens, M1
Bartlett, N1
Ganguly, S1
De Nicolao, G2
Poggesi, I2
Accordi, B1
Bresolin, S1
Basso, G1
Lujan, JV1
Lengerke-Diaz, PA1
Jacobs, C1
Moreno-Cortes, EF1
Ramirez-Segura, CA1
Choi, MY2
McCarthy, C1
Heinen, A1
Castro, JE1
Vijayvargiya, P1
Girmenia, C1
Pane, F1
Tura, S1
Barosi, G1
Slupsky, JR2
Bibikova, E1
Charuworn, P1
Linghu, B1
Tang, PSC1
Ni, A1
Darif, M1
Xing, G1
Mun, Y1
Ferrante, L1
Mobasher, M1
Stark, T1
Reddy, V1
Dreiling, LK1
Bhargava, P1
Best, S1
Bruss, N1
Berger, A1
Sondermann, K1
Gülsaran, SK1
Baysal, M1
Demirci, U1
Baş, V1
Kirkizlar, HO1
Umit, E1
Demir, AM1
Manohar, S1
Bansal, A1
Wanchoo, R1
Sakhiya, V1
Lucia, S1
Jhaveri, KD1
Advani, P1
Galik, B1
Marosvári, D1
Fésüs, V1
Nagy, Á1
Krizsán, S1
Reiniger, L1
Kozma, A1
Ádám, E1
Gyenesei, A1
Iliakis, T1
Pardalis, V1
Bitsani, C1
Vassilakopoulos, TP1
Angelopoulou, M1
Tsaftaridis, P1
Papaioannou, P1
Koudouna, A1
Kalyva, S1
Kyrtsonis, MC1
Panayiotidis, P1
Hanna, KS1
O'Dwyer, M2
Gołos, A1
Fradley, MG1
Gliksman, M1
Emole, J1
Viganego, F1
Rhea, I1
Welter-Frost, A1
Armanious, M1
Lee, DH1
Walko, C1
Shah, B1
Chavez, JC3
McLeod, H1
Schabath, MB1
Ghasoub, R1
Albattah, A1
Elazzazy, S1
Alokka, R1
Nemir, A1
Alhijji, I1
Taha, R1
Chartomatsidou, E1
Rovida, A1
Akritidou, MA1
Belloni, D1
Ferrero, E1
Trangas, T1
Anagnostopoulos, A1
Brock, K1
Muñoz-Vicente, S1
Yates, FJ1
Bishop, R1
Boucher, R1
MacDonald, D1
Fegan, C3
McCaig, A1
Pettitt, A1
Orsini, F1
Truchan Graczyk, M1
Sharif-Askari, B1
Doyon, D1
Paliouras, M1
Aloyz, R1
Frustaci, A1
Efremov, DG3
Gui, F1
Jiang, J1
He, Z1
Deng, Z1
Lu, Y1
Chen, G1
Su, J1
Zhang, YM1
Yun, CH1
Weisberg, E1
Zhang, J2
Deng, X1
Lemal, R4
Buggy, JJ12
Rai, K2
Herman, SE12
Sun, X1
Hsieh, MM1
Raffeld, M1
Chapman, CM1
Chen, J1
Aue, G4
Tisdale, JF1
Pérez-Galán, P2
Singh, K1
Mazumder, S1
Kalaycio, M1
Almasan, A1
Grant, B3
Chang, BY7
Hedrick, E2
Prins, RC1
Burke, RT1
Tyner, JW1
Druker, BJ1
Loriaux, MM1
Sharma, SP1
Cheng, S3
Ma, J3
Guo, A6
Leonard, JP1
Liu, M1
Bojnik, E1
Stefanovski, MR1
Goettl, VM1
Smucker, KA1
Dubovsky, JA3
Towns, WH1
MacMurray, J1
Davis, ME1
Gobessi, S2
Richards, DA1
Bhatt, V1
Alejandro, L1
Michael, A1
Ganetsky, A2
Smucker, K2
Zhong, Y3
Lucas, D1
Williams, K2
Rassenti, L1
Ghia, E1
Flynn, J3
Dias, AL1
Jain, D1
Cameron, F1
Sanford, M1
Guha, M1
Mustafa, RZ3
Gyamfi, JA2
Farooqui, M7
Lipsky, A3
Saba, N3
Martyr, S5
Valdez, J7
Calvo, KR5
Pedersen, LB2
Marti, GE4
Tang, CH1
Ranatunga, S1
Kriss, CL1
Cubitt, CL1
Tao, J1
Pinilla-Ibarz, JA1
Del Valle, JR1
Hu, CC1
Wodarz, D3
Komarova, NL2
James, D4
Porter, DL3
Aschenbrenner, DS1
Setty, M1
Perez, AR2
Racchumi, J1
Xu, G1
Wu, H1
Steggerda, SM2
Leslie, C1
Liu, TM2
Zapatka, M2
Xue, L1
Versele, M1
Dave, SS1
Yilmaz, AS1
Pocock, C1
de Vos, S1
Jones, JJ2
Fardis, M2
McGreivy, J2
Mannis, G1
Wu, D1
Dea, T1
Mauro, T1
Hsu, G1
Zhuang, SH2
Viganò, M2
Mangia, G1
Lampertico, P2
McDermott, J1
Jimeno, A1
Spaargaren, M3
de Rooij, MF3
Koskinas, JS1
Deutsch, M1
Adamidi, S1
Skondra, M1
Tampaki, M1
Alexopoulou, A1
Manolakopoulos, S1
Pectasides, D1
Bruhn, C1
Kamel, S1
Horton, L1
Levade, M1
Burbury, K1
Tan, S1
Cole-Sinclair, M1
Reynolds, J1
Filshie, R1
Schischka, S1
Khot, A1
Sandhu, S2
Nandurkar, H1
Hartmann, E1
Rosin, NY2
Jeyakumar, G1
Cardenas-Turanzas, M1
Lerner, S1
Zacharian, G1
Rosenwald, A1
Smith, DD1
Goldstein, L1
Kunkel, LA1
Dong, S2
Kutok, J1
Da Roit, F1
Engelberts, PJ1
Taylor, RP1
Breij, EC1
Gritti, G1
Introna, M1
Parren, PW1
Beurskens, FJ1
Golay, J1
Buggins, AG1
Jones, CH1
Lee, R1
Marostica, E1
Loury, D1
de Trixhe, XW1
Vermeulen, A1
Advani, R1
Badar, T1
Lee, CS1
Rattu, MA1
Kim, SS1
Mehta, P2
Johnsurd, J1
Govindarajan, R1
Desai, AV1
El-Bakkar, H1
Abdul-Hay, M1
Lin, TS1
Larson, R1
Marcucci, G1
McMullen, JR1
Boey, EJ1
Ooi, JY1
Famà, R1
Ciardullo, C1
Monti, S1
Rossi, F1
D'Agaro, T1
Farooqui, MZ8
Marti, G3
Hughes, TE1
Yuan, C3
Lee, YS4
Arthur, DC1
Childs, R1
Young, NS1
Cervantes-Gomez, F3
George, B1
Dangi-Garimella, S1
Till, KJ1
Pettitt, AR1
Giri, S1
Hahn, A1
Yaghmour, G1
Martin, MG1
Shaw, Y1
Bilotti, E1
Dunbar, N1
Marx-Wood, CR1
Skee, D1
Murphy, J1
Loury, DJ1
Chauhan, V1
Mannaert, E1
Tsang, M1
Conte, M2
Tran, A1
Friedberg, JW1
Kim, ES1
Dhillon, S1
Borah, BJ1
Sanford, DS1
Bergmann, M2
Kuil, A2
Kersten, MJ1
Pals, ST2
Hing, ZA1
Beckwith, KA2
Williams, E1
Faderl, S1
Shpall, E1
Hosing, C1
Khouri, IF1
Champlin, R1
Zhang, SQ1
Smith, SM3
Zhang, SY1
Lynn Wang, Y1
Wang, SY1
Ebert, T1
Jaekel, N1
Schubert, S1
Al-Ali, HK1
Peluso, M1
Fu, M1
Faia, K1
Kutok, JL1
Chamakhi, I1
Toze, C1
Assaily, W1
Robinson, S1
Strattan, E1
Zhang, X3
Spoelstra, SL1
Xargay-Torrent, S2
López-Guerra, M2
Rosich, L2
Montraveta, A2
Roldán, J2
Rodríguez, V1
Villamor, N2
Aymerich, M2
Lagisetti, C1
Webb, TR1
López-Otín, C1
Campo, E2
Colomer, D2
Hamasy, A1
Smith, CI1
Nagar, V1
Stefanos, M1
Munneke, B1
West, JS1
Neuenburg, JK1
Hall, N1
Thieblemont, C2
Rhein, C1
Stingo, F1
Smith, SC1
Rogers, M1
Wotherspoon, A1
Grisafi, D1
Maestro, A1
Grumi, C1
Piazzoni, L1
Tirone, G1
Fiore, W1
Tessari, R1
Gianardi, V1
Gatti, M1
Tasca, F1
Generali, D1
Ravelli, A1
Lanza, F1
Scaglione, F1
de Claro, RA1
McGinn, KM1
Verdun, N1
Lee, SL1
Chiu, HJ1
Saber, H1
Brower, ME1
Chang, CJ1
Pfuma, E1
Habtemariam, B1
Bullock, J1
Nie, L1
Chen, XH1
Lu, DR1
Al-Hakim, A1
Kane, RC1
Kaminskas, E1
Justice, R1
Farrell, AT1
Pazdur, R1
Skarzynski, M1
Salem, D2
Gunti, S1
Kardava, L1
Moir, S1
Notkins, AL1
Gayko, U1
Fung, M1
Faust, E1
Price, S1
Doyle, M1
Bari, S1
Dietrich, MF1
Collins, RH1
Gerber, DE1
Lipsky, AH1
Cullinane, AM1
Nghiem, K1
Uzel, G1
Holland, SM1
Lozier, JN1
Boissard, F1
Fournié, JJ1
Poupot, M1
Khan, K1
Malik, AI1
Almarzouqi, SJ1
Morgan, ML1
Yalamanchili, S1
Chevez-Barrios, P1
Lee, AG1
Patel, V1
Bingman, A1
Goede, V2
Thirdborough, SM1
Valle-Argos, B1
Linley, A1
Krysov, S1
Hidalgo, MS1
Leonard, E1
Ishfaq, M1
Wagner, SD1
Willis, AE1
Coldwell, MJ1
Ave, E1
Lessi, F1
Giorgi, CA1
Castelli, M1
Zambello, R1
Davies, N1
Oldreive, C1
Petermann, E1
Stewart, G1
Brown, J1
Lau, A1
Taylor, M1
Ren, L1
Gautam, S1
Elavazhagan, S1
Fatehchand, K1
Stiff, A1
Reader, BF1
Butchar, JP1
Suri, D1
Brower, V1
Gomez-Rodriguez, J1
Biancotto, A1
Braylan, RC1
Lee-Vergés, E1
Jiménez, L1
Cabezas, S1
Clot, G1
Pinyol, M1
Arimany-Nardí, C1
Roué, G2
Pastor-Anglada, M1
Islam, P1
Strelec, L1
Kaye, AH1
Brooks, S1
Nasta, S1
de Jésus Ngoma, P1
Kabamba, B1
Dahlqvist, G1
Sempoux, C1
Lanthier, N1
Shindano, T1
Horsmans, Y1
Galanina, N2
Link, CS1
Teipel, R1
Heidenreich, F1
Rücker-Braun, E1
Schmiedgen, M1
Reinhardt, J1
Oelschlägel, U1
von Bonin, M1
Middeke, JM1
Muetherig, A1
Trautmann-Grill, K1
Platzbecker, U1
Bornhäuser, M1
Foluso, O1
Glick, A1
Stender, M1
Jaiyesimi, I1
Patel, PR1
Ruella, M1
Zheng, Z1
Barrett, DM1
Lacey, SF1
McGettigan, SE1
Cook, DR1
Hulitt, J1
Kudchodkar, SB1
Cogdill, AP1
Gill, S1
Levine, BL1
Dougé, A1
Ravinet, A1
Bay, JO1
Guièze, R1
Kimber, T1
Shumilov, E1
Ströbel, P1
Hasenkamp, J1
Hellige, N1
Bleckmann, A1
Haase, D1
Braulke, F1
Jung, W1
Schanz, J1
Binder, M2
Trümper, L1
Bacher, U1
Malcikova, J1
Vela, CM1
McBride, A1
Bitar, C1
Bray, A1
Cowen, EW1
Sicre de Fontbrune, F1
Pannetier, M1
Michonneau, D1
Socié, G1
Peffault De Latour, R1
Wanquet, A2
Birsen, R2
Hunault, M1
Cavazzini, F1
Formigaro, L1
Konoplev, SN1
Yigit, B1
Halibozek, PJ1
O'Keeffe, MS1
Arnason, J1
Avigan, D1
Bhan, A1
Cen, O1
Longnecker, R1
Wang, N1
Engel, P1
Terhorst, C1
Mulvey, JJ1
Nuovo, GJ1
Magro, CM1
Damon, LE1
Li, PP1
Lu, K1
Geng, LY1
Zhou, XX1
Li, XY1
Bojarczuk, K1
Sasi, BK1
Tucker, DL1
Mihailescu, L1
Riordan, R1
Kumar Patel, V1
Sarosiek, K1
Stewart, C1
Dubuc, AM1
Fraser, C1
Han, Y1
Zou, L1
Sougnez, C1
Carter, SL1
Cibulskis, K1
Zenz, T1
Werner, L1
Dal Cin, P1
Kharchencko, P1
Lander, E1
Gabriel, S1
Letai, A2
Weitz, DA1
Nowak, MA1
Schliffke, S1
Akyüz, N1
Ford, CT1
Mährle, T1
Thenhausen, T1
Krohn-Grimberghe, A1
Knop, S1
Bokemeyer, C1
Manzoni, D1
Catallo, R1
Chebel, A1
Roualdes, O1
Magaud, JP1
Ffrench, M1
Hallek, MJ1
Lee, HJ1
Gallardo, M1
Ma, H1
Larsson, CA1
Mejia, A1
Hornbaker, MJ1
Qi, Y1
Su, X1
Pageon, LR1
Quintas-Cardama, A1
Post, SM1
Oppermann, S1
Ylanko, J1
Hariharan, S1
Oakes, CC1
Brauer, PM1
Zúñiga-Pflücker, JC1
Leber, B1
Andrews, DW1
Chan, KL1
Lokan, J1
Prince, HM1
Marini, BL1
Samanas, L1
Perissinotti, AJ1
Colombatti, A1
Saleh, LM1
Anastas, V1
Barber, E1
Corrigan-Cummins, M1
Sarasua, SM1
Zhao, Z1
Abousamra, NK1
Elbaz, O1
Abdelghaffar, HA1
Lutz, M1
Schulze, AB1
Rebber, E1
Wiebe, S1
Zoubi, T1
Grauer, OM1
Keßler, T1
Kerkhoff, A1
Lenz, G1
Berdel, WE1
Pavlasova, G1
Cerna, K1
Osickova, J1
Calogero, R1
Jerussi, T1
Gea-Banacloche, J1
Couzens, L1
Eichelberger, MC1
Walliser, C1
Hermkes, E1
Schade, A1
Wiese, S1
Deinzer, J1
Désiré, L1
Gierschik, P1
Kohli, PB1
Katewa, A1
Gogol, E1
Belmont, LD1
Choy, R1
Penuel, E1
Burton, L1
Eigenbrot, C1
Yu, C1
Ortwine, DF1
Bowman, K1
Franke, Y1
Estevez, A1
Mortara, K1
Li, H1
Lin, M1
Bergeron, P1
Crawford, JJ1
Tsui, ST1
Strelec, LE1
Vandegrift, A1
Fitzpatrick, DM1
Feldman, T1
Kaur, G1
Porter, D1
Evens, AM1
Audrito, V1
Grisendi, G1
Ward, CM1
Whalley, D1
Hilmer, SN1
Al Nawakil, C1
Goudot, FX1
Meune, C1
Kadri, S1
Van Slambrouck, C1
Long, B1
Ming, M1
Furtado, LV1
Segal, JP1
Stock, W1
Tang, WJ1
Karouzakis, P1
Thirman, MJ1
Ilhan, O1
Stevens-Brogan, M1
Berger, JR1
Sartor, O1
Carson, KR1
Hrushesky, WJ1
Raisch, DW1
Armitage, JO1
Voltan, R1
Rimondi, E1
Melloni, E1
Casciano, F1
Arcidiacono, MV1
Celeghini, C1
Zauli, G1
Secchiero, P1
Gozzetti, A1
Candi, V1
Brambilla, CZ1
Papini, G1
Fabbri, A1
Bocchia, M1
Sławińska, M1
Barańska-Rybak, W1
Sobjanek, M1
Wilkowska, A1
Mital, A1
Nowicki, R1
Reinhardt, HC1
Koffman, B1
Schorr, A1
Jeyakumar, D1
El-Asmar, J1
Hamadani, M1
Ayala, E1
Poole, A1
Girard, N1
Clayton, F1
Tantravahi, SK1
Goldschmidt, N1
Rund, D1
Bottoni, A1
Rizzotto, L1
Lai, TH1
Reiff, S1
El-Gamal, D1
Issara, K1
Yossi, S1
Caraivan, I1
Ryan, CE1
Sahaf, B1
Logan, AC1
Dyer, MJ1
Rezvani, AR1
Miklos, DB1
Merten, JA1
Bartoo, GT1
Leis, J1
Hussaini, MO1
Rehman, A1
Horna, P1
Bonnet, C1
Boubaya, M1
Choquet, S1
Re, D1
Fahri, J1
Lamy, T1
Troussard, X1
Dietrich, PY1
Noseworthy, PA1
Chen, L1
Cui, B1
Zhang, L1
Widhopf Ii, GF1
Kazianka, L1
Drucker, C1
Thomas, W1
Melchardt, T1
Struve, S1
Einberger, C1
Heinz, M1
Hauswirth, A1
Raderer, M1
Pabinger, I1
Quehenberger, P1
Jilma, B1
Quintela, A1
Sujobert, P1
Farber, CM1
Mahadevan, D1
Brooks, HD1
Fanning, S1
Klein, L1
Greenwald, DR1
Katchman, H1
Sorensen, S1
Trambitas, C1
Robins, H1
Yusko, E1
Vignali, M1
Coffey, G1
Conley, P1
Pandey, A1
Deeks, ED1
Deng, J1
Isik, E1
Mikudina, B1
Goodall, M1
Adler, AI1
Li, KW1
Amer, AM1
Hellerstein, MK1
Turner, SM1
Emson, CL1
Yan, XJ1
Kreiniz, N1
Bejar, J1
Plascencia, C1
Chan, TS1
Au-Yeung, R1
Chim, CS1
Wong, SC1
Kwong, YL1
Compagno, M1
Pighi, C1
Cheong, TC1
Meng, FL1
Poggio, T1
Yeap, LS1
Karaca, E1
Blasco, RB1
Langellotto, F1
Ambrogio, C1
Voena, C1
Kasar, SN1
Gostissa, M1
Alt, FW1
Chiarle, R1
Albitar, A1
Ma, W1
DeDios, I1
Estella, J1
Ahn, I1
Albitar, M1
Banerjee, R1
Glynn, RJ1
Walewska, R1
Savage, KJ1
Michaud, GF1
Moslehi, JJ1
Loscertales Pueyo, J1
Giraldo, P1
Martínez, R1
Piggin, A1
Bayly, E1
Mądro, E1
Piotrowska, M1
Drozd-Sokołowska, J1
Kyrcz-Krzemień, S1
Hałka, J1
Wieszczy, P1
Vojdeman, FJ1
Kirkby, N1
van T' Veer, MB1
Itälä-Remes, MA1
Wu, KL1
Alemayehu, WG1
Wittebol, S1
Kozak, T1
Walewski, J1
Abrahamse-Testroote, MCJ1
van Oers, MHJ1
Lee, A1
Imlay-Gillespie, L1
Mulligan, S1
Shumack, S1
Campidelli, A1
Lequeu, H1
Jerkeman, M1
Dreyling, M1
Staudt, L1
Fabian, C1
Yeh, P1
Hunter, T1
Sinha, D1
Ftouni, S1
Wallach, E1
Jiang, D1
Chan, YC1
Wong, SQ1
Silva, MJ1
Vedururu, R1
Doig, K1
Lam, E1
Arnau, GM1
Semple, T1
Wall, M1
Zivanovic, A1
Agarwal, R1
Petrone, P1
Jones, K1
Westerman, D1
Papenfuss, AT1
Dawson, MA1
Dawson, SJ1
Merle-Béral, H1
Barbier, S1
Bras, M1
Sarfati, M1
Susin, SA1
Gordon, AL1
Ramanunni, A1
Ponader, S1
Geest, CR1
Winer, ES1
Ingham, RR1
Castillo, JJ1
Advani, RH1
Boyd, TE1
Rodriguez, S1
Lindemalm, S1
Liliemark, J1
Juliusson, G1
Larsson, R1
Albertioni, F1
Moshynska, O1
Moshynskyy, I1
Misra, V1
Saxena, A1
Zilioli, VR1
Fantini, NN1
Pasquini, MC1
Deliliers, GL1
Colombo, M1

Clinical Trials (75)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT02910583]Phase 2323 participants (Actual)Interventional2016-09-28Active, not recruiting
A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia Patients With Risk of Early Disease Progr[NCT02863718]Phase 3515 participants (Actual)Interventional2014-04-30Completed
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487]Phase 3269 participants (Actual)Interventional2013-03-31Completed
A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia o[NCT02264574]Phase 3229 participants (Actual)Interventional2014-10-06Completed
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)[NCT02048813]Phase 3529 participants (Actual)Interventional2014-02-20Active, not recruiting
A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion[NCT01500733]Phase 286 participants (Actual)Interventional2012-01-05Active, not recruiting
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)[NCT01724346]Phase 3232 participants (Actual)Interventional2012-08-28Completed
A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma[NCT02303392]Phase 134 participants (Actual)Interventional2015-03-11Active, not recruiting
A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations[NCT03226301]Phase 2230 participants (Anticipated)Interventional2017-06-23Active, not recruiting
Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors[NCT05643235]50 participants (Anticipated)Interventional2022-11-01Recruiting
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707]Phase 3391 participants (Actual)Interventional2012-06-30Completed
Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma:a Single-center, Open-label, Pragmatic Clinical Trial[NCT05020392]Phase 324 participants (Anticipated)Interventional2021-09-14Recruiting
Prospective, Open-label, Multicentre Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Ofatumumab and Ibrutinib Followed by Ibrutinib and Ofatumumab Maintenance in CLL Patients[NCT02689141]Phase 266 participants (Actual)Interventional2016-02-04Completed
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT03734016]Phase 3652 participants (Actual)Interventional2018-11-01Active, not recruiting
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069]Phase 2199 participants (Actual)Interventional2010-06-30Completed
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]Phase 1/Phase 2133 participants (Actual)Interventional2010-05-31Completed
Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment.[NCT02824159]121 participants (Actual)Observational2016-04-30Completed
A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in [NCT02950051]Phase 3926 participants (Actual)Interventional2016-12-13Active, not recruiting
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic[NCT01611090]Phase 3578 participants (Actual)Interventional2012-09-19Completed
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)[NCT02427451]Phase 1/Phase 287 participants (Actual)Interventional2015-08-03Active, not recruiting
A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy[NCT03301207]Phase 125 participants (Actual)Interventional2017-10-20Completed
A Phase I/II Trial of Ruxolitinib (Jakafi) in Patients With Chronic Lymphocytic Leukemia Who Are Unfit for Conventional First-line Therapy Due to Age or 17p Deletions[NCT02015208]Phase 1/Phase 213 participants (Actual)Interventional2014-04-30Completed
A Phase I/II Trial of Ruxolitinib in Chronic Lymphocytic Leukemia Patients at Risk for Progression on Ibrutinib[NCT02912754]Phase 1/Phase 236 participants (Anticipated)Interventional2017-03-31Not yet recruiting
"Phase II, Multicenter, Trial, Exploring Chemo-free Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup"[NCT02666898]Phase 2135 participants (Actual)Interventional2015-10-31Completed
A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)[NCT02301156]Phase 3126 participants (Actual)Interventional2015-01-27Completed
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy[NCT02717611]Phase 260 participants (Actual)Interventional2016-03-08Active, not recruiting
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and Ibrutinib (BIG) Followed by GA101 and Ibrutinib Maintenance in CLL Patients (CLL2-BIG Protocol)[NCT02345863]Phase 266 participants (Actual)Interventional2015-01-16Completed
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and ABT-199 Followed by ABT-199 and GA101 Maintenance in CLL Patients[NCT02401503]Phase 266 participants (Actual)Interventional2015-05-06Active, not recruiting
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)[NCT02756897]Phase 2234 participants (Actual)Interventional2016-07-07Active, not recruiting
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)[NCT01886872]Phase 3547 participants (Actual)Interventional2013-12-09Active, not recruiting
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia[NCT02477696]Phase 3533 participants (Actual)Interventional2015-07-28Active, not recruiting
Prospective Economic Analysis: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib + Rituximab vs Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)[NCT02414022]55 participants (Actual)Observational2015-04-15Active, not recruiting
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]40 participants (Actual)Observational [Patient Registry]2018-12-01Completed
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)[NCT02332980]Phase 265 participants (Actual)Interventional2015-02-19Completed
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia[NCT02029443]Phase 1/Phase 2306 participants (Actual)Interventional2014-01-30Active, not recruiting
A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)[NCT01589302]Phase 2154 participants (Actual)Interventional2012-05-21Active, not recruiting
Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia[NCT00281983]Phase 1/Phase 2100 participants (Actual)Interventional2000-06-30Completed
A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis[NCT03529955]Phase 28 participants (Actual)Interventional2018-06-12Completed
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy[NCT02141282]Phase 2127 participants (Actual)Interventional2014-09-10Completed
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents[NCT03816683]229 participants (Actual)Observational2019-04-01Active, not recruiting
A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma[NCT05014100]Phase 255 participants (Anticipated)Interventional2021-09-01Not yet recruiting
A Phase I Study of Lenalidomide in Combination With Rituximab and Ibrutinib in Relapsed and Refractory CLL and SLL[NCT02200848]Phase 15 participants (Actual)Interventional2014-04-30Terminated (stopped due to Recruitment difficulties and toxicity)
A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)[NCT02801578]Phase 2/Phase 311 participants (Actual)Interventional2016-07-06Completed
A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment[NCT04059081]Phase 231 participants (Anticipated)Interventional2019-07-09Recruiting
Ibrutinib vs Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed (CLL)[NCT02007044]Phase 2208 participants (Anticipated)Interventional2013-12-06Active, not recruiting
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies[NCT02268851]Phase 145 participants (Actual)Interventional2014-11-30Active, not recruiting
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies[NCT02329847]Phase 1/Phase 2144 participants (Actual)Interventional2015-03-11Completed
A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.[NCT02006485]Phase 1160 participants (Actual)Interventional2013-12-13Completed
A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19[NCT00466531]Phase 1/Phase 250 participants (Actual)Interventional2007-03-21Active, not recruiting
A Phase 2 Study of MRD Adapted Therapy With Venetoclax-obinutuzumab in Patients With High or Intermediate BALL Risk Relapsed or Refractory CLL, With Addition of Acalabrutinib in Patients Who Fail to Achieve MRD Eradication[NCT04560322]Phase 240 participants (Anticipated)Interventional2020-10-19Recruiting
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]Phase 1/Phase 22 participants (Actual)Interventional2019-04-11Terminated (stopped due to Insufficient accrual)
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]Phase 322 participants (Actual)Interventional2019-12-09Active, not recruiting
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236]Phase 127 participants (Actual)Interventional2015-06-18Active, not recruiting
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947]Phase 23 participants (Actual)Interventional2018-12-01Completed
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895]40 participants (Actual)Observational2017-07-21Active, not recruiting
Expression of CD19 Complex in Lymphoproliferative Disorders[NCT04734470]92 participants (Anticipated)Observational2021-03-31Not yet recruiting
A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients[NCT01520519]Phase 240 participants (Actual)Interventional2012-02-27Completed
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma[NCT01236391]Phase 2115 participants (Actual)Interventional2011-02-28Completed
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma[NCT00849654]Phase 166 participants (Actual)Interventional2009-02-28Completed
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias[NCT02580552]Phase 166 participants (Actual)Interventional2016-02-09Completed
Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097]Phase 215 participants (Anticipated)Interventional2022-10-30Not yet recruiting
Zanubrutinib in Relapsed or Refractory Warm Autoimmune Hemolytic Anemia: a Prospective Cohort Study[NCT05922839]Phase 222 participants (Anticipated)Interventional2023-06-30Not yet recruiting
An Open-Label, Sequential and 2-Way Crossover Pharmacokinetic Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Subjects[NCT01866033]Phase 18 participants (Actual)Interventional2013-06-30Completed
Open-Label, Randomized, 4-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765[NCT01820936]Phase 152 participants (Actual)Interventional2013-03-31Completed
A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01292135]Phase 133 participants (Actual)Interventional2011-02-28Completed
An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia[NCT01217749]Phase 1/Phase 271 participants (Actual)Interventional2010-12-31Completed
Exploring Patient Experiences of Individuals Joining Chronic Lymphocytic Leukemia Clinical Trials[NCT05899543]500 participants (Anticipated)Observational2024-07-31Not yet recruiting
Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)[NCT01747486]Phase 242 participants (Actual)Interventional2013-01-02Completed
The Roles of Education and Patient Engagement to Improve Symptom Management and the Quality of Life for Patients With Chronic Lymphocytic Leukemia[NCT03231579]85 participants (Actual)Observational2017-07-21Completed
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)[NCT02514083]Phase 229 participants (Actual)Interventional2015-12-09Active, not recruiting
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK (Bruton Tyrosine Kinase) or PI3K-Delta (Phosphoinositide-3-kinase) Inhibitor Therapy[NCT02742090]Phase 251 participants (Actual)Interventional2016-04-21Completed
An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17)[NCT01744691]Phase 2145 participants (Actual)Interventional2013-01-31Completed
A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)[NCT01752426]Phase 1/Phase 230 participants (Actual)Interventional2012-12-17Completed
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725]Phase 114 participants (Actual)Interventional2019-08-29Active, not recruiting
Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria.[NCT03868722]Phase 2/Phase 3212 participants (Anticipated)Interventional2019-10-11Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate

CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD up to primary analysis data cutoff date of 15 December 2020. Median follow-up time was 27.9 months at the time of the primary analysis.

Interventionpercentage of participants (Number)
FD Cohort, Non-Del 17p Population: All Treated55.9
FD Cohort: All Treated55.3

FD Cohort: DOR

Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 24 months landmark time was presented. (NCT02910583)
Timeframe: From initial documentation of a response, until PD or death from any cause, whichever occurs first. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).

Interventionpercentage of participants (Number)
FD Cohort, Non-Del 17p Population: All Treated96.1
FD Cohort: All Treated94.7

FD Cohort: Kaplan-Meier Estimate of OS Rate at 24 Months Landmark Time

OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of OS rate at 24 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to time of death. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).

Interventionpercentage of participants (Number)
FD Cohort, Non-Del 17p Population: All Treated97.7
FD Cohort: All Treated98.1

FD Cohort: Kaplan-Meier Estimate of PFS Rate at 24 Months Landmark Time

PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of PFS rate at 24 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).

Interventionpercentage of participants (Median)
FD Cohort, Non-Del 17p Population: All Treated96.2
FD Cohort: All Treated94.8

FD Cohort: ORR

ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD up to primary analysis data cutoff date of 15 December 2020. Median follow-up time was 27.9 months at the time of the primary analysis.

Interventionpercentage of participants (Number)
FD Cohort, Non-Del 17p Population: All Treated95.6
FD Cohort: All Treated96.2

FD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)

TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) < 5 cm AND absolute lymphocyte count (ALC) < 25 x 10^9/L; Medium=Any LN 5 cm to < 10 cm OR ALC ≥ 25 x 10^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10^9/L AND any LN ≥ 5 cm. (NCT02910583)
Timeframe: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).

Interventionpercentage of participants (Number)
FD Cohort: All Treated94.1

MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants

DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia [IWCLL] criteria [Halleck et al]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time. (NCT02910583)
Timeframe: 1 year after randomization

Interventionpercentage of participants (Number)
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)100.0
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)95.3

MRD Cohort: CRR (CR/CRi Rate)

CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).

Interventionpercentage of participants (Number)
MRD Cohort: All Treated62.8
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)72.1
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)60.5
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib74.2
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax56.3

MRD Cohort: Duration of Response (DOR)

Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of DOR at 36 months landmark time was presented. (NCT02910583)
Timeframe: From initial documentation of a response, until PD or death from any cause, whichever occurs first. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).

Interventionpercentage of participants (Number)
MRD Cohort: All Treated94.7
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)100.0
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)95.3
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib96.7
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax96.7

MRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 36 Months Landmark Time

OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of OS rate at 36 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).

Interventionpercentage of participants (Number)
MRD Cohort: All Treated99.4
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)100.0
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)100.0
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib96.7
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax100.0

MRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 36 Months Landmark Time

PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of PFS rate at 36 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).

Interventionpercentage of participants (Number)
MRD Cohort: All Treated95.6
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)100.0
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)95.3
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib96.7
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax96.7

MRD Cohort: Overall Response Rate (ORR)

ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).

Interventionpercentage of participants (Number)
MRD Cohort: All Treated97.0
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)100.0
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)100.0
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib100.0
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax100.0

MRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax)

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

Interventionng/mL (Geometric Mean)
MRD Cohort: All Treated88.5

MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F)

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

InterventionL/h (Geometric Mean)
MRD Cohort: All Treated833

MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz)

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

Intervention1/h (Geometric Mean)
MRD Cohort: All Treated0.132

MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

Interventionng*h/mL (Geometric Mean)
MRD Cohort: All Treated48993

MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

InterventionL/h (Geometric Mean)
MRD Cohort: All Treated8.16

MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

Interventionng/mL (Geometric Mean)
MRD Cohort: All Treated3034

MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

Interventionhours (Median)
MRD Cohort: All Treated6.00

MRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)

TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) < 5 cm AND absolute lymphocyte count (ALC) < 25 x 10^9/L; Medium=Any LN 5 cm to < 10 cm OR ALC ≥ 25 x 10^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10^9/L AND any LN ≥ 5 cm. (NCT02910583)
Timeframe: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).

Interventionpercentage of participants (Number)
MRD Cohort: All Treated90.0

FD Cohort: MRR

MRR is defined as the percentage of participants who achieve MRD-negativity in either peripheral blood (PB) or bone marrow (BM) and achieve confirmed clinical response PR or better per 2008 IWCLL criteria (Halleck et al.). MRD-negativity is defined as <1 CLL cell per 10,000 leukocytes (<1 x 10^4), as assessed by flow cytometry of a PB or BM aspirate sample. Confirmed MRD-negative response for randomization purposes requires MRD-negativity serially over at least 3 cycles, with negativity in both BM and PB. (NCT02910583)
Timeframe: From randomization date until before any reintroduced treatment. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).

,
Interventionpercentage of participants (Number)
BM or PBBMPB
FD Cohort, Non-Del 17p Population: All Treated78.761.876.5
FD Cohort: All Treated78.659.776.7

FD Cohort: Percentage of Participants With TEAEs, Treatment-Emergent SAEs, and Discontinuations Due to TEAEs

An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization >24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug. (NCT02910583)
Timeframe: From first dose until 30 days following last dose of study drug (up to data cutoff date of 15 Dec 2020). Treatment duration for the FD cohort was 13.3 months for ibrutinib and 11.1 for venetoclax.

Interventionpercentage of participants (Number)
Any TEAEAny Grade >=3 TEAEAny Ibrutinib (Ibr)-Related TEAEAny Grade >=3 Ibrutinib-Related TEAEAny Venetoclax (Ven)-Related TEAEAny Grade >=3 Venetoclax-Related TEAEAny TEAE Leading to Ibr or Ven DiscontinuationAny TEAE Leading to Ibr or Ven Discontinuation: Ibr OnlyAny TEAE Leading to Ibr or Ven Discontinuation: Ven OnlyAny TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and VenAny TEAE Leading to Ibr or Ven Dose ReductionAny TEAE Leading to Ibr Only Dose ReductionAny TEAE Leading to Ven Only Dose ReductionAny TEAE Leading to Both Ibr and Ven Dose ReductionAny SAEAny Grade >= 3 SAEAny SAE Related to Ibr or VenAny Ibr-related SAEAny Ven-related SAEFatal TEAEMajor Hemorrhage TEAEGrade >= 3 Major Hemorrhage TEAEMajor Hemorrhage SAE
FD Cohort: All Treated99.462.392.544.784.344.75.03.101.920.85.711.33.822.619.513.211.38.20.61.91.31.3

MRD Cohort: MRD-Negativity Rate (MRR)

"MRR is defined as the percentage of participants who achieve MRD-negativity in either peripheral blood (PB) or bone marrow (BM) and achieve confirmed clinical response PR or better per 2008 IWCLL criteria (Halleck et al.). MRD-negativity is defined as <1 CLL cell per 10,000 leukocytes (<1 x 10^4), as assessed by flow cytometry of a PB or BM aspirate sample. Confirmed MRD-negative response for randomization purposes requires MRD-negativity serially over at least 3 cycles, with negativity in both BM and PB.~This rate is calculated in the uMRD Not Confirmed randomized population during the period from randomization date and before any reintroduced treatment." (NCT02910583)
Timeframe: From randomization date until before any reintroduced treatment. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).

,,,
Interventionpercentage of participants (Number)
PB or BMBMPB
MRD Cohort: All Treated81.176.879.3
MRD Cohort/uMRD Not Confirmed: All Participants63.554.058.7
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib51.641.948.4
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax75.065.668.8

MRD Cohort: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Discontinuations Due to TEAEs

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization >24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug. (NCT02910583)
Timeframe: From first dose until 30 days following last dose of study drug (up to data cutoff date of 15 Dec 2020). Treatment duration for the MRD cohort was 28.7 months for ibrutinib and 15.4 for venetoclax.

,,,,
Interventionpercentage of participants (Number)
Any TEAEAny Grade >=3 TEAEAny Ibrutinib (Ibr)-Related TEAEAny Grade >=3 Ibrutinib-Related TEAEAny Venetoclax (Ven)-Related TEAEAny Grade >=3 Venetoclax-Related TEAEAny TEAE Leading to Ibr or Ven DiscontinuationAny TEAE Leading to Ibr or Ven Discontinuation: Ibr OnlyAny TEAE Leading to Ibr or Ven Discontinuation: Ven OnlyAny TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and VenAny TEAE Leading to Ibr or Ven Dose ReductionAny TEAE Leading to Ibr Only Dose ReductionAny TEAE Leading to Ven Only Dose ReductionAny TEAE Leading to Both Ibr and Ven Dose ReductionAny SAEAny Grade >= 3 SAEAny SAE Related to Ibr or VenAny Ibr-related SAEAny Ven-related SAEFatal TEAEMajor Hemorrhage TEAEGrade >= 3 Major Hemorrhage TEAEMajor Hemorrhage SAE
MRD Cohort: All Treated100.073.894.557.980.544.512.87.31.24.324.414.65.54.331.126.218.315.95.50.62.41.82.4
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)100.079.193.055.886.051.24.72.32.3020.914.04.72.327.925.616.311.64.702.32.32.3
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)100.065.193.048.876.734.9000023.39.311.62.318.616.311.69.37.00000
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib100.071.096.861.380.645.29.79.70022.616.106.535.529.022.619.49.73.23.23.23.2
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax100.075.093.862.596.956.312.53.109.431.321.93.16.337.528.118.818.83.106.33.16.3

MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Area Under the Plasma Concentration-Time Curve (AUC) Over the Last 24-hour Dosing Interval (AUC0-24h); AUC From Time Zero to the Time of Last Quantifiable Concentration (AUClast)

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

Interventionng*h/mL (Geometric Mean)
AUC0-24hAUClast
MRD Cohort: All Treated504480

MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Time to Cmax (Tmax); Time of Last Measurable Concentration (Tlast); Terminal Elimination Half-Life (t1/2,Term)

(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

Interventionhours (Median)
tmaxtlastt1/2term
MRD Cohort: All Treated2.0024.05.30

ORR (Overall Response Rate)

ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Interventionpercentage of participants (Number)
Ibrutinib82.4
Chlorambucil35.3

Overall Survival (OS)

OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionMonths (Median)
IbrutinibNA
ChlorambucilNA

PFS (Progression Free Survival)

"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionMonths (Median)
IbrutinibNA
Chlorambucil18.9

Proportion of Sustained Hemoglobin Improvement

The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib45.6
Chlorambucil20.3

Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia

In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib84.3
Chlorambucil45.5

Proportion of Sustained Platelet Improvement

The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib27.2
Chlorambucil11.3

Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib77.1
Chlorambucil42.9

Final Analysis: ORR Based on Investigator Assessment

ORR, defined as the percentage of participants achieving a best overall response of protocol-specified CR, CRi, nPR or PR per investigator assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate. (NCT02264574)
Timeframe: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

Interventionpercentage of participants (Number)
IBR+OB91.2
CLB+OB81.0

Final Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 48

"OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive.~As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 48 [final analysis]) are presented." (NCT02264574)
Timeframe: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).

Interventionpercentage of participants (Number)
IBR+OB80.5
CLB+OB81.3

Final Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48

"PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease.~As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented." (NCT02264574)
Timeframe: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).

Interventionpercentage of participants (Number)
IBR+OB74.0
CLB+OB22.0

Final Analysis: PFS in High-Risk Population (del17p/TP53 Mutation/Del 11q/Unmutated Immunoglobulin Heavy Chain Variable Region [IGHV]) Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48

"PFS was analyzed within the high-risk population of participants with del17p or TP53 mutation or del 11q or IGHV unmutated at baseline per central lab results. PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease.~As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented." (NCT02264574)
Timeframe: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).

Interventionpercentage of participants (Number)
IBR+OB70.3
CLB+OB8.0

Final Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response

Percentage of participants who achieved MRD-negative response, defined as < 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders. (NCT02264574)
Timeframe: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

Interventionpercentage of participants (Number)
IBR+OB24.8
CLB+OB17.2

Final Analysis: Rate of Sustained Hemoglobin Improvement

Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase ≥ 2 g/dL over baseline continuously for ≥ 56 days without blood transfusions or growth factors. (NCT02264574)
Timeframe: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

Interventionpercentage of participants (Number)
IBR+OB44.2
CLB+OB44.0

Final Analysis: Rate of Sustained Platelet Improvement

Percentage of participants with platelet counts increase ≥ 50% over baseline continuously for ≥ 56 days without blood transfusion or growth factors. (NCT02264574)
Timeframe: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

Interventionpercentage of participants (Number)
IBR+OB30.1
CLB+OB14.7

Primary Analysis: Overall Response Rate (ORR) Based on IRC Assessment

ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), or partial response (PR) per IRC assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

Interventionpercentage of participants (Number)
IBR+OB88.5
CLB+OB73.3

Primary Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 30

"OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive.~As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier landmark estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 30 [primary analysis]) are presented." (NCT02264574)
Timeframe: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).

Interventionpercentage of participants (Number)
IBR+OB85.5
CLB+OB84.9

Primary Analysis: PFS in High-Risk Sub-Population (del17p/TP53 Mutation/Del 11q) Based on IRC Assessment - Kaplan Meier Landmark Estimates at Month 30

"PFS was analyzed within the high-risk sub-population of participants with del17p or TP53 mutation or del 11q at baseline per central lab results. PFS was defined as time from the date randomization to the date of first IRC-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease.~As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented." (NCT02264574)
Timeframe: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).

Interventionpercentage of participants (Number)
IBR+OB82.4
CLB+OB14.1

Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30

"PFS was defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease.~The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented." (NCT02264574)
Timeframe: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).

Interventionpercentage of participants (Number)
IBR+OB78.5
CLB+OB31.1

Primary Analysis: Rate of Clinically Meaningful Improvement in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EuroQol Five-Dimension (EQ-5D-5L)

Percentage of participants with EQ-5D-5L utility score increase ≥ 0.08 points over baseline at or prior to initiation of subsequent antineoplastic therapy. The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life, comprising 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. Participants with missing EQ-5D-5L data were considered not achieving clinically meaningful improvement. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

Interventionpercentage of participants (Number)
IBR+OB54.9
CLB+OB56.0

Primary Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response

Percentage of participants who achieved MRD-negative response, defined as < 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

Interventionpercentage of participants (Number)
IBR+OB20.4
CLB+OB17.2

Primary Analysis: Rate of Sustained Hemoglobin Improvement

Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase ≥ 2 g/dL over baseline continuously for ≥ 56 days without blood transfusions or growth factors. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

Interventionpercentage of participants (Number)
IBR+OB39.8
CLB+OB44.0

Primary Analysis: Rate of Sustained Platelet Improvement

Percentage of participants with platelet counts increase ≥ 50% over baseline continuously for ≥ 56 days without blood transfusion or growth factors. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

Interventionpercentage of participants (Number)
IBR+OB29.2
CLB+OB13.8

Primary Analysis: Rate of Grade ≥ 3 or Serious Infusion-Related Reaction (IRR) Adverse Events

Percentage of participants experiencing grade ≥ 3 (severe or life threatening) or serious IRR adverse events that started on the day of an obinutuzumab infusion and were assessed as related or possibly related to obinutuzumab. Categories included those events with the Medical Dictionary for Regulatory Activities (MedDRA) dictionary preferred term of IRR and those events which are among the customized standardized MedDRA query (SMQ) for IRR. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).

,
Interventionpercentage of participants (Number)
IRR (Preferred Term)By Customized SMQ
CLB+OB8.69.5
IBR+OB2.74.4

Overall Survival (OS) Rate at 3 Years

Overall survival was defined as time from randomization to death from any cause or date last known alive. Overall survival rate at 3 years was estimated using the method of Kaplan-Meier. (NCT02048813)
Timeframe: Assessed every 3 months until progression; after progression, assessed every 3 months for first 2 years, every 6 months for years 3-5, up to 4 years and 8 months

InterventionProportion of participants (Number)
Arm A (Ibrutinib, Rituximab)0.988
Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide)0.915

Progression-free Survival (PFS) Rate at 3 Years

"PFS was defined as the time from randomization to CLL progression or death, whichever occurred first. Progression is characterized by any of the following:~≥ 50% increase from nadir since start of treatment (tx) in the sum of the products of at least 2 lymph nodes on 2 consecutive examinations 2 weeks apart~≥ 50% increase from nadir since start of tx in the size of liver and/or spleen~≥ 50% increase in the absolute number of circulating lymphocytes not due to tumor flare reaction. The absolute lymphocyte count must be ≥ 5x10^9/L to qualify as disease progression.~Transformation to a more aggressive histology (e.g. Richter's syndrome or prolymphocytic leukemia with > 55% prolymphocytes). For patients who achieve a complete response or nodular partial response, progression is defined as recurrence of circulating leukemia cell clone in the peripheral blood and an absolute lymphocyte count > 5x10^9/L and/or recurrence of palpable lymphadenopathy > 1.5 cm by physical exam." (NCT02048813)
Timeframe: Assessed every 3 months until progression up to 4 years and 8 months

InterventionProportion of participants (Number)
Arm A (Ibrutinib, Rituximab)0.894
Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide)0.729

Overall Response Rate at 6 Months

"The primary endpoint was response after 6 cycles of therapy. Overall response rate was calculated as complete response plus partial response, based on the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria.as follows:~Complete response (CR): all group A and group B criteria are met~Group A criteria: resolution of enlarged lymph nodes, normal size spleen and liver, absolute lymphocyte count < 4,000/uL, normocellular bone marrow with < 30% lymphocytes without nodules~Group B criteria: improved blood count (platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL)~Partial response (PR): at least 2 of the group A criteria plus one of the group B criteria are met~Group A criteria: >=50% decrease in target lymph nodes, >=50% decrease in spleen size, >=50% decrease in liver size, 50% reduction in marrow infiltrates~Group B criteria: platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL" (NCT01500733)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Elderly Cohort93.9
TP53 Cohort95.8

OS (Overall Survival)

OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up

Interventionmonths (Median)
Ofatumumab (Arm A)65.1
Ibrutinib (Arm B)67.7

Overall Response Rate (ORR) by Independent Review Committee (IRC)

Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled

Interventionpercentage of participants (Number)
Ofatumumab (Arm A)4.1
Ibrutinib (Arm B)42.6

Overall Response Rate (ORR) by Investigator

Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Interventionpercentage of participants (Number)
Ofatumumab (Arm A)22.4
Ibrutinib (Arm B)87.7

PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.

Interventionmonths (Median)
Ofatumumab (Arm A)8.1
Ibrutinib (Arm B)NA

Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Interventionmonths (Median)
Ofatumumab (Arm A)8.1
Ibrutinib (Arm B)44.1

Rate of Sustained Hemoglobin and Platelet Improvement

Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

,
Interventionpercentage of participants (Number)
Hgb Improvement in patient with baseline anemiaPlatelet improvement in baseline thrombocytopenia
Ibrutinib (Arm B)69.778.4
Ofatumumab (Arm A)32.69.4

ORR as Determined by Independent Review Committee (IRC)

"ORR is the percentage of participants with PR or higher, (CR/CRi) + PR + nodular PR per IRC assessment using the modified 2008 IWCLL guidelines with modification for treatment-related lymphocytosis for participants with CLL and per Lugano Classification for NHL for participants with SLL" (NCT03734016)
Timeframe: Up to approximately 3 years and 9 months

InterventionPercentage of participants (Number)
Zanubrutinib86.2
Ibrutinib75.7

Overall Response Rate (ORR) as Determined by Investigator Assessment

"ORR is percentage of participants with partial response (PR) or higher, (defined as Complete response/ Complete response with incomplete bone marrow recovery (CR/CRi) + PR + nodular PR) per investigator assessment using the modified 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines with modification for treatment-related lymphocytosis for participants with CLL and per Lugano Classification for non-Hodgkin lymphoma (NHL)) for participants with Small lymphocytic lymphoma (SLL)" (NCT03734016)
Timeframe: Up to approximately 3 years and 9 months

InterventionPercentage of participants (Number)
Zanubrutinib83.5
Ibrutinib74.2

Death Event

All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug

InterventionParticipants (Count of Participants)
IBRUTINIB/PCI-3276542

Number of Subjects With Adverse Events

Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

InterventionParticipants (Count of Participants)
A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH199

Progressive Disease (PD)

A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

InterventionParticipants (Count of Participants)
IBRUTINIB/PCI-3276570

Food Effect Cohort Assessments

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Intervention (Number)
Food Effect Cohort1.65

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

InterventionParticipants (Number)
PCI-32765116
Food Effect11

Percentage of Participants Achieving Response

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive71
Relapsed/ Refractory75.3
Food Effect56.3

Progression Free Survival Rate at 24 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive96.3
Relapsed/ Refractory73.6
Food- EffectNA

Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)

Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported. (NCT01611090)
Timeframe: Baseline to EOT (Up to 2 years)

Interventionmilligram per liter (mg/L) (Mean)
Ibrutinib+BR-0.46
Placebo+BR-0.23

Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment

"EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from 1 = not at all to 4 = very much. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from 1 = very poor to 7 = excellent. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms." (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-2.1
Placebo+BR-4.1

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment

The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility. (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR0.0
Placebo+BR0.0

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment

The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-4.3
Placebo+BR4.0

Change From Baseline in FACIT-Fatigue Scale at End of Treatment

FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-0.9
Placebo+BR0.0

Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale

Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Up to 2 years

InterventionMonths (Number)
Ibrutinib+BR6.5
Placebo+BR4.6

Number of Participants Who Received Subsequent Antineoplastic Therapy

Number of participants who received subsequent antineoplastic therapy was reported. (NCT01611090)
Timeframe: Up to 5 years

InterventionParticipants (Count of Participants)
Ibrutinib+BR52
Placebo+BR61

Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms

The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia. (NCT01611090)
Timeframe: From the date of randomization to disease progression (Up to 2 years)

InterventionParticipants (Count of Participants)
Ibrutinib+BR0
Placebo+BR0

Overall Response Rate (ORR)

ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/liter (L), platelets >100*10^9/L, Hgb >11 gram per deciliter (g/dL) and absolute lymphocyte count <4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: >=50% decrease in ALC, >=50% decrease in sum products of up to 6 lymph nodes, >=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils >1.5*10^9/L, Platelets >100*10^9/L and Hgb>11 g/dL or >=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly. (NCT01611090)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Ibrutinib+BR87.2
Placebo+BR66.1

Overall Survival (OS)

OS was defined as the interval between the date of randomization and the date of death from any cause. (NCT01611090)
Timeframe: Up to 5 years

InterventionMonths (Median)
Ibrutinib+BRNA
Placebo+BRNA

Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response

MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders. (NCT01611090)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Ibrutinib+BR28.7
Placebo+BR5.9

Progression-free Survival (PFS)

PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); >=50% increase in existing lymph nodes; >=50% increase in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) or >=50% increase from nadir count confirmed on >=2 serial assessments if absolute lymphocyte count (ALC) >=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology. (NCT01611090)
Timeframe: Up to 5 years

InterventionMonths (Median)
Ibrutinib+BR65.12
Placebo+BR14.32

Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment

The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

,
InterventionUnits on the scale (Mean)
Lost weightDry mouthBruisesAbdominal discomfortTemperature going up and downNight sweatsSkin problemsFeel illFeel lethargicFelt slowed downLimited in planning activitiesWorried about health in the futureTrouble with chest infectionsTrouble with other infectionsRepeated courses of antibioticsWorried about picking up infection
Ibrutinib+BR0.10.30.10.10.1-0.60.40.10.10.30.20.00.20.70.90.3
Placebo+BR0.00.10.00.00.0-0.30.30.20.00.00.10.00.00.10.00.2

Percentage of Participants With Sustained Hematologic Improvement

Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (>)100* 109/liter (L) if baseline less than or equal to (<=) 100*109/L or increase >= 50 percent (%) over baseline; 2) Hemoglobin >11 gram per deciliters (g/dL) if baseline <= 11 g/dL or increase >= 2 g/dL over baseline. (NCT01611090)
Timeframe: Up to 5 years

,
InterventionPercentage of Participants (Number)
HemoglobinPlatelets
Ibrutinib+BR36.730.8
Placebo+BR29.121.8

Complete Response (CR) Rate

The CR rate was defined as the percentage of participants who achieved CR. CR criteria: No evidence of new disease; ALC <4 x 10^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC >1.5 x 10^9/L, platelets ≥100 x 10^9/L, Hgb ≥110 g/L. (NCT02301156)
Timeframe: Up to 62 months

Interventionpercentage of participants (Number)
Ublituximab + Ibrutinib18.8
Ibrutinib4.8

Duration of Response (DOR)

DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC<4x10^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC>1.5x10^9/L,Platelets≥100x10^9/L,Hgb≥110 g/L.PR:Response in 2 or more:ALC<4x10^9/L,>=50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC>1.5x10^9/L,Platelets>100x10^9/L,Hgb>110 g/L or >=50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;≥50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of >50% in platelets/>20g/L in Hgb from highest on-study count. (NCT02301156)
Timeframe: From the first dose of study drug until the first documentation of PD or death whichever occurs first or up to 62 months

Interventionmonths (Median)
Ublituximab + IbrutinibNA
Ibrutinib39.1

Minimum Residual Disease (MRD) Negativity Rate

MRD negativity rate was defined as the percentage of participants who were MRD negative post-baseline. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow. (NCT02301156)
Timeframe: Up to 62 months

Interventionpercentage of participants (Number)
Ublituximab + Ibrutinib45.3
Ibrutinib9.7

Overall Response Rate (ORR)

ORR: Percentage of participants with best overall response of partial response(PR) and complete response(CR). CR criteria: No evidence of new disease; Absolute lymphocyte count(ALC)<4x10^9/liter(L); Regression of all target nodal masses to ≤1.5 centimeters(cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)>1.5x10^9/L,platelets≥100x10^9/L,hemoglobin (Hgb)≥110 gram per liter(g/L). PR criteria: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC<4x10^9/L or >=50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC>1.5x10^9/L,platelets>100x10^9/L,Hgb>110g/L or >=50% increase over baseline in any of these. (NCT02301156)
Timeframe: Up to 62 months

Interventionpercentage of participants (Number)
Ublituximab + Ibrutinib84.4
Ibrutinib69.4

Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related. (NCT02301156)
Timeframe: From the first dose up to 30 days after the last dose of study drug (up to 57.3 months)

Interventionpercentage of participants (Number)
Ublituximab + Ibrutinib100
Ibrutinib100

Progression-Free Survival (PFS)

PFS was defined as the time from the date of randomization until the date of first documentation of definitive disease progression (PD) or date of death from any cause, whichever occurs first. PD requires at least one of the following: New nodes >1.5 cm in the LD and >1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, >50% decrease from the highest on-study platelet count, >20 g/L decrease from the highest on-study Hgb. (NCT02301156)
Timeframe: From the randomization until the first documentation of PD or death whichever occurs first or up to 62 months

Interventionmonths (Median)
Ublituximab + IbrutinibNA
Ibrutinib47.2

Time to Response (TTR)

TTR was defined as the interval from the randomization to the first documentation of CR or PR. CR criteria: No evidence of new disease; ALC <4 x 10^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC >1.5 x 10^9/L, platelets ≥100 x 10^9/L, Hgb ≥110 g/L. PR criteria: No evidence of new disease; Response in 2 of following when abnormal at baseline: ALC<4 x 10^9/L or >=50% decrease from baseline in SPD of target nodal lesions; splenomegaly; hepatomegaly; >=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; and Response in 1 of the following: ANC>1.5 x 10^9/L, platelets>100 x 10^9/L, Hgb>110 g/L or >=50% increase over baseline in any of these. (NCT02301156)
Timeframe: From the randomization up to 62 months

Interventionmonths (Median)
Ublituximab + Ibrutinib2.0
Ibrutinib3.9

Duration of Response

"The duration of response of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy.~DOR is calculated as date of disease progression or death (censoring date for censored subjects) - date of achieving the first CR, CRi, nPR, or PR + 1." (NCT02717611)
Timeframe: From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)

InterventionMonths (Median)
AcalabrutinibNA

Overall Survival

The overall survival of ACP-319 (acalabrutinib) in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy (NCT02717611)
Timeframe: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).

InterventionMonths (Median)
AcalabrutinibNA

Progression-Free Survival

"The progression-free survival of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy.~PFS is calculated as date of disease progression or death (censoring date for censored subjects) - first dose date + 1." (NCT02717611)
Timeframe: From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).

InterventionMonths (Median)
AcalabrutinibNA

The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)

"The overall response rate (ORR) of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy.~ORR is defined as the proportion of subjects achieving a best overall response (BOR) of either complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) at or before initiation of subsequent anticancer therapy. ORR will be analyzed per investigator's assessment." (NCT02717611)
Timeframe: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 4 years and 7 months). 1 cycle = 28 days

InterventionPercentage of participants (Number)
Acalabrutinib70.0

Time-to-Next Treatment

"The time to next treatment of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy.~TTNT is defined as the time from date of first acalabrutinib treatment to date of institution of subsequent anticancer therapy for CLL or death due to any cause, whichever comes first. Subjects who do not have the above specified events prior to the data cutoff date will be censored at the date of last visit. TTNT will be calculated as follows:~(Earlier date of institution of subsequent anticancer therapy for CLL or date of death due to any cause) - date of first dose + 1. For censored subjects, date of last visit will replace earlier date of use of subsequent anticancer therapy for CLL or date of death due to any cause in the calculation." (NCT02717611)
Timeframe: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)

InterventionMonths (Median)
Acalabrutinib44.0

Duration of Response (DOR) (Complete Response [CR], CCR, Nodular Partial Response [nPR], Partial Response [PR], and PRL)

The Kaplan-Meier method will be used to estimate median DOR. DOR is the time from first objective status to progression or death. CR requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly/splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate & biopsy must be normocellular for age. PR requires >= 50% decrease in peripheral lymphocyte count from pre-treatment value, >= 50% reduction in lymphadenopathy, and/or ≥ 50% reduction in splenomegaly/hepatomegaly. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). PR with the exception of having less than a 50% reduction in peripheral lymphocyte count will be considered a PR except persistent lymphocytosis (PRL). (NCT01886872)
Timeframe: From the date of first response until progression or death, performed at 2.5 years after the last patient enrolled; up to 4 years.

Interventionmonths (Median)
Arm A (Rituximab, Bendamustine Hydrochloride)50
Arm B (Ibrutinib)NA
Arm C (Ibrutinib, Rituximab)NA

Overall Survival (OS) at 2 Years

The Kaplan-Meier method will be used to estimate the rate of overall survival at 2 years in each treatment arm. OS will be measured from the date of registration to the date of the event (i.e., death) or the date of last follow-up to evaluate that event. Patients who are event-free at their last follow-up evaluation will be censored at that time point. (NCT01886872)
Timeframe: From the date of registration to the date of death, assessed up to 2 years

Interventionpercentage of patients (Number)
Arm A (Rituximab, Bendamustine Hydrochloride)95
Arm B (Ibrutinib)90
Arm C (Ibrutinib, Rituximab)94

Percentage of Patients Achieving a Biopsy-proven Complete Response (CR)

Complete response (CR) requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly or splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate and biopsy must be normocellular for age. Complete response rate and corresponding exact binomial 95% confidence intervals provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.

Interventionpercentage of patients (Number)
Arm A (Rituximab, Bendamustine Hydrochloride)26
Arm B (Ibrutinib)7
Arm C (Ibrutinib, Rituximab)12

Percentage of Patients Achieving Any Response to Treatment (Overall Response Rate [ORR] [Complete Response [CR], CCR, Nodular Partial Response [nPR], Partial Response [PR], and PRL])

Complete response (CR) requires all of the following: absence of lymphadenopathy >1.5 cm on physical exam/CT scan, no hepatomegaly/splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate & biopsy must be normocellular for age. Partial response (PR) requires >= 50% decrease in peripheral lymphocyte count from pre-treatment value, >= 50% reduction in lymphadenopathy, and/or ≥ 50% reduction in splenomegaly/hepatomegaly. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). PR with the exception of having less than a 50% reduction in peripheral lymphocyte count will be considered a PR except persistent lymphocytosis (PRL).Overall response rate and corresponding exact binomial 95% CI provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled;up to 4 years.

Interventionpercentage of patients (Number)
Arm A (Rituximab, Bendamustine Hydrochloride)75
Arm B (Ibrutinib)93
Arm C (Ibrutinib, Rituximab)94

Percentage of Patients Achieving Complete (CR and CCR) or Nodular Partial Response (nPR)

Complete response (CR) requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly or splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate and biopsy must be normocellular for age. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). Response rate and corresponding exact binomial 95% confidence intervals provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.

Interventionpercentage of patients (Number)
Arm A (Rituximab, Bendamustine Hydrochloride)33
Arm B (Ibrutinib)10
Arm C (Ibrutinib, Rituximab)23

Percentage of Patients Who Attain Minimal Residual Disease (MRD) Negative Status

Estimated using the number of patients who achieve minimal residual disease divided by the total number randomized to that treatment arm. Corresponding exact binomial 95% confidence intervals for MRD rates will be calculated. (NCT01886872)
Timeframe: Cycle 9 Day 1 Evaluation

Interventionpercentage of patients (Number)
Arm A (Rituximab, Bendamustine Hydrochloride)8
Arm B (Ibrutinib)1
Arm C (Ibrutinib, Rituximab)4

Progression Free Survival (PFS)

The Kaplan-Meier method will be used to estimate the progression free survival distributions for each arm, with median estimates provided. Progression is defined as any one of the following: an increase in number of blood lymphocytes by >= 50% with >= 5000 B lymphocytes/mL in patients on Arm A or those on Arms 2 or 3 no longer receiving ibrutinib, >= 50% increase in the products of at least 2 lymph nodes on 2 consecutive determination 2 weeks apart, >= 50% increase in the size of the liver/spleen, transformation to a more aggressive histology, progression of any cytopenia (i.e. decrease of Hb levels > 2g/dL). Progression free survival time will be the time to either progression or death whichever occurs first. (NCT01886872)
Timeframe: Time from study entry to the time of documented disease progression or death. The analysis was event driven, performed at 2.5 years after the last patient enrolled;up to 4 years.

Interventionmonths (Median)
Arm A (Rituximab, Bendamustine Hydrochloride)43
Arm B (Ibrutinib)NA
Arm C (Ibrutinib, Rituximab)NA

Progression Free Survival (PFS) Rate at 2 Years

The Kaplan-Meier method will be used to estimate the rate of progression free survival at 2 years in each treatment arm. Progression is defined as any one of the following: an increase in number of blood lymphocytes by >= 50%, >= 50% increase in the products of at least 2 lymph nodes on 2 consecutive determination 2 weeks apart, >= 50% increase in the size of the liver/spleen, transformation to a more aggressive histology, progression of any cytopenia (i.e. decrease of Hb levels > 2g/dL). Progression free survival time will be the time to either progression or death whichever occurs first. (NCT01886872)
Timeframe: Time from study entry to the time of documented disease progression or death, assessed up to 2 years

Interventionpercentage of patients (Number)
Arm A (Rituximab, Bendamustine Hydrochloride)74
Arm B (Ibrutinib)87
Arm C (Ibrutinib, Rituximab)88

The Rate of Grade 3, 4, or 5 Treatment-related Non-hematologic Adverse Events (Toxicities)

The rate of grade 3, 4, or 5 treatment-related non-hematologic adverse events (toxicities) by arm; excludes adverse events occurring post-crossover for patients in Arm A (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.

Interventionpercentage of patients (Number)
Arm A (Rituximab, Bendamustine Hydrochloride)41
Arm B (Ibrutinib)48
Arm C (Ibrutinib, Rituximab)39

Number of Participants With Treatment-emergent Atrial Fibrillation

Number of participants with treatment-emergent atrial fibrillation (including atrial flutter) are reported. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)

InterventionParticipants (Count of Participants)
Acalabrutinib32
Ibrutinib49

Number of Participants With Treatment-emergent Infections Grade >= 3

Number of participants with treatment-emergent infections Grade >=3 are reported. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)

InterventionParticipants (Count of Participants)
Acalabrutinib98
Ibrutinib101

Number of Participants With Treatment-emergent Richter's Transformation

Richter's transformation is defined as the occurrence of an aggressive lymphoma in participants with a previous or concomitant diagnosis of CLL. Richter's transformation was assessed by central pathology. Number of participants with treatment-emergent Richter's transformation are reported. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)

InterventionParticipants (Count of Participants)
Acalabrutinib13
Ibrutinib14

Overall Survival (OS)

The OS is defined as the time from date of randomization to date of death due to any cause. The OS is assessed using the Kaplan-Meier method. (NCT02477696)
Timeframe: Baseline (Days -28 to -1) through 83.7 months (maximum observed duration)

InterventionMonths (Median)
AcalabrutinibNA
IbrutinibNA

Percentage of Participants With Lymphocytosis

Percentage of participants with at least one occurrence of treatment-related lymphocytosis defined as an elevation in ALC of >= 50% compared with baseline and a postbaseline assessment of > 5000/μL in the peripheral blood are reported. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)

InterventionPercentage of participants (Number)
Acalabrutinib72.5
Ibrutinib74.3

Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment

The PFS is defined as the time from date of randomization to the date of first IRC-assessed PD or death due to any cause, whichever occurred first. PD (per International Workshop on Chronic Lymphocytic Leukemia [iwCLL] 2008 criteria): Lymphocytes >= 50% increase over baseline, or >= 50% increase in lymphadenopathy/hepatomegaly/splenomegaly, or >= 50% platelets or > 2 g/dL hemoglobin decreases from baseline secondary to chronic lymphocytic leukemia (CLL). The PFS is assessed using the Kaplan-Meier method. (NCT02477696)
Timeframe: Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)

InterventionMonths (Median)
Acalabrutinib38.4
Ibrutinib38.4

Number of Participants With Abnormal Vital Signs Reported as TEAEs

Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (body temperature, blood pressure, heart rate, and respiratory rate). (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)

,
InterventionParticipants (Count of Participants)
Abnormal loss of weightBlood pressure fluctuationBlood pressure increasedBlood pressure decreasedBlood pressure systolic increasedBody temperature decreasedBody temperature increasedBradycardiaBreath sounds abnormalCardiac murmurDyspnoeaDyspnoea exertionalHeart rate increasedHeart rate irregularHypertensionHypotensionHyperpyrexiaOrthostatic hypotensionPalpitationsPyrexiaTachycardiaWeight decreasedWeight increasedWhite coat hypertension
Acalabrutinib0021010301402012615121266729130
Ibrutinib113010111227510707011555723101

Number of Participants With Electrocardiogram (ECG) Abnormality at Baseline

Number of participants with ECG abnormality at baseline are reported. (NCT02477696)
Timeframe: Baseline (Days -28 to -1)

,
InterventionParticipants (Count of Participants)
Abnormal, not clinically significantAbnormal, clinically significant
Acalabrutinib864
Ibrutinib981

Number of Participants With Shift From Baseline to Worst (Grade 3 and 4) Postbaseline in Eastern Cooperative Oncology Group (ECOG) Performance Status

The ECOG performance status assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=death. Number of participants with shift from baseline (Days -28 to -1) to worst Grade 3 and 4 in ECOG performance status are reported. (NCT02477696)
Timeframe: Baseline (Days -28 to -1) through 83.5 months (maximum observed duration)

,
InterventionParticipants (Count of Participants)
Baseline=0; Postbaseline=3Baseline=1; Postbaseline=3Baseline=2; Postbaseline=3Baseline=0; Postbaseline=4Baseline=1; Postbaseline=4Baseline=2; Postbaseline=4
Acalabrutinib034000
Ibrutinib151000

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)

,
InterventionParticipants (Count of Participants)
Any TEAEsAny TESAEs
Acalabrutinib262161
Ibrutinib259177

Number of Participants With Treatment-emergent Laboratory Abnormalities

Number of participants with treatment-emergent laboratory abnormalities are reported. Laboratory abnormality is defined as any abnormal finding during analysis of hematology and serum chemistry. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)

,
InterventionParticipants (Count of Participants)
Absolute neutrophil count (decreased)Haemoglobin (decreased)Platelets (decreased)Leukocytes (decreased)Leukocytes (increased)Absolute lymphocyte count (ALC) (decreased)ALC (increased)Alanine aminotransferase (increased)Albumin (decreased)Alkaline phosphatase (increased)Aspartate aminotransferase (increased)Bilirubin (increased)Calcium (decreased)Calcium (increased)Creatinine (increased)Glucose (decreased)Glucose (increased)Phosphate (decreased)Potassium (decreased)Potassium (increased)Sodium (decreased)Sodium (increased)Urate (increased)
Acalabrutinib1241391196068667173316642465615164521932762267070
Ibrutinib13513111664846572704460586971111681323744052374696

Complete Response Rate

Will be defined as complete response or incomplete blood count recovery. Estimated by the number of patients who achieve an incomplete blood count recovery or complete response divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true complete response rate will be calculated in each arm. (NCT02332980)
Timeframe: 1 year

Interventionproportion of participants (Number)
Arm A (CLL)0.0400
Arm B (NHL)0
Arm C (CLL With Richters)0
Arm A (Continuation Phase)0.4000
Arm C (Continuation Phase)0

Confirmed All Response Rate of Patients Treated With Combination Therapy

Confirmed response rate will be estimated by the number of patients with an objective status of complete response, incomplete blood count recovery, nodular partial response, clinical complete response or partial response while on the combination therapy divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate to the combination will be calculated. In addition, the responders on this study will be further examined in an exploratory manner to determine if there are any patterns in prognostic factors or disease characteristics, including whether the patient had a Richter's transformation or ibrutinib-resistant disease, for both single agent pembrolizumab and combination therapy responders. (NCT02332980)
Timeframe: 1 year

Interventionproportion of participants (Number)
Arm A (Continuation Phase)0.6000
Arm C (Continuation Phase)0.1538

Duration of Response

The distribution of duration of response will be estimated using the method of Kaplan-Meier. Duration of response (DR) is defined for all evaluable patients who have achieved a PR, nPR, CCR, CRi, or CR (Arms A and B) or PMR, CMR, PR or CR (Arm C) as the date at which the patient's objective status is first noted to be a PR, nPR, CCR, CRi, or CR (Arms A and B) or PMR, CMR, PR or CR (Arm C) to the earliest date relapse is documented. (NCT02332980)
Timeframe: 5 years

InterventionMonths (Median)
Arm A (CLL)6.9
Arm A (Continuation Phase)5.9
Arm C (Continuation Phase)NA

Incidence of Adverse Events

Will be measured per National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Adverse events will be evaluated for single-agent pembrolizumab in each arm and also for the combination of pembrolizumab and the signal inhibitor in Arm A and Arm C. This outcome is reported in the adverse events section of this report. (NCT02332980)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Arm A (CLL)25
Arm B (NHL)23
Arm C (CLL With Richters)17
Arm A (Continuation Phase)5
Arm C (Continuation Phase)13

Overall Survival

The distribution of overall survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

InterventionMonths (Median)
Arm A (CLL)10.6
Arm B (NHL)48.6
Arm C (CLL With Richters)11.5
Arm A (Continuation Phase)11.7
Arm C (Continuation Phase)13.3

Progression-free Survival of Patients Treated in Single Agent Phase

The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT02332980)
Timeframe: 5 years

InterventionMonths (Median)
Arm A (CLL)2.8
Arm B (NHL)4.2
Arm C (CLL With Richters)2.2

Progression-free Survival of Patients Treated With Combination Therapy

The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT02332980)
Timeframe: 5 years

InterventionMonths (Median)
Arm A (Continuation Phase)7.6
Arm C (Continuation Phase)5.4

Proportion of Patients Who Achieve a Confirmed Response

Confirmed response is defined to be a partial response, nodular partial response, clinical complete response, confirmed response with incomplete blood count recovery or confirmed response (Arm A and B), or complete metabolic response, partial metabolic response, partial response, or confirmed response (Arm C). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial confidence intervals for the true success proportion will be calculated. (NCT02332980)
Timeframe: 1 year

Interventionproportion of responders (Number)
Arm A (CLL)0.0800
Arm B (NHL)0
Arm C (CLL With Richters)0

Time to Next Treatment for Patients on Combination Therapy

The distribution of time to next treatment will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

InterventionMonths (Median)
Arm A (Continuation Phase)7.7
Arm C (Continuation Phase)3.2

Time to Next Treatment for Patients Treated With Single-agent Pembrolizumab

The distribution of time to next treatment will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

InterventionMonths (Median)
Arm A (CLL)3.0
Arm B (NHL)5.3
Arm C (CLL With Richters)3.0

Treatment-free Survival of Patients Treated With Combination Therapy

The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

InterventionMonths (Median)
Arm A (Continuation Phase)7.7
Arm C (Continuation Phase)3.2

Treatment-free Survival of Patients Treated With Single-agent Pembrolizumab

The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

InterventionMonths (Median)
Arm A (CLL)2.7
Arm B (NHL)4.6
Arm C (CLL With Richters)2.9

Duration of Response (DOR) as Assessed by the Investigator

The DoR is defined as the time from the date of achieving the first CR, CRi, or PR to the date of progressive disease (PD) or death due to any cause, whichever occurred first. The CR, CRi, or PR are defined in the above outcome measure. For CLL/SLL, PD is defined as lympho >=50% increase from baseline with >= 5000 B lymphocytes/µL, progressive cytopenias by bone marrow biopsy, appearance of any new lesion or new appearance of hepatomegaly or splenomegaly or >= 50 % increase in lymphadenopathy/hepatomegaly/splenomegaly, platelets decrease of >=50% from baseline secondary to CLL or < 100,000/µL and worsening bone marrow or Hb decrease of > 2 g/dL from baseline secondary to CLL or decrease to less than 100 g/L and worsening bone marrow. For RS, PD is defined as an increase by 25 % in longest diameter, new lesion or assessable disease progression. The DoR was estimated using Kaplan-Meier method. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)

InterventionMonths (Median)
Cohort 133.3
Cohort 2a26.7
Cohort 2b77.3
Cohort 2c43.0
Cohort 3NA
Cohort 4a64.1
Cohort 4bNA
Cohort 7NA
Cohort 11NA

Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1

Participants with DLTs in Phase 1 are reported. The DLT was defined as any of the following events unless the adverse event is clearly related to disease progression or the participant's current medical history and associated comorbidities: (1) Any Grade 3 or greater nonhematologic toxicity with the exceptions of alopecia and Grade 3 nausea, vomiting, and diarrhea that respond to supportive therapy; (2) Hematologic toxicities including Grade 4 neutropenia lasting more than 5 days, Grade 4 or Grade 3 thrombocytopenia with bleeding or any requirement for platelets transfusion, Grade 3 or greater febrile neutropenia (body temperature of 38.5 degrees Celsius or more), or Grade 4 anemia, unexplained by underlying disease; or (3) Dosing delay due to toxicity for > 7 consecutive days. (NCT02029443)
Timeframe: From Day 1 to Day 28 after first dose of study drug

InterventionParticipants (Count of Participants)
Cohort 10
Cohort 2a0
Cohort 2b0
Cohort 30
Cohort 4a0
Cohort 4b0

Percentage of Participants With Objective Response (OR) as Assessed by the Investigator

For CLL/SLL, OR is defined as complete remission (CR), CR with incomplete marrow recovery (CRi), or partial remission (PR). CR: lymphocytes (lympho) <4×10^9/L, normocellular bone marrow (BM), normal lymph nodes (NLN), liver and spleen (L/S), absolute neutrophil count (ANC) >1.5×10^9/L, platelets >100×10^9/L, hemoglobin (Hb) >11g/dL. Cri: lympho <4×10^9/L, hypocellular BM, NLN, L/S, persistent anemia, hrombocytopenia, or neutropenia. PR: >=50% reduction in lymphadenopathy and/or enlargement of L/S or lympho (<5×10^9/L or >=50% decrease from baseline) and criteria of ANC/platelets/Hb per CR or >=50% improvement over baseline. Hematology result were without exogenous growth factors/transfusion. For RS, OR as CR or PR by Cheson et al. 2014 based on PET/CT scans and bone marrow. CR: disappearance of all detectable clinical evidence of disease and disease-related symptoms and PR: >=50% decrease in sum of the product diameter of 6 largest nodal masses and no new sites of disease. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)

InterventionPercentage of participants (Number)
Cohort 1100.0
Cohort 2a75
Cohort 2b92.1
Cohort 2c93.8
Cohort 3100.0
Cohort 4a100.0
Cohort 4b100.0
Cohort 797.3
Cohort 11100.0

Progression Free Survival (PFS) as Assessed by the Investigator

The PFS is defined as the time from the date of first dose of study drug to the date of first PD or death due to any cause, whichever occurred first. For CLL/SLL, PD is defined as lympho >= 50 % increase from baseline with >= 5000 B lymphocytes/µL, progressive cytopenias by bone marrow biopsy, appearance of any new lesion or new appearance of hepatomegaly or splenomegaly or >= 50 % increase in lymphadenopathy/hepatomegaly/splenomegaly, platelets decrease of >= 50 % from baseline secondary to CLL or < 100,000/µL and worsening bone marrow or Hb decrease of > 2 g/dL from baseline secondary to CLL or decrease to less than 100 g/L and worsening bone marrow. For RS, PD is defined as an increase by 25 % in longest diameter, new lesion or assessable disease progression. The PFS was estimated using Kaplan-Meier method. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)

InterventionMonths (Median)
Cohort 138.3
Cohort 2a33.1
Cohort 2b79.1
Cohort 2c46.6
Cohort 3NA
Cohort 4a67.8
Cohort 4bNA
Cohort 7NA
Cohort 11NA

Apparent Oral Clearance (CL/F) of Acalabrutinib

The CL/F of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
InterventionL/hr (Mean)
Day 1Day 8
Cohort 1114176
Cohort 10156167
Cohort 11137188
Cohort 2a193216
Cohort 2b212162
Cohort 2c112122
Cohort 3265131
Cohort 4a169344
Cohort 4b108191
Cohort 7315389
Cohort 8a35294.5
Cohort 8b311336
Cohort 9142132

Apparent Volume of Distribution (Vz/F) of Acalabrutinib

The Vz/F of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
InterventionL (Mean)
Day 1Day 8
Cohort 1268286
Cohort 10235533
Cohort 11158234
Cohort 2a574302
Cohort 2b450333
Cohort 2c182165
Cohort 32100172
Cohort 4a1480739
Cohort 4b133384
Cohort 79301180
Cohort 8a2600125
Cohort 8b422726
Cohort 9171179

Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours (AUC0-6) of Acalabrutinib

The AUC0-6 of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
Interventionhr*ng/mL (Mean)
Day 1Day 8
Cohort 1971631
Cohort 1011001250
Cohort 11789642
Cohort 2a12501180
Cohort 2b819858
Cohort 2c21701660
Cohort 318801750
Cohort 4a29601630
Cohort 4b19501690
Cohort 717401480
Cohort 8a3622080
Cohort 8b670834
Cohort 916901860

Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Acalabrutinib

The AUC0-inf of Acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
Interventionhr*ng/mL (Mean)
Day 1Day 8
Cohort 11040621
Cohort 1013501580
Cohort 11940652
Cohort 2a13201200
Cohort 2b855956
Cohort 2c24401990
Cohort 320502360
Cohort 4a32501750
Cohort 4b19701780
Cohort 719101540
Cohort 8a5742120
Cohort 8b801963
Cohort 917701750

Area Under the Plasma Concentration-time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of Acalabrutinib

The AUC0-last of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
Interventionhr*ng/mL (Mean)
Day 1Day 8
Cohort 11030729
Cohort 1011001260
Cohort 11850660
Cohort 2a12701180
Cohort 2b795850
Cohort 2c22801850
Cohort 320302020
Cohort 4a34301750
Cohort 4b19501560
Cohort 717901400
Cohort 8a5391180
Cohort 8b570748
Cohort 918601710

Maximum Observed Plasma Concentration (Cmax) of Acalabrutinib

The Cmax of Acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
Interventionng/mL (Mean)
Day 1Day 8
Cohort 1685521
Cohort 10727610
Cohort 11930633
Cohort 2a754805
Cohort 2b706812
Cohort 2c19501350
Cohort 313501350
Cohort 4a1550902
Cohort 4b16001320
Cohort 713901020
Cohort 8a206939
Cohort 8b554616
Cohort 911901460

Number of Participants With Clinically Abnormal Vital Signs Reported as TEAEs

Participants with clinically abnormal vital signs (blood pressure, respiratory rate, pulse rate, or body temperature) reported as TEAEs are reported. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)

,,,,
InterventionParticipants (Count of Participants)
TachycardiaBradycardiaPyrexiaHyperpyrexiaHypothermiaProcedural hypotensionBlood pressure increasedDyspnoeaDyspnoea exertionalHypertensionHypotensionOrthostatic hypotensionEssential hypertensionHypertensive crisisMalignant hypertensionPalpitations
Ibrutinib Relapsed/Refractory Cohort0000000210200000
Ibrutinib-intolerant Cohort20100000616511000
Relapsed/Refractory Cohort36390000275307001013
Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort3061000301100010
Treatment-naive Cohort81140111185281250004

Number of Participants With Clinically Important Laboratory Abnormalities With Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or More

Participants with clinically important laboratory abnormalities with CTCAE Grade 3 or more are reported. Laboratory analysis included hematology, clinical chemistry, amylase, lipase, cardiac troponin I, hepatitis B and C testing, and urinalysis. The CTCAE version 4.03 is a descriptive terminology is used for AE reporting. The CTCAE v4.03 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 3 as severe AE, Grade 4 as life-threatening or disabling AE, and Grade 5 as death related to AE. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)

,,,,
InterventionParticipants (Count of Participants)
Hemoglobin, platelets or neutrophils decreasedAbsolute neutrophil count (decreased)Hemoglobin (decreased)Platelets (decreased)Leukocytes (decreased)Leukocytes (increased)Absolute lymphocyte count (decreased)Absolute lymphocyte count (increased)Urate (increased)Sodium (decreased)Phosphate (decreased)Potassium (increased)Glucose (increased)Alanine aminotransferase (increased)Calcium (increased)Aspartate aminotransferase (increased)Magnesium (increased)Potassium (decreased)Albumin (decreased)Calcium (decreased)Alkaline phosphatase (increased)Amylase (increased)Bilirubin (increased)Creatinine (increased)Lipase (increased)
Ibrutinib Relapsed/Refractory Cohort4331020120000000000000000
Ibrutinib-intolerant Cohort141134372782113100000000000
Relapsed/Refractory Cohort72571720122920292412933352222212221
Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort191385606353100110010110000
Treatment-naive Cohort30235322178155151102211000001

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)

,,,,
InterventionParticipants (Count of Participants)
Any TEAEsAny TESAEs
Ibrutinib Relapsed/Refractory Cohort63
Ibrutinib-intolerant Cohort3320
Relapsed/Refractory Cohort13486
Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort2818
Treatment-naive Cohort9950

Number of Participants With Treatment Emergent Events of Clinical Interest (ECI)

The treatment emergent ECI included the events identified based on preclinical findings, emerging data from clinical studies relating to acalabrutinib, and pharmacological effects of approved Bruton's tyrosine kinase (BTK) inhibitors and reported after the first dose of the study drug. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)

,,,,
InterventionParticipants (Count of Participants)
Atrial fibrillationVentricular tachyarrhythmiasAnemiaNeutropeniaOther LeukopeniaThrombocytopeniaMajor hemorrhageHepatotoxicityHypertensionInfectionsInterstitial lung disease/PneumonitisSecond primary malignancies, excluding non-melanoma skinTumor lysis syndrome
Ibrutinib Relapsed/Refractory Cohort0011001004000
Ibrutinib-intolerant Cohort40451441725030
Relapsed/Refractory Cohort1222226210114311181231
Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort3010130403218010
Treatment-naive Cohort60109118429863140

Terminal Elimination Half-life (t1/2) of Acalabrutinib

The t1/2 of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
InterventionHours (Mean)
Day 1Day 8
Cohort 11.481.09
Cohort 101.011.67
Cohort 110.7810.811
Cohort 2a1.440.942
Cohort 2b0.9140.995
Cohort 2c0.9930.902
Cohort 32.890.886
Cohort 4a3.521.38
Cohort 4b0.8691.13
Cohort 71.411.02
Cohort 8a4.830.914
Cohort 8b0.9001.25
Cohort 90.7980.867

Terminal Elimination Rate Constant (λz) of Acalabrutinib

The λz of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
Intervention1/hr (Mean)
Day 1Day 8
Cohort 10.6790.655
Cohort 100.7060.603
Cohort 110.9160.894
Cohort 2a0.7500.744
Cohort 2b0.8480.793
Cohort 2c0.7550.798
Cohort 30.5020.797
Cohort 4a0.5570.578
Cohort 4b0.8040.679
Cohort 70.7560.745
Cohort 8a0.3730.758
Cohort 8b0.7840.623
Cohort 90.8800.857

Time of Maximum Plasma Concentration (Tmax) of Acalabrutinib

The Tmax of Acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8

,,,,,,,,,,,,
InterventionHours (Median)
Day 1Day 8
Cohort 11.011.05
Cohort 101.001.58
Cohort 110.6420.533
Cohort 2a0.9170.517
Cohort 2b0.7500.750
Cohort 2c1.001.03
Cohort 31.001.00
Cohort 4a1.000.700
Cohort 4b0.7580.758
Cohort 70.7830.750
Cohort 8a1.301.49
Cohort 8b0.7830.908
Cohort 90.9921.00

Cancer-Specific Stress as Measured by the Impact of Event Scale-Revised (IES-R)

Cancer-Specific Stress was measured by the Impact of Event Scale-Revised Participants rated the intensity of these feelings using a five-point Likert scale ranging from 0=not at all to 4=extremely. Patients rated the frequency of their feelings or events for the previous week before treatment. The items were summed for a total score that ranged from 0 to 64 (NCT01589302)
Timeframe: Up to 2 years

Interventionunits on a scale (Mean)
Treatment (Ibrutinib)9.18

Cognitive-Affective Depressive Symptoms as Measured by the Beck Depression Inventory-2nd Edition (BDI-II)

The Beck Depression Inventory-2nd edition is a 21-item measure of depressive symptoms. Scores were calculated representing the cognitive-affective and the somatic symptoms associated with depression (e.g. sadness, pessimism, loss of pleasure) during past month on scale from 0 to 3. Items were summed, with higher scores indicating more depressive symptoms. The scores on the scale from range from 0 to 42. (NCT01589302)
Timeframe: at 5 months

Interventionunits on a scale (Mean)
Treatment (Ibrutinib)1.88

Effectiveness of Ibrutinib Bridging Patients to Allogeneic Stem Cell Transplant and Outcome of Patients Following This Intervention

The number of participants with successful Allogenic Stem Cell Transplant (NCT01589302)
Timeframe: Up to 2 years

Interventionparticipants (Number)
Treatment (Ibrutinib)1

Fatigue Symptom Inventory (FSI) Interference Quality of Life as Measured by a 11-item Total Disruption Index Sub Scale of Fatigue Symptoms Inventory

The Fatigue Interference quality of life measures is a 11-item self reported questionnaire used to measure frequency, severity and daily pattern of fatigue Symptoms as well as impact of QOL in the past week. The Total Disruption Index (TDI) an 7 item subset of FSI was used. Items were rated on a 11-point Likert scale from 0=no interference to 10=extreme interference. Total scores could range from 0 to 70, with higher scores indicating greater fatigue interference. (NCT01589302)
Timeframe: at 5 months

Interventionunits on a scale (Mean)
Treatment (Ibrutinib)9.70

Mental Health Quality of Life Was Measured by the Mental Component Summary Score of the Medical Outcomes Study

SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning. (NCT01589302)
Timeframe: at 5 months

Interventionunits on a scale (Mean)
Treatment (Ibrutinib)53.98

Negative Mood Quality of Life Measured by a 37-item Questionnaire

The Profile of Mood States-Short Form (POMS-SF) yields six subscales, Tension, Depression, Anger, Vigor, Fatigue, and Confusion. A total mood disturbance score is found by summing the six subscales. Total Mood Disturbance (TMD) scores range from -24 to 124 with higher scores indicating greater mood disturbance. (NCT01589302)
Timeframe: at 5 months

Interventionunits on a scale (Mean)
Treatment (Ibrutinib)0.89

Physical Health Quality of Life as Measured by a 12 Item Short-Form Health Survey

Physical Health Quality of life measures were administered during screening and on Days 1 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru Cycle 24 and at time of progression and /or end of treatment. SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning. (NCT01589302)
Timeframe: up to 5 months

Interventionunits on a scale (Mean)
Treatment (Ibrutinib)44.23

Resistance Studies of Ibrutinib

Percentage of patients with BTK C481S mutation or PLCG2 mutation (NCT01589302)
Timeframe: Up to 4 years

Interventionpercentage of patients (Number)
Treatment (Ibrutinib)13.2

Sleep Through Quality of Life as Measured by a Medical Outcomes Study-Sleep Scale

Sleep problems quality of life measures is a six-item sleep problems index I of the Medical Outcomes Study-Sleep Scale used to assess sleep problems. Participants reported how often they experience six specific difficulties with sleep on a 6-point Likert scale (1=All of the time to 6=None of the time). Scores transformed into a 0-100 scale with higher scores indicating greater sleep problems. (NCT01589302)
Timeframe: at 5 months

Interventionunits on a scale (Mean)
Treatment (Ibrutinib)24.08

2-year Kaplan-Meier Estimate of OS for Relapsed and Refractory CLL Patients Treated With Single Agent PCI-32765

Time from date of first treatment with ibrutinib until the date of progression or death from any cause. Those alive and progression free are censored at the date of last clinical assessment. (NCT01589302)
Timeframe: 2 years

Interventionpercent of patients (Number)
All patientsDel(17p)non-Del(17p)
Treatment (Ibrutinib)696672

Best Overall Response Rate Using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group Guidelines

Responders were subjects who achieved a complete response (CR), partial response (PR) or PR with persistent lymphocytosis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01589302)
Timeframe: up to 2 years

Interventionpercentage of patients (Number)
All patientsDel(17p)non-Del(17p)
Treatment (Ibrutinib)636659

Determine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL.

We will summarize our findings for this endpoint independently as well within each cohort (del17p vs other cytogenetic groups). We will evaluate the proportion of patients who are progression-free and alive at two years or have gone on to transplant (treatment successes) over the total number of evaluable patients; eligible patients who received at least one dose of therapy are considered evaluable. Assuming that the number of treatment successes as defined above is binomially distributed, we will also include 95% binomial confidence intervals for the estimates corresponding to each cohort. (NCT01589302)
Timeframe: up to 2 years

Interventionpercentage of patients (Number)
All patientsDel(17p)non-Del(17p)
Treatment (Ibrutinib)646464

Number of Patients With 6 Month ORR of Single Agent Ibrutinib in Relapsed and Refractory CLL Patients

The 6 month overall response rates overall response rate (ORR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT01589302)
Timeframe: Up to 6 months

Interventionpatients (Number)
All patientsDel(17p)Non-del(17p)
Treatment (Ibrutinib)636659

Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Adverse events grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 with the attribution of either definite, possible or probable related. (NCT01589302)
Timeframe: Up to 2 years post treatment

Interventionpatients (Number)
AnemiaFebrible NeutropeniaLeukocytosisAtrial FibrillationDiarrheaGastric HemorrhageGastrointestinal Disorders-otherMucositis OralNauseaDeathEdema LimbFatigueGeneral Disorders and Admin Site ConditionsCholecystitisBronchial InfectionInfections and Infestations-otherLung InfectionOtitis MediaSepsisSkin InfectionUrinary Tract InfectionAlanine Aminotransferase IncreasedBlood Bilirubin IncreasedLymphocyte Count DecreasedLymphocyte Count IncreasedNeutrophil Count DecreasedPlatelet Count DecreasedWhite Blood Cell DecreasedHyperuricemiaHypophosphatemiaArthralgiaArthritisHematuriaHypoxiaRespiratory FailureRash Maculo-papularHematomaHypertension
Treatment (Ibrutinib)132181211121112114101221111454408104121211117

Percentage of Patients With Overall Survival (OS)

Time from date of first treatment with ibrutinib until the date of death from any cause or the date of last contact for those alive. (NCT01589302)
Timeframe: 2 years

Interventionpercent of patients (Number)
All patientsDel(17p)non-Del(17p)
Treatment (Ibrutinib)787581

An Additional Endpoint Analysis Would Assess the MMT-8 Score in Patients With Muscle Disease as Measured at 3 and 6 Months Compared to Baseline.

"MMT-8 (Manual Muscle Testing-8) score is a validated tool to assess muscle strength. Calculate the mean change in MMT-8 score at 3 and 6 month(s) compared to baseline in patients with muscle disease.~Units: Units on a scale. Scale goes from 0-150. 150 is perfect strength." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit

Interventionscore on a scale (Mean)
MMT-8 Score at 3 Months143.3
MMT-8 Score at 6 Months144.5

An Additional Secondary Endpoint Analysis Would Assess Quality of Life as Measured at 3 Months Compared to Quality of Life Measured at 6 Months

"Dermatology Life Quality Index (DLQI) is a validated tool to measure quality of life in patients with skin disease. Complete response is defined by a DLQI of zero at 3, and 6 months. Partial response is defined by a decrease of DLQI of at least 5 points at 3, and 6 months compared to baseline. Calculation is performed as the DLQI at 3, and 6 months minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~Units : Units on a scale from 0-30, higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit

Interventionscore on a scale (Mean)
DLQI Score at 3 Months6.3
DLQI Score at 6 Months4.2

An Additional Secondary Endpoint Analysis Would be Durability of Response Measured Participants CDASI Activity Score or Change in Their CDASI Activity Score at 6 Months Compared to 3 Months.

"The durability of response will be measured using the CDASI activity score at 6 months minus CDASI activity score at 3 months. Complete response durability is defined as zero or minus difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Partial response durability is defined as >4 points difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 6 months compared to data collected at 3 months

Interventionscore on a scale (Mean)
CDASI Score at 3 Months16.9
CDASI Score at 6 Months14

The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3 Months.

"Cutaneous dermatomyositis disease area and severity index (CDASI) activity score is a validated tool to measure skin disease activity in dermatomyositis. The overall response rate (ORR) includes partial and complete responses. Complete response is defined by a CDASI activity score of zero. Partial response is defined by a decrease of CDASI activity score of at least 4 points. Calculation is performed as the CDASI activity score at 3 month(s) minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

InterventionParticipants (Count of Participants)
Dermatomyositis Patients With Refractory Cutaneous Disease7

2. The Secondary Endpoint Analysis Would be Safety as Measured by the Number of Participants Experiencing Adverse Events and Serious Adverse Events Occurring During 6 Months of Therapy and 1 Month Follow up.

"The proportion of participants experiencing adverse events and serious adverse events was measured over 7 months period (6 months during the study and 1 month follow up) using Common Terminology Criteria for Adverse Events (CTCAE) v5.0.~Grade refers to severity of the AE. The CTCAE displays Grades 1 to 5 with unique clinical descriptions of severity for each AE:~Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age- appropriate instrumental Activity of Daily Living (ADL) Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated Grade 5 Death related to AE All adverse events subjects experienced were grade 1 or 2 which is mild to moderate in severity." (NCT03529955)
Timeframe: 7 months

InterventionParticipants (Count of Participants)
Headache Grade 1-2Nausea Grade 1-2Diarrhea Grade 1-2Herpes Zoster Grade 1-2Influenza Grade 1-2Pneumonia Grade 1-2Acute sinusitis Grade 1-2Hypertension Grade 1-2Ocular pressure Grade 1-2
Dermatomyositis Patients With Refractory Cutaneous Disease754211111

An Additional Endpoint is to Assess the Gene Expression Profiling and Immunohistochemistry Analysis Change on Skin Biopsies at 3 Months Compared to Baseline.

Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in gene expression profiling and immunohistochemistry stain. Gene expression profiling will be analyzed using inferential statistics with a False Discovery Rate (FDR) of < 0.05. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

,
InterventionChange (Number)
Down regulated genesUp regulated genes
Skin Biopsy at 3 Months Into Apremilast Therapy for Gene Expression Profiling12372
Skin Biopsy at Baseline for Gene Expression Profiling00

An Additional Endpoint is to Assess the Immunohistochemistry Analysis Change on Skin Biopsies at 3 Months Compared to Baseline.

Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in immunohistochemistry stain. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

,
InterventionPercentage of positive cell detection (Mean)
STAT1STAT3
Skin Biopsy at 3 Months Into Apremilast Therapy for IHC50.117.4
Skin Biopsy at Baseline for IHC96.244.3

Duration of Response (DOR)

DOR is defined as the number of days from the date of first response (complete response [CR], complete response with incomplete marrow recovery [CRi], nodular partial remission [nPR], or partial remission [PR]) to the earliest recurrence or progressive disease. DOR was analyzed by Kaplan-Meier (K-M) methodology. (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

Interventionmonths (Median)
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts35.1
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts55.4

Overall Response Rate (ORR)

Overall response rate is defined as the percentage of participants with an overall response (per the investigator assessment) 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) criteria. (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

Interventionpercentage of participants (Number)
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts64.8
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts69.4

Overall Survival (OS)

OS is defined as the number of days from the date of first dose to the date of death for all dosed participants. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology. (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

Interventionmonths (Median)
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts69.6
ABT-199 After Idelalisib Therapy: Main and Expansion CohortsNA

Progression-free Survival (PFS)

PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology. (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

Interventionmonths (Median)
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts24.7
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts43.4

Time to Next Anti-Chronic Lymphocytic Leukemia Treatment (TNNT)

TNNT is defined as the number of days from the date of the first dose of venetoclax to the date of first dose of any non-protocol anti-leukemia therapy (NPT) or death from any cause. For participants who did not take NPT, their data was censored at the last known date to be free of NPT. TTNT was analyzed by Kaplan-Meier methodology. (NCT02141282)
Timeframe: Collected every 3 months for a period of 5 years after the last participant had enrolled into the study

Interventionmonths (Median)
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts24.0
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts37.8

Time to Progression (TTP)

"TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (PD).~TTP was analyzed by Kaplan-Meier (K-M) methodology." (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort

Interventionmonths (Median)
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts36.1
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts43.4

Percentage of Participants With Minimal Residual Disease (MRD) Negativity Status

The rate of MRD response is defined as the percentage of participants who had MRD negative status. (NCT02141282)
Timeframe: Assessed at Week 24, Day 1; after the first Complete Response, Complete Remission with Incomplete Marrow Recovery, or Partial Response; at 12-week interval visits until two consecutive negative MRD levels were reported

,
Interventionpercentage of participants (Number)
Peripheral bloodBone marrow
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts30.86.6
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts25.011.1

Participants With >/= 95 % Bruton's Tyrosine Kinase (BTK) Occupancy

BTK occupancy level measured by fluorescent affinity probe just before dosing and at 4 and 24 hours post-dosing on days 1, 8, and 28 (but before the first dose of the next cycle) of each cycle. (NCT02801578)
Timeframe: 3 cycles, up to 90 days

InterventionParticipants (Count of Participants)
Ibrutinib8

Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) During Phase I

To assess the safety of TGR1202 in combination with ibrutinib relapsed or refractory CLL or MCL. DLT is based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. DLT refers to toxicities experienced at any time during the study treatment, defined as Grade 4 anemia; Grade 4 neutropenia lasting >7 days (while receiving growth factor support); Grade 4 thrombocytopenia lasting > 7 days; Grade ≥3 febrile neutropenia; and Grade ≥3 thrombocytopenia with Grade >2 hemorrhage;Grade ≥ 3 non-hematologic toxicity unresponsive to standard supportive care measure with the exception of asymptomatic Grade ≥3 lab abnormalities that resolve to ≤ Grade 1 or baseline within 7 days;treatment delay of ≥14 days due to unresolved toxicity; and non-hematologic toxicity of Grade 2 (at any time during treatment) that, in the judgment of the Investigators, Study Chair, and the Medical Monitor, is dose-limiting. (NCT02268851)
Timeframe: Participants were assessed every week or more often as needed during Cycle 1 or more often for up to 28 days to assess Dose-limiting toxicities (DLTs) during Phase I

InterventionParticipants (Count of Participants)
CLL: Phase I Cohort 10
MCL: Phase 1 Cohort 10
CLL: Phase I Cohort 20
MCL: Phase I Cohort 20
CLL Phase I/IICohort 3 (RPD2)0
MCL Phase I/II Cohort 3 (RPD2)0

Duration of Response (DoR): Study Cohort

DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and date of first documented evidence of progressive disease or death or date of censoring. iWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (>=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years 11 months

InterventionMonths (Median)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg11.5
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kgNA
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg19.2
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg10.2
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kgNA
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg6.9

Duration of Stable Disease or Better: Study Cohort

Duration of stable disease or better was defined as duration from the start of the treatment until the criteria for progression were met. IWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years and 11 months

InterventionMonths (Median)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg24.8
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg20.8
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg17.38
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg14.55
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg14.1

Overall Response Rate (ORR) as Assessed International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008: Disease Cohort

ORR is percentage of participants achieving a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR) or PR. IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/L, platelets >100*10^9/L, Hgb >11 g/dL and absolute lymphocyte count <4000/mcL; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- >=50% drop in lymphocyte count from baseline or <=4.0*10^9/L with following: >=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, >=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils >1.5*10^9/L, Platelets>100000/mcL and Hgb>11 g/dL or >=50% improvement over baseline in all. This outcome measure was planned to be analyzed for specified arm only. (NCT02329847)
Timeframe: Up to 6 years 11 months

InterventionPercentage of Participants (Number)
Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL)63.3

Overall Response Rate (ORR) as Assessed Non-Hodgkin Lymphoma (NHL), Cheson 2014: Disease Cohort

ORR defined as percentage of participants achieving a CR, CRi, nPR or PR. As per Non-Hodgkin Lymphoma, Cheson 2014, CR is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is >= 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. Progressive disease (PD) >= 50% increase from nadir in the sum of the products of at least two lymph nodes, or appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. This outcome measure was planned to be analyzed for specified arms only. (NCT02329847)
Timeframe: Up to 6 years 11 months

InterventionPercentage of Participants (Number)
Ibrutinib and Nivolumab: Small Lymphocytic Lymphoma (SLL)50.0
Ibrutinib and Nivolumab: Follicular Lymphoma (FL)32.5
Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL)37.8
Ibrutinib and Nivolumab: Richter65.0

Overall Survival (OS): Study Cohort

OS was defined as duration from the date of first dose of study drug to the date of the participant's death. (NCT02329847)
Timeframe: Up to 6 years 11 months

InterventionMonths (Median)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg12.4
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kgNA
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kgNA
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kgNA
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg19.0
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg10.3

Percentage of Participants With Lymphoma-related Symptoms: Study Cohort

Percentage of participants with lymphoma-related symptoms were reported. These symptoms included B-symptoms, recurrent fever, night sweats, weight loss, other disease-related symptoms, itching, fatigue, physical discomfort and any other. (NCT02329847)
Timeframe: Up to 6 years 11 months

InterventionPercentage of Participants (Number)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg14.3
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg42.9
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg74.3
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg25.7
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg54.1
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg60.0

Percentage of Participants With Treatment-emergent Adverse Event (TEAEs): Study Cohort

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs for the treatment phase included events with an onset date/time on or after the start of study intervention through end of study were considered as treatment-emergent. (NCT02329847)
Timeframe: Up to 6 years 10 months

InterventionPercentage of Participants (Number)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg100
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg100
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg100
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg100
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg97.3
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg95.0

Progression-free Survival (PFS): Study Cohort

PFS is defined as the duration from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. IWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years 11 months

InterventionMonths (Median)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg2.0
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg9.1
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg21.6
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg7.6
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg3.2
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg5.0

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

InterventionParticipants (Count of Participants)
Ibrutinib Plus Rituximab0

Number of Participants With a Response

Over all Response = complete remission (CR) + partial remission (PR). Complete remission (CR), requiring absence of peripheral blood clonal lymphocytes by immunophenotyping, absence of lymphadenopathy, absence of hepatomegaly or splenomegaly, absence of constitutional symptoms and satisfactory blood counts; positive or negative minimal residual disease (MRD); Partial remission (PR), defined as ≥ 50% fall in lymphocyte count, ≥ 50% reduction in lymphadenopathy or ≥ 50% reduction in liver or spleen, together with improvement in peripheral blood counts (NCT01520519)
Timeframe: 7 months

InterventionParticipants (Count of Participants)
Rituximab + PCI-3276537

Progression Free Survival (PFS)

Progression free survival defined as the time interval from treatment to progressive disease or death, whichever happens earlier. Participants in complete remission (CR), partial remission (PR) or stable disease (SD) are all counted as progression-free. Survival or times to progression functions estimated using the Kaplan-Meier method. (NCT01520519)
Timeframe: up to 50 months

InterventionMonths (Median)
Rituximab + PCI-3276545

Mean Change From Baseline to Cycle 5 in EORTC QLQ-C30 Global Health Status Score

Mean change from baseline to Cycle 5 in the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) Global Health Status Score according to EORTC QLQ-C30 Scoring Manual (3rd Edition, 2001). For global health status, positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. A change in 5 to 10 points in either direction represents a small change; 10 to 20 points represents a moderate change and greater than 20 points represents a large change. (NCT01236391)
Timeframe: From Baseline to Cycle 5 (Week 20)

Interventionscores on a scale (Mean)
EORTC QLQ-C300.6

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AE (NCT01236391)
Timeframe: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure

Interventionparticipants (Number)
PCI-32765111

PCI-32765 and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765

Area under the plasma concentration-time curve using data collected at 0, 1, 2, 4, 6-8, and 24 hours post dose (AUC0-24h) (NCT01236391)
Timeframe: Performed During the First Month of Receiving PCI-32765

InterventionAUC0-24h (ng*h/mL) (Mean)
PCI-32765 - Day 8953
PCI-45227 (Metabolite)- Day 81263

Percentage of Participants Achieving Response

The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator. CR is a complete disappearance of all disease, no new lesions, lymph nodes must have regressed and be PET negative, spleen and liver should not be palpable and without nodules, and bone marrow must be negative. PR is a >/= 50% decrease in the sum of the product of diameters of the target lesions, and >/= 50% decrease of splenic and hepatic nodules from baseline, no new lesions and no increase in the size of liver, spleen or non-target lesions. (NCT01236391)
Timeframe: The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months

Interventionpercentage of participants with response (Number)
PCI-3276567.6

Incidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib

(NCT01292135)
Timeframe: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.

InterventionPercentage of Participants (Number)
PCI-32765 Plus Bendamustine/Rituximab (BR)53.3
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)33.3

Incidence of Prolonged Hematologic Toxicity Started in Cycle 1

(NCT01292135)
Timeframe: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.

InterventionPercentage of Participants (Number)
PCI-32765 Plus Bendamustine/Rituximab (BR)0
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)0

Overall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.0

(NCT01292135)
Timeframe: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.

InterventionPercentage of Participants (Number)
PCI-32765 Plus Bendamustine/Rituximab (BR)66.7
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)0

Overall Incidence of Serious Adverse Events (SAEs)

(NCT01292135)
Timeframe: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.

InterventionPercentage of Participants (Number)
PCI-32765 Plus Bendamustine/Rituximab (BR)20
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)33.3

Overall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR])

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. Assessment of response to treatment will be done every 2 cycles for the first 6 months and then every 3 months thereafter until disease progression or prior to the administration of a new anticancer therapy and at follow-up visits. (NCT01292135)
Timeframe: From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.

InterventionPercentage of Participants (Number)
PCI-32765 Plus Bendamustine/Rituximab (BR)93.3
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)100

Progression Free Survival Rate at 12 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01292135)
Timeframe: From first dose of any study medication to 12 months after first dose to progressive disease or death or the last clinical assessment before receiving new anticancer therapy or loss to follow-up, whichever occured the earliest.

InterventionPercentage of Participants (Number)
PCI-32765 Plus Bendamustine/Rituximab (BR)85.9
PCI- 32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)100

Sustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline

(NCT01292135)
Timeframe: From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.

InterventionPercentage of Participants (Number)
PCI-32765 Plus Bendamustine/Rituximab (BR)76.2

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AE (NCT01217749)
Timeframe: From first dose of study treatment to within 30 days of last dose or until study closure

Interventionparticipants (Number)
Group 127
Group 220
Group 324

Percentage of Participants Achieving Response

The primary endpoint for the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR), CR with incomplete blood count recovery (Cri), or partial response (PR), according to the guidelines from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL1) published in 2008 for CLL participants and International Working Group for non-Hodgkin's lymphoma (IWG NHL) 2007 criteria for SLL participants, with the modification that treatment-related lymphocytosis will not be considered progressive disease, as evaluated by the investigators. Assessment of disease is based on radiological exams, physical exam, hematological evaluations and, when appropriate, bone marrow results. (NCT01217749)
Timeframe: The median follow-up time on study for all treated participants is 12.5 (range 0.5-19.6) months

Interventionpercentage of participants (Number)
Group 192.6
Group 280.0
Group 370.8

Progression Free Survival (PFS) at 12 Months

"Progressive disease for CLL (Hallek) is characterized by ≥1 of the following:~Appearance of any new lesion, eg lymph nodes (> 1.5 cm), de novo hepatomegaly or splenomegaly, or other organ infiltrates~Increase of ≥50%~in longest diameter of any previous site~in hepatomegaly or splenomegaly~in blood lymphocytes with ≥5x109/L B cells with enlarging lymph node, liver, or spleen~Progressive disease for B cell lymphoma (Cheson) is characterized by any new lesion or increase by ≥ 50% of previously involved sites from nadir:~Appearance of a new lesion(s) >1.5 cm in any axis, ≥ 50% increase in the SPD of >1 node, or ≥50% increase in longest diameter of a previously identified node >1 cm in short axis~Lesions PET+ if FDG-avid lymphoma or PET+ before therapy~50% increase from nadir in the SPD of any liver or spleen lesions~New or recurrent BM involvement~Increase of ≥50% in blood lymphocytes with ≥5x109/L B cells within enlarging lymph node, liver, or spleen" (NCT01217749)
Timeframe: From first dose of study treatment until disease progression, death, or until 12 months

Interventionpercentage of event free participants (Mean)
Group 188.7
Group 285.0
Group 375.0

Safety During Dose-Limiting Toxicity (DLT) Observation Period

Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2 (NCT01217749)
Timeframe: 56 days for Group 1 and 28 days for Group 2

Interventionparticipants who experienced DLT (Number)
Group 10
Group 20

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AE (NCT01744691)
Timeframe: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure

Interventionparticipants (Number)
PCI-32765144

Overall Response Rate

The primary objective of this study is to evaluate the efficacy of ibrutinib in terms of ORR according to an Independent Review Committee (IRC). ORR based upon IRC assessment is the proportion of responders in the all treated population. Responders were subjects who achieved partial response (PR) or better, ie, complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR, per IWCLL 2008 criteria with the clarification for treatment-related lymphocytosis. (NCT01744691)
Timeframe: The median time on study for all treated participants is 33.3 (range 0.5 - 40.1) months

Intervention% of participants with response by PI (Number)
Ibrutinib77.8

Change in Leukemia Cell Death

Stable isotopic labeling with deuterated water (2^H2O) to measure directly the effects of PCI-32765 (ibrutinib) on leukemia cell death in the peripheral blood of participants . (NCT01752426)
Timeframe: every three months, up to one year

Interventionpercentage of cell death (Median)
Daily death rate of blood cells before therapyDaily death rate of blood cells after therapy
Heavy Water + PCI-327650.181.5

Percentage of Recently Born Leukemia Cells Mobilized Into the Blood by PCI-32765 Treatment

Measurement of the fraction of recently born versus older leukemia cells in the peripheral blood of participants before and during PCI-32765 therapy, to determine the effects of PCI-32765 (ibrutinib) therapy on the birth rates of the leukemia cells. (NCT01752426)
Timeframe: every three months, up to one year

Interventionpercentage of leukemia cells (Median)
Daily cell birth rate before therapyDaily cell birth rate during therapy
Heavy Water + PCI-327650.390.05

Reviews

150 reviews available for adenine and B-Cell Chronic Lymphocytic Leukemia

ArticleYear
[Chimeric antigen receptor T cells].
    Bulletin du cancer, 2021, Volume: 108, Issue:10S

    Topics: Adenine; Antibodies, Bispecific; Antigens, CD19; Antigens, Neoplasm; Cell Engineering; Clinical Tria

2021
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Future oncology (London, England), 2022, Volume: 18, Issue:7

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical

2022
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.
    Expert review of hematology, 2022, Volume: 15, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cardiotoxicity; Humans; Hypertension; Leukemia, Lympho

2022
Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.
    Annals of hematology, 2022, Volume: 101, Issue:8

    Topics: Adenine; CD79 Antigens; Central Nervous System; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymp

2022
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia.
    Current opinion in oncology, 2022, 11-01, Volume: 34, Issue:6

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors

2022
Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; T-Lymp

2022
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
    Drug design, development and therapy, 2022, Volume: 16

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cardiotoxicity; Humans; Leukemia, Lymphocytic, Chronic

2022
Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis.
    Leukemia & lymphoma, 2023, Volume: 64, Issue:4

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis

2023
Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence?
    European journal of haematology, 2023, Volume: 111, Issue:1

    Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Ce

2023
Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
    American journal of hematology, 2019, Volume: 94, Issue:11

    Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans

2019
Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
    Medicine, 2019, Volume: 98, Issue:33

    Topics: Abdominal Pain; Adenine; Constipation; Diarrhea; Female; Humans; Leukemia, Lymphocytic, Chronic, B-C

2019
[Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2019, 08-14, Volume: 40, Issue:8

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2019
Ibrutinib in CLL/SLL: From bench to bedside (Review).
    Oncology reports, 2019, Volume: 42, Issue:6

    Topics: Adenine; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidine

2019
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
    Blood reviews, 2020, Volume: 40

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Invasive Fungal Infections; Leukemia, Lymphocy

2020
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on.
    Hematological oncology, 2020, Volume: 38, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi

2020
Clonal dynamics in chronic lymphocytic leukemia.
    Hematology. American Society of Hematology. Education Program, 2019, 12-06, Volume: 2019, Issue:1

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Epigenesis, Genetic; Gene Expression Regulation, L

2019
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
    Hematology. American Society of Hematology. Education Program, 2019, 12-06, Volume: 2019, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antineoplasti

2019
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
    International journal of molecular sciences, 2019, Dec-20, Volume: 21, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Immunotherapy; Leukemia, Lymphocytic,

2019
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
    European journal of haematology, 2020, Volume: 104, Issue:5

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C

2020
An oral drug for chronic lymphocytic leukemia.
    JAAPA : official journal of the American Academy of Physician Assistants, 2020, Volume: 33, Issue:2

    Topics: Adenine; Administration, Oral; Antineoplastic Agents; Atrial Fibrillation; Hemorrhage; Humans; Hyper

2020
The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology.
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2020,Winter, Volume: 33, Issue:1

    Topics: Adenine; Animals; Antineoplastic Agents; Cell Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Ce

2020
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    International journal of hematology, 2020, Volume: 111, Issue:5

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compou

2020
Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
    Mycoses, 2020, Volume: 63, Issue:8

    Topics: Adenine; Aged; Anticarcinogenic Agents; Antifungal Agents; Aspergillosis; Aspergillus; Female; Fungi

2020
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
    Current hematologic malignancy reports, 2020, Volume: 15, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic,

2020
Ibrutinib dose modifications in the management of CLL.
    Journal of hematology & oncology, 2020, 06-05, Volume: 13, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biotransformation; Clinical Stu

2020
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    American journal of clinical dermatology, 2020, Volume: 21, Issue:6

    Topics: Adenine; Administration, Cutaneous; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Biopsy; Drug Er

2020
Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.
    The Journal of molecular diagnostics : JMD, 2020, Volume: 22, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Biomarkers, Tumor; Drug Resistance, Neo

2020
Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Expert review of hematology, 2020, Volume: 13, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers, Tumor; Clinical Decision-Making; Clinical

2020
[Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:16

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother

2020
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:14

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamid

2020
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2021
Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    British journal of haematology, 2021, Volume: 193, Issue:4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu

2021
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    British journal of haematology, 2021, Volume: 193, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials a

2021
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
    Blood cancer journal, 2021, 04-29, Volume: 11, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol

2021
Genomics of Resistance to Targeted Therapies.
    Hematology/oncology clinics of North America, 2021, Volume: 35, Issue:4

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Genomics; Humans; Leuke

2021
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
    Hematology/oncology clinics of North America, 2021, Volume: 35, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt

2021
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Hematology/oncology clinics of North America, 2021, Volume: 35, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Bridged Bicyclo Com

2021
Targeting Bruton's Tyrosine Kinase in CLL.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Le

2021
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
    Expert opinion on drug metabolism & toxicology, 2021, Volume: 17, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Le

2021
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Leu

2021
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
    Expert review of hematology, 2021, Volume: 14, Issue:9

    Topics: Adenine; Aged; COVID-19; Disease Management; Drug Interactions; Drug-Related Side Effects and Advers

2021
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Annals of hematology, 2017, Volume: 96, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; D

2017
Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
    Clinical pharmacokinetics, 2017, Volume: 56, Issue:11

    Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Interactions; Food-Dru

2017
Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
    Expert review of hematology, 2017, Volume: 10, Issue:5

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu

2017
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Annals of hematology, 2017, Volume: 96, Issue:7

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Drug Therapy; Hematopoi

2017
Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
    Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:5

    Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia,

2017
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Drugs & aging, 2017, Volume: 34, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug Discovery; Graft vs Host Dis

2017
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
    Hematology/oncology and stem cell therapy, 2018, Volume: 11, Issue:1

    Topics: Adenine; Allografts; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Huma

2018
Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
    Journal of oncology practice, 2017, Volume: 13, Issue:6

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu

2017
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Humans; Leukemia, Lymp

2017
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:2

    Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Clinical Trials as Topic; Disea

2018
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:7

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Piperidi

2018
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
    Haematologica, 2017, Volume: 102, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Management; Drug Intera

2017
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    American journal of hematology, 2017, Volume: 92, Issue:9

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2017
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anticoagulants; Antineoplastic Agents; Atrial Fibrilla

2018
Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:7

    Topics: Adenine; Antineoplastic Agents; Biomarkers; Humans; Immunoglobulins, Intravenous; Leukemia, Lymphocy

2018
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers, Tumor; Clinical Trials as Topic; Disease P

2018
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Expert opinion on investigational drugs, 2018, Volume: 27, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol

2018
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
    Journal of comparative effectiveness research, 2018, Volume: 7, Issue:5

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C

2018
How should we sequence and combine novel therapies in CLL?
    Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicycl

2017
How I treat CLL patients with ibrutinib.
    Blood, 2018, 01-25, Volume: 131, Issue:4

    Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Autoimmunity; Communicable Diseases; Disease

2018
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
    British journal of haematology, 2018, Volume: 180, Issue:5

    Topics: Adenine; Anticoagulants; Antineoplastic Agents; Arthralgia; Atrial Fibrillation; Diabetes Mellitus,

2018
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
    Expert review of hematology, 2018, Volume: 11, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Drug Resistance, Neoplasm; Humans; Leukemia,

2018
Optimal management of the young patient CLL patient.
    Best practice & research. Clinical haematology, 2018, Volume: 31, Issue:1

    Topics: Adenine; Age Factors; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Immunotherapy; Leuke

2018
Chronic lymphocytic leukaemia.
    Lancet (London, England), 2018, 04-14, Volume: 391, Issue:10129

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Di

2018
Frontline Therapy of CLL: Evolving Treatment Paradigm.
    Current hematologic malignancy reports, 2018, Volume: 13, Issue:2

    Topics: Adenine; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Immunoglobulin Heavy Chains; Immu

2018
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:12

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Autoimmunity; B-Lympho

2018
Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
    Oncology, 2018, Volume: 95, Issue:5

    Topics: Adenine; Aged; Antineoplastic Agents; Disease Progression; Fatal Outcome; Female; Humans; Leukemia,

2018
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:5

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Pi

2019
Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
    Journal of medical case reports, 2018, Nov-16, Volume: 12, Issue:1

    Topics: Adenine; Administration, Topical; Aged; Anterior Chamber; Antihypertensive Agents; Antineoplastic Ag

2018
Selecting Frontline Therapy for CLL in 2018.
    Hematology. American Society of Hematology. Education Program, 2018, 11-30, Volume: 2018, Issue:1

    Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Delet

2018
Relapsed CLL: sequencing, combinations, and novel agents.
    Hematology. American Society of Hematology. Education Program, 2018, 11-30, Volume: 2018, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cl

2018
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
    Blood, 2019, 03-21, Volume: 133, Issue:12

    Topics: Adenine; Aged; Anti-Infective Agents; Anticoagulants; Arthralgia; Atrial Fibrillation; Drug Resistan

2019
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
    PloS one, 2019, Volume: 14, Issue:2

    Topics: Adenine; Atrial Fibrillation; Databases, Factual; Humans; Hypertension; Leukemia, Lymphocytic, Chron

2019
Ibrutinib for the treatment of chronic lymphocytic leukemia.
    Expert review of hematology, 2019, Volume: 12, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cel

2019
Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.
    British journal of haematology, 2019, Volume: 186, Issue:2

    Topics: Adenine; B-Lymphocytes; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Pip

2019
Targeting BTK in CLL: Beyond Ibrutinib.
    Current hematologic malignancy reports, 2019, Volume: 14, Issue:3

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyr

2019
Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.
    Leukemia research, 2019, Volume: 81

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Hematology; Humans; Infection Control; Infe

2019
Ibrutinib induced acute tubular injury: A case series and review of the literature.
    American journal of hematology, 2019, Volume: 94, Issue:9

    Topics: Acute Kidney Injury; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pip

2019
Updates in prognostication and treatment of Waldenström's macroglobulinemia.
    Hematology/oncology and stem cell therapy, 2019, Volume: 12, Issue:4

    Topics: Adenine; Bone Marrow; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Piperid

2019
Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:1

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Comp

2020
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cellulitis; Ecthyma; Humans; Leukemia, Lymphocyt

2020
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019.
    Journal for immunotherapy of cancer, 2019, 08-01, Volume: 7, Issue:1

    Topics: Adenine; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic,

2019
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
    Leukemia & lymphoma, 2013, Volume: 54, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Autoimmune Diseases; B-Lymphocytes; Drug Eval

2013
Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth

2013
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease-Free Survival; Humans; Leukemia, Lymphocytic,

2014
[Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:3

    Topics: Adenine; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Ce

2013
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
    Hematology/oncology clinics of North America, 2013, Volume: 27, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth

2013
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Clinical therapeutics, 2013, Volume: 35, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; B-Lymphocytes; Clinical T

2013
The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
    Pharmacotherapy, 2014, Volume: 34, Issue:3

    Topics: Adenine; Animals; Disease Management; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-

2014
Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
    Cardiovascular & hematological agents in medicinal chemistry, 2013, Volume: 11, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia

2013
Ibrutinib: first global approval.
    Drugs, 2014, Volume: 74, Issue:2

    Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular

2014
[Chronic lymphocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:2

    Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclo

2014
[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chron

2014
Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
    The Medical letter on drugs and therapeutics, 2014, Apr-14, Volume: 56, Issue:1440

    Topics: Adenine; Animals; Clinical Trials as Topic; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Ce

2014
Novel treatments for chronic lymphocytic leukemia and moving forward.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2014

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Ant

2014
Update on ibrutinib.
    Clinical advances in hematology & oncology : H&O, 2013, Volume: 11, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic,

2013
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
    Expert opinion on biological therapy, 2014, Volume: 14, Issue:7

    Topics: Adenine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-

2014
Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    Drugs of today (Barcelona, Spain : 1998), 2014, Volume: 50, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lympho

2014
BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Oncogene, 2015, May-07, Volume: 34, Issue:19

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Humans; Leukemia, Lymphocytic,

2015
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-20, Volume: 32, Issue:27

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch

2014
[Targeted treatment of chronic lymphocytic leukaemia].
    Ugeskrift for laeger, 2014, Apr-07, Volume: 176, Issue:15

    Topics: Adenine; Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leu

2014
Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
    Pharmacotherapy, 2014, Volume: 34, Issue:12

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans;

2014
Ibrutinib: a paradigm shift in management of CLL.
    Expert review of hematology, 2014, Volume: 7, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi

2014
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Disease-Free Survival; Human

2016
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6

    Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicycl

2015
Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations.
    Immunotherapy, 2015, Volume: 7, Issue:1

    Topics: Adenine; Allografts; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemi

2015
Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Drugs, 2015, Volume: 75, Issue:7

    Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as To

2015
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:7

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Ch

2015
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    British journal of haematology, 2015, Volume: 170, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt

2015
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6

    Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2015
Why patients prescribed oral agents for cancer need training: a case study.
    Clinical journal of oncology nursing, 2015, Volume: 19, Issue:3 Suppl

    Topics: Adenine; Administration, Oral; Antineoplastic Agents; Caregivers; Dose-Response Relationship, Drug;

2015
Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD20; Ant

2015
Targets for Ibrutinib Beyond B Cell Malignancies.
    Scandinavian journal of immunology, 2015, Volume: 82, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Leukemia, Lympho

2015
[Ibrutinib: A new drug of B-cell malignancies].
    Bulletin du cancer, 2015, Volume: 102, Issue:6 Suppl 1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Chromosome Deletion; Genes, p53

2015
Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies.
    Current opinion in oncology, 2015, Volume: 27, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Cost-Benefit Analysis; Creatin

2015
Ibrutinib in B lymphoid malignancies.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Top

2015
Ibrutinib: from bench side to clinical implications.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:9

    Topics: Adenine; Antineoplastic Agents; Biomedical Research; Humans; Leukemia, Lymphocytic, Chronic, B-Cell;

2015
Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:3

    Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2016
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Annals of the New York Academy of Sciences, 2015, Volume: 1358

    Topics: Adenine; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph

2015
The clinical safety of ibrutinib in chronic lymphocytic leukemia.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:10

    Topics: Adenine; Animals; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular T

2015
Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.
    Drugs & aging, 2015, Volume: 32, Issue:11

    Topics: Adenine; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Ant

2015
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Haematologica, 2015, Volume: 100, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antibodies, Monoclonal; Antibodies, Monoclona

2015
Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.
    Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015

    Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemi

2015
Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
    Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Drug Resistance,

2016
Ibrutinib for treatment of chronic lymphocytic leukemia.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Mar-15, Volume: 73, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Clinical Trials as Topic; Humans; Leukemia, Lymphocyti

2016
Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic,

2016
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016, Volume: 35

    Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Com

2016
Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:7

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Leukemia, Lymphocyti

2017
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:5

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot

2016
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
    Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:5

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot

2016
Second-generation inhibitors of Bruton tyrosine kinase.
    Journal of hematology & oncology, 2016, 09-02, Volume: 9, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazo

2016
Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
    Leukemia research, 2016, Volume: 50

    Topics: Adenine; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Ta

2016
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Anti-cancer agents in medicinal chemistry, 2017, Volume: 17, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Proliferation; Dose-Respon

2017
Current strategies to create tailored and risk-adapted therapies for CLL patients.
    Best practice & research. Clinical haematology, 2016, Volume: 29, Issue:1

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2016
The 21st century revolution in CLL: Why this matters to patients.
    Best practice & research. Clinical haematology, 2016, Volume: 29, Issue:1

    Topics: Adenine; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To

2016
B cell receptor inhibition as a target for CLL therapy.
    Best practice & research. Clinical haematology, 2016, Volume: 29, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Age Factors; Atrial Fibrillation; Diarrhea; Hemorrhage

2016
Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.
    Best practice & research. Clinical haematology, 2016, Volume: 29, Issue:1

    Topics: Adenine; Allografts; Antibodies, Monoclonal; Antibodies, Neoplasm; Bridged Bicyclo Compounds, Hetero

2016
[Primary lymphoma of the skull: Case report and literature review].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2016, Volume: 20, Issue:8

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Craniotomy; Fema

2016
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Clinical therapeutics, 2017, Volume: 39, Issue:1

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disease-Free Survival; Humans; L

2017
Front-line treatment of CLL in the era of novel agents.
    Cancer treatment reviews, 2017, Volume: 53

    Topics: Adenine; Aged; Antineoplastic Agents; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-C

2017
How I manage ibrutinib-refractory chronic lymphocytic leukemia.
    Blood, 2017, 03-09, Volume: 129, Issue:10

    Topics: Adenine; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocyt

2017
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
    Drugs, 2017, Volume: 77, Issue:2

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines

2017
Novel agents versus chemotherapy as frontline treatment of CLL.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:6

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Hum

2017
Targeting of B-cell receptor signalling in B-cell malignancies.
    Journal of internal medicine, 2017, Volume: 282, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans

2017
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
    Current hematologic malignancy reports, 2012, Volume: 7, Issue:1

    Topics: Adenine; Aminopyridines; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morp

2012
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Drug De

2012
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
    Blood, 2012, Dec-06, Volume: 120, Issue:24

    Topics: Adenine; Aminopyridines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Morphol

2012
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Adenine; Aminopyridines; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship

2012
Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
    Current hematologic malignancy reports, 2013, Volume: 8, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Human

2013

Trials

136 trials available for adenine and B-Cell Chronic Lymphocytic Leukemia

ArticleYear
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
    Blood, 2021, 12-16, Volume: 138, Issue:24

    Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols;

2021
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
    Blood, 2021, 12-23, Volume: 138, Issue:25

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Human

2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 12-01, Volume: 39, Issue:34

    Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Het

2021
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
    Blood, 2022, 01-13, Volume: 139, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Female; Humans; K

2022
Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
    Cancer medicine, 2021, Volume: 10, Issue:24

    Topics: Adenine; Aged; Female; Humans; Janus Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle A

2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    EBioMedicine, 2021, Volume: 74

    Topics: Adenine; Antibodies, Viral; BNT162 Vaccine; COVID-19; Female; Hematopoietic Stem Cell Transplantatio

2021
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
    American journal of hematology, 2022, 03-01, Volume: 97, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Gene Deletion; Humans; Leukemia, Lymphocytic, Chron

2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
    Haematologica, 2022, 09-01, Volume: 107, Issue:9

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chloramb

2022
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
    Blood, 2022, 03-03, Volume: 139, Issue:9

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2022
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:7

    Topics: Adenine; Adult; Arthralgia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; M

2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
    Blood advances, 2022, 06-14, Volume: 6, Issue:11

    Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine

2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
    Blood advances, 2022, 06-14, Volume: 6, Issue:11

    Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine

2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
    Blood advances, 2022, 06-14, Volume: 6, Issue:11

    Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine

2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
    Blood advances, 2022, 06-14, Volume: 6, Issue:11

    Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine

2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
    Blood, 2022, 07-14, Volume: 140, Issue:2

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Huma

2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 08-02, Volume: 28, Issue:15

    Topics: Adenine; Adult; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell,

2022
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
    The Lancet. Oncology, 2022, Volume: 23, Issue:6

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu

2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 09-15, Volume: 28, Issue:18

    Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Heterocyclic Compou

2022
Ibrutinib and rituximab for chronic lymphocytic leukaemia.
    The Lancet. Oncology, 2019, Volume: 20, Issue:9

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphoc

2019
A cross-trial comparison of single-agent ibrutinib
    Haematologica, 2020, Volume: 105, Issue:4

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-

2020
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    American journal of hematology, 2019, Volume: 94, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I

2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    American journal of hematology, 2019, Volume: 94, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I

2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    American journal of hematology, 2019, Volume: 94, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I

2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    American journal of hematology, 2019, Volume: 94, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I

2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
    Leukemia, 2020, Volume: 34, Issue:3

    Topics: Adenine; Aged; Aged, 80 and over; Chlorambucil; Disease-Free Survival; Drug Administration Schedule;

2020
Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Journal of clinical and experimental hematopathology : JCEH, 2019, Volume: 59, Issue:4

    Topics: Adenine; Aged; Asian People; Female; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mi

2019
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
    Blood, 2020, 02-13, Volume: 135, Issue:7

    Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Male; Middle Age

2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
    Haematologica, 2021, 02-01, Volume: 106, Issue:2

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamus

2021
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Future oncology (London, England), 2020, Volume: 16, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chronic Disease; Clinical Trials, Phase III as Topic;

2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2020
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
    Leukemia, 2020, Volume: 34, Issue:8

    Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Be

2020
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Blood, 2020, 12-17, Volume: 136, Issue:25

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Gene Expression

2020
Ibrutinib for Chronic Lymphocytic Leukemia with
    The New England journal of medicine, 2020, 07-30, Volume: 383, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Follow-

2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:13

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemi

2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-01, Volume: 38, Issue:31

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2020
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
    American journal of hematology, 2020, Volume: 95, Issue:11

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survi

2020
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
    Leukemia research, 2020, Volume: 97

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2020
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
    Pharmacology research & perspectives, 2020, Volume: 8, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contrace

2020
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
    Blood, 2021, 02-25, Volume: 137, Issue:8

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2021
Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL)
    BMJ open, 2020, 10-15, Volume: 10, Issue:10

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cr

2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Blood, 2021, 02-25, Volume: 137, Issue:8

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Com

2021
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
    Blood, 2021, 05-20, Volume: 137, Issue:20

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Cardio

2021
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
    Leukemia research, 2021, Volume: 102

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunophenotyping; Leukemia

2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    The Lancet. Haematology, 2021, Volume: 8, Issue:4

    Topics: Adenine; Administration, Intravenous; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Age

2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
    Blood, 2021, 06-24, Volume: 137, Issue:25

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoimmune

2021
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
    Investigational new drugs, 2021, Volume: 39, Issue:4

    Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemot

2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
    Haematologica, 2021, 09-01, Volume: 106, Issue:9

    Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inh

2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Leukemia, 2021, Volume: 35, Issue:12

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Annals of hematology, 2021, Volume: 100, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Bispecific

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood, 2021, 11-11, Volume: 138, Issue:19

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    JAMA oncology, 2021, Aug-01, Volume: 7, Issue:8

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic

2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
    Leukemia, 2021, Volume: 35, Issue:10

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillatio

2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 11-01, Volume: 39, Issue:31

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides;

2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 11-01, Volume: 39, Issue:31

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides;

2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 11-01, Volume: 39, Issue:31

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides;

2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 11-01, Volume: 39, Issue:31

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides;

2021
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:11

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; H

2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Blood, 2021, 12-30, Volume: 138, Issue:26

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia,

2021
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Blood, 2017, 05-11, Volume: 129, Issue:19

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease-Free Survival; Dose-Res

2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
    British journal of haematology, 2017, Volume: 178, Issue:2

    Topics: Adenine; Aged; Anticoagulants; Antineoplastic Agents; Female; Guideline Adherence; Hemorrhage; Human

2017
BTK
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-01, Volume: 35, Issue:13

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
    Blood, 2017, 06-29, Volume: 129, Issue:26

    Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Cell Transformation, Neoplastic

2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
    Leukemia, 2018, Volume: 32, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2018
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
    British journal of haematology, 2018, Volume: 182, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Alemtuzumab; Antineoplastic Combined Chemotherap

2018
Ibrutinib treatment improves T cell number and function in CLL patients.
    The Journal of clinical investigation, 2017, Aug-01, Volume: 127, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Be

2017
Ibrutinib treatment improves T cell number and function in CLL patients.
    The Journal of clinical investigation, 2017, Aug-01, Volume: 127, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Be

2017
Ibrutinib treatment improves T cell number and function in CLL patients.
    The Journal of clinical investigation, 2017, Aug-01, Volume: 127, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Be

2017
Ibrutinib treatment improves T cell number and function in CLL patients.
    The Journal of clinical investigation, 2017, Aug-01, Volume: 127, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Be

2017
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
    Blood, 2017, 09-21, Volume: 130, Issue:12

    Topics: Adenine; Adult; Aged; Alemtuzumab; Allografts; Antineoplastic Agents, Immunological; Combined Modali

2017
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
    Annals of hematology, 2017, Volume: 96, Issue:10

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Disease-Free Survival; Female;

2017
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
    Trials, 2017, 08-22, Volume: 18, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chem

2017
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2018
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
    Nature communications, 2017, 12-19, Volume: 8, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combine

2017
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
    Leukemia & lymphoma, 2018, Volume: 59, Issue:9

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Bl

2018
p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.
    Oncogene, 2018, Volume: 37, Issue:11

    Topics: Adenine; Adult; Animals; beta-Arrestins; Case-Control Studies; Cells, Cultured; Endosomes; Germ-Line

2018
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
    Haematologica, 2018, Volume: 103, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human

2018
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Aspergillosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; P

2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; L

2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; L

2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; L

2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; L

2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    JAMA oncology, 2018, 05-01, Volume: 4, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd

2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    JAMA oncology, 2018, 05-01, Volume: 4, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd

2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    JAMA oncology, 2018, 05-01, Volume: 4, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd

2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    JAMA oncology, 2018, 05-01, Volume: 4, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd

2018
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
    Cancer medicine, 2018, Volume: 7, Issue:4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans;

2018
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female;

2018
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female;

2018
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female;

2018
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female;

2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Bone marrow transplantation, 2019, Volume: 54, Issue:1

    Topics: Adenine; Adult; Aged; Allografts; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoieti

2019
Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.
    Cancer, 2018, 08-01, Volume: 124, Issue:15

    Topics: Adenine; Aged; B-Cell Activating Factor; Biomarkers, Tumor; Cell Proliferation; Female; Humans; Immu

2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
    British journal of haematology, 2018, Volume: 182, Issue:4

    Topics: Adenine; Adult; Aftercare; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 17

2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:10

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Blood, 2018, 10-11, Volume: 132, Issue:15

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi

2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
    American journal of hematology, 2018, Volume: 93, Issue:11

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Hum

2018
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
    Blood, 2018, 11-22, Volume: 132, Issue:21

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Dose-Response Relationship, Drug; Female; Humans

2018
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers; Follow-Up Studies; Humans; Leukemia, Lymph

2019
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia, 2019, Volume: 33, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2019
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol

2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol

2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol

2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol

2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:1

    Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Ch

2019
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
    Blood, 2019, 03-07, Volume: 133, Issue:10

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combin

2019
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    The Lancet. Haematology, 2019, Volume: 6, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Heterocycl

2019
Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    International journal of hematology, 2019, Volume: 109, Issue:3

    Topics: Adenine; Asian People; Female; Follow-Up Studies; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-C

2019
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    The Lancet. Haematology, 2019, Volume: 6, Issue:2

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic

2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    The Lancet. Haematology, 2019, Volume: 6, Issue:2

    Topics: Adenine; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dose-Response Relationship, Drug; Fema

2019
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
    American journal of hematology, 2019, Volume: 94, Issue:5

    Topics: Adenine; Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocyti

2019
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
    Blood, 2019, 05-09, Volume: 133, Issue:19

    Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Cell Proliferation; Cytidine Deaminase; Down-Re

2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
    Blood, 2019, 05-09, Volume: 133, Issue:19

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Femal

2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
    Blood, 2019, 05-09, Volume: 133, Issue:19

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Femal

2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
    Blood, 2019, 05-09, Volume: 133, Issue:19

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Femal

2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
    Blood, 2019, 05-09, Volume: 133, Issue:19

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Femal

2019
Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
    Cancer medicine, 2019, Volume: 8, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemo

2019
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
    Blood, 2019, 05-30, Volume: 133, Issue:22

    Topics: Adenine; Aged; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pipe

2019
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    JCI insight, 2019, 04-02, Volume: 5

    Topics: Adenine; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2019
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
    American journal of hematology, 2019, Volume: 94, Issue:7

    Topics: Adenine; Autoimmune Diseases; Disease-Free Survival; Female; Hematologic Diseases; Humans; Leukemia,

2019
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience.
    Hematological oncology, 2019, Volume: 37, Issue:4

    Topics: Adenine; Adolescent; Adult; Child; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocy

2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
    Pharmaceutical research, 2019, May-01, Volume: 36, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin

2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
    Blood advances, 2019, 05-14, Volume: 3, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzam

2019
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
    Future oncology (London, England), 2019, Volume: 15, Issue:19

    Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cl

2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    The New England journal of medicine, 2019, 05-30, Volume: 380, Issue:22

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-20, Volume: 37, Issue:30

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic

2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    The Lancet. Haematology, 2019, Volume: 6, Issue:9

    Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dr

2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2019, 08-01, Volume: 381, Issue:5

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Imm

2019
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2013
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
    Leukemia, 2014, Volume: 28, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Coculture Techni

2014
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym

2014
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym

2014
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym

2014
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym

2014
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
    Blood, 2014, May-22, Volume: 123, Issue:21

    Topics: Adenine; Aged; Bone Marrow; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymp

2014
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.
    Leukemia, 2014, Volume: 28, Issue:11

    Topics: Adenine; Aged; Blood Viscosity; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell;

2014
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
    Blood, 2014, Jun-26, Volume: 123, Issue:26

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
    Future oncology (London, England), 2015, Volume: 11, Issue:1

    Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Anti

2015
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M

2014
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
    Annals of hematology, 2015, Volume: 94, Issue:2

    Topics: Adenine; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug

2015
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
    Blood, 2014, Dec-04, Volume: 124, Issue:24

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Antineoplastic Agents; B-Lymp

2014
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human

2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human

2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human

2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud

2015
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
    Blood, 2015, May-07, Volume: 125, Issue:19

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Cohort Studies; Female

2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
    Blood, 2015, Aug-13, Volume: 126, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antib

2015
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.
    Future oncology (London, England), 2015, Volume: 11, Issue:13

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Double-Blind Me

2015
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Blood, 2015, 11-05, Volume: 126, Issue:19

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; B-Lymphocytes; Bone Marrow; F

2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Haematologica, 2015, Volume: 100, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Factor VIII; Female; Follow-Up Studies; Hemorrhage; Humans;

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    The Lancet. Oncology, 2016, Volume: 17, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atr

2016
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Apr-01, Volume: 22, Issue:7

    Topics: Adenine; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Bone Marrow; Cell Communication; C

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood, 2016, Mar-03, Volume: 127, Issue:9

    Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy

2016
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
    JAMA dermatology, 2016, 06-01, Volume: 152, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Female

2016
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Haematologica, 2016, Volume: 101, Issue:6

    Topics: Adenine; Aged; Anemia; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mi

2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Blood, 2016, 10-13, Volume: 128, Issue:15

    Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P

2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Blood, 2016, 10-13, Volume: 128, Issue:15

    Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P

2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Blood, 2016, 10-13, Volume: 128, Issue:15

    Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P

2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Blood, 2016, 10-13, Volume: 128, Issue:15

    Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P

2016
Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
    JAMA oncology, 2016, Dec-01, Volume: 2, Issue:12

    Topics: Adenine; Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Influenza Vaccines; Influenza,

2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    The Lancet. Oncology, 2016, Volume: 17, Issue:10

    Topics: Adenine; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Genes, p53; Humans; Leukemi

2016
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
    Haematologica, 2016, Volume: 101, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Drug Resista

2016
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
    Blood, 2016, 12-22, Volume: 128, Issue:25

    Topics: Adenine; Adult; Aged; B-Lymphocytes; Chimerism; Cohort Studies; Female; Germinal Center; Graft vs Ho

2016
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
    British journal of haematology, 2017, Volume: 176, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Comb

2017
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
    British journal of haematology, 2018, Volume: 181, Issue:2

    Topics: Adenine; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperi

2018
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia.
    Cancer letters, 2004, Jul-16, Volume: 210, Issue:2

    Topics: Adenine; Administration, Oral; Area Under Curve; Humans; Infusions, Intravenous; Leukemia, Hairy Cel

2004

Other Studies

566 other studies available for adenine and B-Cell Chronic Lymphocytic Leukemia

ArticleYear
Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 11-01, Volume: 39, Issue:31

    Topics: Adenine; Aged; Aged, 80 and over; Canada; Cardiovascular Diseases; Case-Control Studies; Cohort Stud

2021
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:12

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines;

2021
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
    Blood advances, 2021, 12-28, Volume: 5, Issue:24

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pharmaceutical Preparations; Piperidines; P

2021
Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib.
    BMJ case reports, 2021, Sep-21, Volume: 14, Issue:9

    Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphoc

2021
Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.
    Blood advances, 2021, 12-14, Volume: 5, Issue:23

    Topics: Adenine; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Leukemia, Lymphoc

2021
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
    Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:3

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Py

2022
Ibrutinib's off-target mechanism: cause for dose optimization.
    Cancer biology & therapy, 2021, 12-02, Volume: 22, Issue:10-12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi

2021
Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:10

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2021
Treatment with ibrutinib does not induce a
    Haematologica, 2022, 01-01, Volume: 107, Issue:1

    Topics: Adenine; Clonal Evolution; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Tumor Suppre

2022
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.
    European journal of haematology, 2022, Volume: 108, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Cause of Death; Comorbidity; Disease Management; Female; Hu

2022
Ibrutinib skin toxicities: Report of two cases.
    Journal of cutaneous pathology, 2022, Volume: 49, Issue:4

    Topics: Adenine; Aged; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cel

2022
Successful treatment of cutaneous Acanthamoeba castellanii infection with miltefosine in a patient with chronic lymphocytic leukaemia on ibrutinib.
    The Journal of antimicrobial chemotherapy, 2022, 02-02, Volume: 77, Issue:2

    Topics: Acanthamoeba castellanii; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylcholine

2022
Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome.
    Hematological oncology, 2022, Volume: 40, Issue:2

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Transcriptome

2022
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.
    Journal of translational medicine, 2021, 11-22, Volume: 19, Issue:1

    Topics: Adenine; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear

2021
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    British journal of haematology, 2022, Volume: 196, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc

2022
Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib.
    Clinical and experimental dermatology, 2022, Volume: 47, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Blister; Hemorrhage; Humans; Leukemia, Lymphocyt

2022
Is there a role for anti-CD20 antibodies in CLL?
    Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD2

2021
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzam

2021
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:4

    Topics: Adenine; Adult; Cardiac Tamponade; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged

2022
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
    Blood, 2022, 04-07, Volume: 139, Issue:14

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Sin

2022
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:6

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Mult

2022
Atypical "accelerated" chronic lymphocytic leukemia with abnormal lymphocyte chromatin clumping, bone involvement, and exceptional response to Imbruvica.
    Cancer reports (Hoboken, N.J.), 2022, Volume: 5, Issue:9

    Topics: Adenine; Aged; B-Lymphocytes; Chromatin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pip

2022
[Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:1

    Topics: Adenine; Aged; Cryptococcosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines

2022
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
    American journal of hematology, 2022, Volume: 97, Issue:5

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Protein Kinase Inhi

2022
Research progress in overcoming ibrutinib drug resistance.
    Drugs of today (Barcelona, Spain : 1998), 2022, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antineoplastic Agents; Drug Resistance; Drug Resistance, Neoplasm; Humans; Leukemia,

2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
    Blood, 2022, 06-02, Volume: 139, Issue:22

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu

2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
    The New England journal of medicine, 2022, 02-24, Volume: 386, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt

2022
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
    Haematologica, 2022, 06-01, Volume: 107, Issue:6

    Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Leukemia, Lymphocytic, C

2022
The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.
    Thrombosis research, 2022, Volume: 212

    Topics: Adenine; Adult; Constriction, Pathologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine

2022
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:8

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Retros

2022
Campylobacter infection in 4 patients treated with ibrutinib.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2022, Volume: 41, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Campylobacter Infections; Diarrhea; Humans; Leukemia,

2022
Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases.
    Current oncology (Toronto, Ont.), 2022, 02-27, Volume: 29, Issue:3

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Primary Myelofibrosis

2022
Is ibrutinib the gold standard for therapy - naive elderly patients with CLL?
    Leukemia & lymphoma, 2022, Volume: 63, Issue:6

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines

2022
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
    Current oncology (Toronto, Ont.), 2022, 04-15, Volume: 29, Issue:4

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2022
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
    Blood, 2022, 07-28, Volume: 140, Issue:4

    Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence,

2022
Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
    British journal of haematology, 2022, Volume: 198, Issue:3

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nocardia Infections; Piperidines

2022
Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
    Advances in therapy, 2022, Volume: 39, Issue:7

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C

2022
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
    Science signaling, 2022, 05-31, Volume: 15, Issue:736

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt

2022
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
    Blood advances, 2022, 09-27, Volume: 6, Issue:18

    Topics: Adenine; Calcium; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines

2022
A CAPTIVATE-ing new regimen for CLL.
    Blood, 2022, 06-02, Volume: 139, Issue:22

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2022
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
    British journal of haematology, 2022, Volume: 198, Issue:4

    Topics: Adenine; Australia; Duration of Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines

2022
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:8

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors

2022
Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study.
    American journal of hematology, 2022, Volume: 97, Issue:9

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies;

2022
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
    Leukemia, 2022, Volume: 36, Issue:8

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamus

2022
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia.
    Molecular oncology, 2022, Volume: 16, Issue:16

    Topics: Adenine; Chromosomes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; p21-Activated Kinases; Piperid

2022
Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.
    Journal of clinical and experimental hematopathology : JCEH, 2022, Sep-28, Volume: 62, Issue:3

    Topics: Adenine; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Product Surveillance, P

2022
Ibrutinib frontline in young patients with CLL.
    Blood, 2022, 07-14, Volume: 140, Issue:2

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab

2022
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
    British journal of haematology, 2022, Volume: 199, Issue:2

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu

2022
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
    Leukemia, 2022, Volume: 36, Issue:8

    Topics: Adenine; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progres

2022
A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.
    BMC nephrology, 2022, 07-23, Volume: 23, Issue:1

    Topics: Adenine; Aged, 80 and over; Endothelial Cells; ErbB Receptors; Glomerulonephritis, Membranoprolifera

2022
A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib.
    Molecules (Basel, Switzerland), 2022, Jul-25, Volume: 27, Issue:15

    Topics: Adenine; Humans; Laboratories, Clinical; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthalenes; Piper

2022
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:12

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C

2022
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort.
    Blood advances, 2023, 02-28, Volume: 7, Issue:4

    Topics: Adenine; Aged, 80 and over; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines

2023
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-14, Volume: 28, Issue:20

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cr

2022
Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia.
    Anti-cancer drugs, 2022, 09-01, Volume: 33, Issue:8

    Topics: Adenine; Colorectal Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pa

2022
An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.
    The American journal of case reports, 2022, Aug-26, Volume: 23

    Topics: Adenine; Adult; Aged, 80 and over; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Ce

2022
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib.
    Blood cancer journal, 2022, 09-01, Volume: 12, Issue:9

    Topics: Adenine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles

2022
Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Adenine; Cross-Sectional Studies; Fatigue; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient S

2022
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
    Pathology oncology research : POR, 2022, Volume: 28

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leu

2022
Richter transformation to aggressive plasmablastic neoplasm related to selection of a
    Leukemia & lymphoma, 2023, Volume: 64, Issue:1

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Plasma Cells

2023
Severe Postoperative Bleeding Secondary to Ibrutinib Intake.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2023, 01-01, Volume: 49, Issue:1

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors

2023
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL.
    Nature reviews. Clinical oncology, 2023, Volume: 20, Issue:2

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors

2023
Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib.
    Cancer research and treatment, 2023, Volume: 55, Issue:2

    Topics: Adenine; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kin

2023
Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib.
    Internal medicine (Tokyo, Japan), 2023, 09-15, Volume: 62, Issue:18

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Tre

2023
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
    Leukemia, 2023, Volume: 37, Issue:4

    Topics: Adenine; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Tum

2023
Bleeding complication following a shave biopsy in a patient taking ibrutinib.
    Dermatology online journal, 2022, Dec-15, Volume: 28, Issue:6

    Topics: Adenine; Biopsy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibit

2022
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
    Leukemia, 2023, Volume: 37, Issue:7

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu

2023
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
    Blood advances, 2023, 08-22, Volume: 7, Issue:16

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retrospective Studies

2023
Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia.
    Hematological oncology, 2023, Volume: 41 Suppl 1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi

2023
Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia.
    Annals of hematology, 2023, Volume: 102, Issue:8

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Rituximab; Secondary Prevention

2023
Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    British journal of haematology, 2023, Volume: 203, Issue:4

    Topics: Adenine; Aspergillosis; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell;

2023
New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer, 2023, 11-01, Volume: 129, Issue:21

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Recurrence

2023
Ibrutinib outperforms FCR in CLL.
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:10

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituxi

2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    The New England journal of medicine, 2019, 08-22, Volume: 381, Issue:8

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
    The New England journal of medicine, 2019, 08-22, Volume: 381, Issue:8

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
    Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:11

    Topics: Abnormal Karyotype; Adenine; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11

2019
Can Combination Targeted Therapy Bring About Another Paradigm Shift in Chronic Lymphocytic Leukemia?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-20, Volume: 37, Issue:30

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2019
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
    Leukemia, 2020, Volume: 34, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Amyloid Precursor Protein Secretases; Animals; Calcium; Dia

2020
Autoimmune hemolytic anemia, adverse event to venetoclax.
    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2019, Sep-01, Volume: 43, Issue:5

    Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemoth

2019
Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
    International journal of hematology, 2019, Volume: 110, Issue:6

    Topics: Adenine; Aged; Cryoglobulinemia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines;

2019
Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
    Journal of immunology (Baltimore, Md. : 1950), 2019, 10-15, Volume: 203, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Cell Proli

2019
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
    Mycoses, 2019, Volume: 62, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Immunocompromised Host; Invasive Fungal Inf

2019
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17 Suppl 1, Issue:1

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chloramb

2019
The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy.
    Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2019, Oct-16, Volume: 48, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cunninghamella; Humans; Immunocompromised Host;

2019
Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
    American journal of hematology, 2020, Volume: 95, Issue:1

    Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidine

2020
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
    American journal of hematology, 2019, Volume: 94, Issue:12

    Topics: Adenine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles;

2019
Ibrutinib-associated oral ulcers.
    Oral oncology, 2020, Volume: 100

    Topics: Adenine; Aged; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Metr

2020
Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
    Leukemia research, 2019, Volume: 87

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antineoplastic Combined Chemotherapy

2019
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.
    Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:12

    Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Female; Health Care Costs; Health Resources; Hu

2019
[Improvement of autoimmune cytopenia with ibrutinib in a chronic lymphocytic leukemia patient complicated by monoclonal immunoglobulin deposition disease].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2019, Volume: 60, Issue:10

    Topics: Adenine; Aged; Antibodies, Monoclonal; Autoimmune Diseases; Female; Humans; Leukemia, Lymphocytic, C

2019
[Richter syndrome successfully treated with ibrutinib monotherapy: two case reports].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2019, Volume: 60, Issue:10

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Piperidine

2019
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.
    Bone marrow transplantation, 2020, Volume: 55, Issue:5

    Topics: Adenine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Ma

2020
Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Current oncology (Toronto, Ont.), 2019, Volume: 26, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Canada

2019
[Aspergillus spondylodiscitis in a patient treated with ibrutinib].
    Medecine et maladies infectieuses, 2020, Volume: 50, Issue:3

    Topics: Adenine; Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Asp

2020
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Pharmacological research, 2020, Volume: 151

    Topics: Adenine; Animals; Cell Line, Tumor; Enzyme Stability; HEK293 Cells; HSP90 Heat-Shock Proteins; Human

2020
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
    Annals of hematology, 2019, Volume: 98, Issue:12

    Topics: Adenine; Aged, 80 and over; Cryptococcosis; Dermatomycoses; Female; Humans; Leukemia, Lymphocytic, C

2019
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
    Annals of hematology, 2019, Volume: 98, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin

2019
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
    Oncology (Williston Park, N.Y.), 2019, Nov-14, Volume: 33, Issue:11

    Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth

2019
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
    American journal of hematology, 2020, Volume: 95, Issue:3

    Topics: Adenine; Aged; Aged, 80 and over; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Fe

2020
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia.
    JAMA network open, 2019, 12-02, Volume: 2, Issue:12

    Topics: Adenine; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Leukemia, Lymphocytic, Chroni

2019
Relapsed disease and aspects of undetectable MRD and treatment discontinuation.
    Hematology. American Society of Hematology. Education Program, 2019, 12-06, Volume: 2019, Issue:1

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged Bicyclo Co

2019
Two-drug combination benefits patients with chronic lymphocytic leukemia.
    Cancer, 2020, 01-01, Volume: 126, Issue:1

    Topics: Adenine; B-Lymphocytes; Drug Combinations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidin

2020
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
    Leukemia, 2020, Volume: 34, Issue:6

    Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Prot

2020
A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Leukemia research, 2020, Volume: 89

    Topics: Adenine; Area Under Curve; Female; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluor

2020
The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    British journal of haematology, 2020, Volume: 188, Issue:6

    Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd

2020
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.
    Nature communications, 2020, Jan-29, Volume: 11, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chromatin; Epigenome; Epigenomics; Gene Expression Pro

2020
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
    Blood, 2020, 04-09, Volume: 135, Issue:15

    Topics: Adenine; Cell Proliferation; Disease Progression; Humans; Immunotherapy; Integrin alpha4; Leukemia,

2020
Ibrutinib-induced polyneuropathy: A case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2020
[Chronic lymphocytic leukemia].
    Der Internist, 2020, Volume: 61, Issue:3

    Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leuk

2020
Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:7

    Topics: Adenine; Aged; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Ki

2020
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
    Blood, 2020, 05-07, Volume: 135, Issue:19

    Topics: Adenine; Adult; Aged; Antigens, CD19; Combined Modality Therapy; Drug Resistance, Neoplasm; Feasibil

2020
Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report.
    BMC infectious diseases, 2020, Feb-24, Volume: 20, Issue:1

    Topics: Adenine; Aged; Aspergillosis; Aspergillus; Central Nervous System Infections; Humans; Leukemia, Lymp

2020
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Leukemia research, 2020, Volume: 91

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Col

2020
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
    Haematologica, 2021, 04-01, Volume: 106, Issue:4

    Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidi

2021
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
    Cancer medicine, 2020, Volume: 9, Issue:10

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Deprescriptions; Dose-Response Relationship, Drug; Female;

2020
An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.
    International journal of environmental research and public health, 2020, 03-16, Volume: 17, Issue:6

    Topics: Adenine; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 11; Exercise; Humans; Leuk

2020
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Incidence; Leukemia, Lympho

2020
Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Annals of hematology, 2021, Volume: 100, Issue:1

    Topics: Adenine; Aged; Antineoplastic Agents; Comorbidity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; M

2021
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
    Blood, 2020, 06-11, Volume: 135, Issue:24

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds

2020
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Blood, 2020, 06-18, Volume: 135, Issue:25

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Bridge

2020
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2020, 08-28, Volume: 37, Issue:3

    Topics: Adenine; Antineoplastic Agents; Hepatitis B Core Antigens; Hepatitis B virus; Humans; Leukemia, Lymp

2020
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Leukemia, 2021, Volume: 35, Issue:1

    Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molec

2021
Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
    Clinical pharmacokinetics, 2020, Volume: 59, Issue:9

    Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthalenes; Piperidines

2020
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 07-15, Volume: 26, Issue:14

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benza

2020
CAR-T and ibrutinib vs CLL: sequential or simultaneous?
    Blood, 2020, 05-07, Volume: 135, Issue:19

    Topics: Adenine; Feasibility Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles

2020
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
    Haematologica, 2021, 04-01, Volume: 106, Issue:4

    Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocyt

2021
Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
    Advances in therapy, 2020, Volume: 37, Issue:7

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2020
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
    British journal of cancer, 2020, Volume: 123, Issue:2

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological;

2020
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
    Leukemia, 2020, Volume: 34, Issue:7

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Betacoronavi

2020
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
    British journal of haematology, 2020, Volume: 190, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus;

2020
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Annals of hematology, 2021, Volume: 100, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Disease Management; Female; Follow-Up

2021
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
    Journal of thrombosis and haemostasis : JTH, 2020, Volume: 18, Issue:10

    Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines;

2020
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
    Blood, 2020, 10-22, Volume: 136, Issue:17

    Topics: Adenine; Aged; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Leukemia,

2020
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:10

    Topics: Adenine; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Piperidines; Pyrazoles

2020
[Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020, 05-14, Volume: 41, Issue:5

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Meningitis, Cryptococcal; Piperidines; Pyra

2020
Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL).
    Leukemia & lymphoma, 2020, Volume: 61, Issue:11

    Topics: Adenine; Glucose; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lipid Metabolism; Piperidines; Pyr

2020
Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
    Annals of hematology, 2021, Volume: 100, Issue:2

    Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic,

2021
LC-FACSeq is a method for detecting rare clones in leukemia.
    JCI insight, 2020, 06-18, Volume: 5, Issue:12

    Topics: Adenine; Clonal Evolution; Clone Cells; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Mu

2020
Patterns of use and safety of ibrutinib in real-life practice.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:3

    Topics: Adenine; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-

2021
The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.
    Leukemia research, 2020, Volume: 95

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers, Tu

2020
Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 135

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Decision-Making; Female; France; H

2020
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
    Anticancer research, 2020, Volume: 40, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; H

2020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
    Leukemia, 2020, Volume: 34, Issue:9

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Betacoronavirus; Comorbidity;

2020
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
    Advances in medical sciences, 2020, Volume: 65, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resist

2020
Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic.
    Current oncology (Toronto, Ont.), 2020, Volume: 27, Issue:3

    Topics: Adenine; Ambulatory Care; Antineoplastic Agents; Appointments and Schedules; Betacoronavirus; Canada

2020
Atypical Painful Purpuric Cutaneous Nodules With Ibrutinib.
    The American Journal of dermatopathology, 2020, Volume: 42, Issue:12

    Topics: Adenine; Aged; Antineoplastic Agents; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell

2020
Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    British journal of haematology, 2020, Volume: 191, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Diagnostic Errors; Female; Humans

2020
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    International journal of cancer, 2021, 01-15, Volume: 148, Issue:2

    Topics: Adenine; Antigens, CD19; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocyte

2021
Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:10

    Topics: Adenine; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Myco

2020
Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
    Leukemia research, 2020, Volume: 96

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Drug Synergism; Histamine Antagonists; Huma

2020
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.
    Haematologica, 2021, 09-01, Volume: 106, Issue:9

    Topics: Adenine; Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Receptor

2021
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
    European journal of haematology, 2020, Volume: 105, Issue:5

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Ly

2020
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
    Medecine et maladies infectieuses, 2020, Volume: 50, Issue:8

    Topics: Adenine; Cryptococcosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase

2020
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Annals of hematology, 2020, Volume: 99, Issue:10

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2020
Bringing hospital care closer to patients amidst COVID-19.
    The Lancet. Haematology, 2020, Volume: 7, Issue:9

    Topics: Adenine; Betacoronavirus; Checklist; Coronavirus Infections; COVID-19; Hematologic Neoplasms; Humans

2020
Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
    Aging, 2020, 08-27, Volume: 12, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protoc

2020
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:14

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Hemostasis; Humans; Leukemia, Lymphocytic, Chronic

2020
Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:10

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Costs; Female; Health

2020
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
    The oncologist, 2020, Volume: 25, Issue:11

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyr

2020
[Haemorrhagic complications following ibrutinib intake after dermatological surgery].
    Annales de dermatologie et de venereologie, 2020, Volume: 147, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell;

2020
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
    Blood advances, 2020, 09-22, Volume: 4, Issue:18

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Piperidine

2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cancer medicine, 2020, Volume: 9, Issue:22

    Topics: Adenine; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplast

2020
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Aspergillosis; Aspergillus fumi

2020
Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
    BMJ case reports, 2020, Sep-29, Volume: 13, Issue:9

    Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation

2020
ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
    Virchows Archiv : an international journal of pathology, 2021, Volume: 478, Issue:4

    Topics: Adenine; Adult; Anaplastic Lymphoma Kinase; Biomarkers; Female; Histiocytosis; Humans; Leukemia, Lym

2021
Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
    Annals of hematology, 2021, Volume: 100, Issue:12

    Topics: Adenine; Aged; Ecthyma; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pseudomon

2021
Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients.
    Hematological oncology, 2021, Volume: 39, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Immunoglobulin A; Infect

2021
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
    Current medical research and opinion, 2020, Volume: 36, Issue:12

    Topics: Adenine; Aged; Cost Savings; Female; Health Care Costs; Humans; Immunotherapy; Leukemia, Lymphocytic

2020
Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 02-20, Volume: 39, Issue:6

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Pyrazoles; Pyrimidi

2021
Ibrutinib-Induced Skin Rash
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2021, Feb-25, Volume: 38, Issue:1

    Topics: Adenine; Aged; Biopsy; Exanthema; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Ce

2021
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.
    Haematologica, 2020, 10-05, Volume: 106, Issue:5

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C

2020
Enterobius vermicularis Infection of the Lung Associated With the Use of Ibrutinib in a Patient With Chronic Lymphocytic Leukemia.
    American journal of therapeutics, 2020, 10-12, Volume: 28, Issue:6

    Topics: Adenine; Enterobiasis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung; Piperidines

2020
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
    Journal of immunology (Baltimore, Md. : 1950), 2020, 11-15, Volume: 205, Issue:10

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance,

2020
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
    Journal of immunology (Baltimore, Md. : 1950), 2020, 11-15, Volume: 205, Issue:10

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance,

2020
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
    Journal of immunology (Baltimore, Md. : 1950), 2020, 11-15, Volume: 205, Issue:10

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance,

2020
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
    Journal of immunology (Baltimore, Md. : 1950), 2020, 11-15, Volume: 205, Issue:10

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance,

2020
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
    Leukemia, 2021, Volume: 35, Issue:6

    Topics: Adenine; Aged; Biomarkers, Tumor; Chemokine CXCL13; Female; Follow-Up Studies; Humans; Leukemia, Lym

2021
Cost-effectiveness targeting CLL.
    Blood, 2020, 10-22, Volume: 136, Issue:17

    Topics: Adenine; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazol

2020
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Deglutition Disorders; Female; Huma

2021
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Hematological oncology, 2021, Volume: 39, Issue:2

    Topics: Adenine; Aged; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia,

2021
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2021, Feb-25, Volume: 38, Issue:1

    Topics: Adenine; Aged; Biomarkers; Biopsy; Cardiac Tamponade; Echocardiography; Female; Humans; Leukemia, Ly

2021
Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:4

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Hum

2021
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
    Blood, 2021, 05-06, Volume: 137, Issue:18

    Topics: Adenine; Adult; Aged; Biomarkers, Tumor; CD40 Antigens; Female; Follow-Up Studies; Gene Expression R

2021
Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:4

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines

2021
Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    European journal of haematology, 2021, Volume: 106, Issue:3

    Topics: Adenine; Biomarkers, Tumor; Drug Resistance, Neoplasm; Genetic Testing; High-Throughput Nucleotide S

2021
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
    European journal of haematology, 2021, Volume: 106, Issue:3

    Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognos

2021
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:3

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyr

2021
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
    European journal of haematology, 2021, Volume: 106, Issue:3

    Topics: Adenine; Aged; Cross Infection; Humans; Incidence; Inpatients; Leukemia, Lymphocytic, Chronic, B-Cel

2021
Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    British journal of haematology, 2021, Volume: 192, Issue:2

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents, Immunological; An

2021
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    eLife, 2020, 11-23, Volume: 9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Catalytic Domain; COVID-19; Dasatinib; Humans; Leukemi

2020
Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2021, Mar-01, Volume: 32, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antithrombins; Atrial Fibrillation; Dabigatran;

2021
EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
    Biochemical pharmacology, 2021, Volume: 183

    Topics: Adenine; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Br

2021
Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.
    Cells, 2020, 12-22, Volume: 10, Issue:1

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Comp

2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
    European journal of haematology, 2021, Volume: 106, Issue:4

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor;

2021
IBRUTINIB FOR CONTROL OF CHOROIDAL AND ORBITAL METASTASIS FROM CHRONIC LYMPHOCYTIC LEUKEMIA.
    Retinal cases & brief reports, 2023, Mar-01, Volume: 17, Issue:2

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inh

2023
Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
    Annals of hematology, 2022, Volume: 101, Issue:1

    Topics: Adenine; Aged; Brain; Humans; Intracranial Hemorrhages; Leukemia, Lymphocytic, Chronic, B-Cell; Male

2022
The Eyes Cannot See What the Mind Does Not Know: Endocrinological Side Effects of Ibrutinib.
    WMJ : official publication of the State Medical Society of Wisconsin, 2020, Volume: 119, Issue:4

    Topics: Adenine; Aged, 80 and over; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prote

2020
Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates.
    BMJ case reports, 2021, Jan-19, Volume: 14, Issue:1

    Topics: Adenine; Aged; Ecthyma; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Piperidine

2021
Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
    Clinical pharmacology and therapeutics, 2021, Volume: 110, Issue:1

    Topics: Adenine; Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymp

2021
Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
    Ocular immunology and inflammation, 2022, May-19, Volume: 30, Issue:4

    Topics: Adenine; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Lymphocytic, Chronic, B-

2022
[Successful treatment with silver nitrate chemical cauterization for paronychia and granulation in a patient with chronic lymphocytic leukemia undergoing ibrutinib therapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2021, Volume: 62, Issue:1

    Topics: Adenine; Aged; Cautery; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Paronychia; Piperidine

2021
Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
    Current medical research and opinion, 2021, Volume: 37, Issue:4

    Topics: Adenine; Bendamustine Hydrochloride; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Ce

2021
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    American journal of hematology, 2021, 05-01, Volume: 96, Issue:5

    Topics: Adenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia

2021
Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:7

    Topics: Adenine; Agammaglobulinemia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Ki

2021
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
    Blood cancer journal, 2021, 02-18, Volume: 11, Issue:2

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2021
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
    Journal of hematology & oncology, 2021, 02-24, Volume: 14, Issue:1

    Topics: Adenine; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gl

2021
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cysteine; Drug Resistance, Neoplasm; Humans; Leukemia,

2021
Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.
    Haematologica, 2021, 08-01, Volume: 106, Issue:8

    Topics: Adenine; COVID-19; Humans; Immunity, Innate; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pr

2021
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
    Blood cancer journal, 2021, 03-13, Volume: 11, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Apoptosis; Drug Synergism; Female; Heterocyclic Compounds,

2021
MARCKS affects cell motility and response to BTK inhibitors in CLL.
    Blood, 2021, 08-19, Volume: 138, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Movement; Humans; Leukemia, Lymphocytic, Chronic,

2021
Cerebral aspergillosis in a patient on ibrutinib therapy.
    British journal of haematology, 2021, Volume: 193, Issue:6

    Topics: Adenine; Adrenal Cortex Hormones; Aged; Aspergillosis; Aspergillus fumigatus; Brain Diseases; Humans

2021
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
    Blood, 2021, 09-02, Volume: 138, Issue:9

    Topics: Adaptor Proteins, Signal Transducing; Adenine; Cell Line, Tumor; Cell Movement; Forkhead Box Protein

2021
Immediate reaction to ibrutinib amenable to oral desensitization.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:7

    Topics: Adenine; Aged; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Leukemia, Lympho

2021
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
    Leukemia, 2021, Volume: 35, Issue:11

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosomes, Human, Pair 2; Cohort

2021
[Intravenous immunoglobulin in combination with ibrutinib for the treatment of IgM-type M protein associated peripheral neuropathy complicated with chronic lymphocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2021, Volume: 62, Issue:3

    Topics: Adenine; Aged; Humans; Immunoglobulin M; Immunoglobulins, Intravenous; Leukemia, Lymphocytic, Chroni

2021
A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
    Clinical advances in hematology & oncology : H&O, 2020, Volume: 18 Suppl 10, Issue:6

    Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Disease-Free Survival; Female; Flow Cytometry;

2020
An Eschar-like souvenir from a journey to Colombia: Ecthyma gangrenosum as a differential diagnosis of tropical diseases in immunocompromised patients - a case report.
    BMC infectious diseases, 2021, Apr-12, Volume: 21, Issue:1

    Topics: Adenine; Administration, Intravenous; Aged; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Col

2021
Select Antitumor Cytotoxic CD8
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 08-15, Volume: 27, Issue:16

    Topics: Adenine; CD8-Positive T-Lymphocytes; Cells, Cultured; Humans; Leukemia, Lymphocytic, Chronic, B-Cell

2021
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
    American journal of hematology, 2021, 08-01, Volume: 96, Issue:8

    Topics: Adenine; Aged; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidin

2021
Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
    Internal medicine (Tokyo, Japan), 2021, Oct-15, Volume: 60, Issue:20

    Topics: Adenine; Aged; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines;

2021
Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.
    Clinical and experimental dermatology, 2021, Volume: 46, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2021
Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
    Clinical drug investigation, 2021, Volume: 41, Issue:7

    Topics: Adenine; Aged; Databases, Factual; Drug Prescriptions; Female; Health Care Costs; Humans; Italy; Leu

2021
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury.
    Scientific reports, 2021, 06-07, Volume: 11, Issue:1

    Topics: Acute Kidney Injury; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B

2021
Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 08-15, Volume: 27, Issue:16

    Topics: Adaptive Immunity; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles;

2021
Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Annals of hematology, 2021, Volume: 100, Issue:11

    Topics: Adenine; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Female; Humans; Leukemia, Lymphocytic, Ch

2021
Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
    Leukemia research, 2021, Volume: 109

    Topics: Activities of Daily Living; Adenine; Aged; Cytokines; Female; Follow-Up Studies; Humans; Leukemia, L

2021
Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma.
    The Israel Medical Association journal : IMAJ, 2021, Volume: 23, Issue:6

    Topics: Adenine; Adenocarcinoma of Lung; Aged; ErbB Receptors; Humans; Leukemia, Lymphocytic, Chronic, B-Cel

2021
Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
    Journal of immunology (Baltimore, Md. : 1950), 2021, 07-15, Volume: 207, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; B-Lymphocytes; Cell Adhesion; Cell Survival

2021
Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Annals of hematology, 2022, Volume: 101, Issue:3

    Topics: Adenine; Adult; Central Nervous System Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; L

2022
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Drug Resistance, Ne

2021
Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:7

    Topics: Adenine; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Retrospectiv

2021
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    British journal of haematology, 2021, Volume: 195, Issue:1

    Topics: Adenine; Aged; Biopsy; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chr

2021
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
    Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:3

    Topics: Adenine; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; Cell Line, Tumo

2022
Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
    Leukemia research, 2021, Volume: 110

    Topics: Adenine; Antineoplastic Agents, Immunological; Clonal Evolution; Clone Cells; Humans; Immunoglobulin

2021
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
    Blood, 2021, 12-09, Volume: 138, Issue:23

    Topics: Abnormal Karyotype; Adenine; Adult; Aged; Aged, 80 and over; Clonal Evolution; Female; Humans; Leuke

2021
Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report.
    Annals of palliative medicine, 2022, Volume: 11, Issue:5

    Topics: Adenine; Aged; Chylothorax; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pleur

2022
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Pathology, 2022, Volume: 54, Issue:1

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Genes,

2022
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:14

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors

2021
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:13

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors

2021
Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:12

    Topics: Adenine; Aged; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell

2021
Effect of Ibrutinib on Hmphocytic Leukemia: a Single-Center Experience.
    Hematology/oncology and stem cell therapy, 2022, Dec-23, Volume: 15, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protei

2022
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
    British journal of haematology, 2021, Volume: 195, Issue:4

    Topics: Adenine; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytomegalo

2021
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
    Blood advances, 2021, 08-24, Volume: 5, Issue:16

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cel

2021
Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:11

    Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyri

2021
Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:12

    Topics: Adenine; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cel

2021
Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2021, 12-07, Volume: 38, Issue:4

    Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidine

2021
Targeted therapies: Ibrutinib: new option for relapsed MZL.
    Nature reviews. Clinical oncology, 2017, 03-20, Volume: 14, Issue:4

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Py

2017
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Leukemia, 2017, Volume: 31, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; C2 Domains; Drug Resistance, Neoplasm; Humans; Leukemi

2017
Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.
    Oncotarget, 2017, May-23, Volume: 8, Issue:21

    Topics: Adenine; Adult; Aged; Cell Proliferation; Cytokines; Female; Humans; Leukemia, Lymphocytic, Chronic,

2017
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
    British journal of haematology, 2017, Volume: 178, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents;

2017
Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
    American journal of hematology, 2017, Volume: 92, Issue:8

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; France; Humans; Leukemia, Ly

2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 05-01, Volume: 28, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic

2017
The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:10

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Humans; Leukemia, Lymphocytic, C

2017
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Blood, 2017, 07-13, Volume: 130, Issue:2

    Topics: Adenine; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; D

2017
A complex case of ibrutinib treatment for a CLL patient on haemodialysis.
    British journal of haematology, 2018, Volume: 181, Issue:6

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimid

2018
Is HBV prophylaxis required during CLL treatment with ibrutinib?
    Leukemia & lymphoma, 2017, Volume: 58, Issue:12

    Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Biomarkers; Hepatitis B; Humans; Leukemia, Lymphoc

2017
Imbruvica
    British journal of nursing (Mark Allen Publishing), 2017, May-25, Volume: 26, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Drug Industry; Humans; Le

2017
Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
    Anticancer research, 2017, Volume: 37, Issue:6

    Topics: Adenine; Aged; Antineoplastic Agents; Biopsy; Cell Transformation, Neoplastic; Disease Progression;

2017
Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:12

    Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis;

2017
Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
    European journal of haematology, 2017, Volume: 99, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols;

2017
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
    Advances in therapy, 2017, Volume: 34, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, A

2017
The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.
    Haematologica, 2017, Volume: 102, Issue:9

    Topics: Adenine; Aminoimidazole Carboxamide; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Synerg

2017
Ibrutinib may impair serological responses to influenza vaccination.
    Haematologica, 2017, Volume: 102, Issue:10

    Topics: Adenine; Humans; Influenza Vaccines; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles;

2017
Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.
    Hematological oncology, 2018, Volume: 36, Issue:1

    Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma

2018
Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:3

    Topics: Adenine; Communicable Diseases; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B

2018
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
    Tumori, 2017, Nov-15, Volume: 103, Issue:Suppl. 1

    Topics: Adenine; Aged; Cell Transformation, Neoplastic; Disease Progression; Humans; Leukemia, Lymphocytic,

2017
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    Journal of immunology (Baltimore, Md. : 1950), 2017, 08-15, Volume: 199, Issue:4

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20;

2017
Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
    Journal of medical economics, 2017, Volume: 20, Issue:10

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch

2017
Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:3

    Topics: Adenine; Antiviral Agents; HIV; HIV Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male

2018
Splenic rupture following temporary cessation of ibrutinib.
    British journal of haematology, 2017, Volume: 179, Issue:3

    Topics: Adenine; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lympho

2017
Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib.
    British journal of haematology, 2018, Volume: 182, Issue:5

    Topics: Adenine; Aged; Case-Control Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; M

2018
Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.
    Journal of clinical pharmacy and therapeutics, 2018, Volume: 43, Issue:1

    Topics: Adenine; Aged; Autoantibodies; Glutamate Decarboxylase; Humans; Insulin Antibodies; Leukemia, Lympho

2018
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17S

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Atrial Fibrillation; B-Lympho

2017
Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis.
    PharmacoEconomics, 2017, Volume: 35, Issue:8

    Topics: Adenine; Adult; Antineoplastic Agents; Clinical Decision-Making; Cost-Benefit Analysis; Genomics; Hu

2017
Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
    BMC medicine, 2017, 08-16, Volume: 15, Issue:1

    Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2017
Staphylococcal Scalded Skin Syndrome Caused by a Rare Variant of Exfoliative-toxin-A+ S. aureus in an Adult Immunocompromised Woman.
    Acta dermato-venereologica, 2018, 01-12, Volume: 98, Issue:1

    Topics: Adenine; Anti-Bacterial Agents; Antineoplastic Agents; Biopsy; Exfoliatins; Female; Humans; Immunoco

2018
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
    Haematologica, 2017, Volume: 102, Issue:11

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models,

2017
Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jul-01, Volume: 28, Issue:suppl_4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Ge

2017
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
    International journal of cancer, 2018, 01-15, Volume: 142, Issue:2

    Topics: Adenine; Aged; Biomarkers, Tumor; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Hum

2018
Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis.
    The American Journal of dermatopathology, 2018, Volume: 40, Issue:2

    Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neutro

2018
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Leukemia, 2018, Volume: 32, Issue:4

    Topics: Adenine; Aged; B-Lymphocytes, Regulatory; B7-H1 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-

2018
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
    Cancer research, 2017, 12-15, Volume: 77, Issue:24

    Topics: Adenine; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assay

2017
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
    Leukemia, 2018, Volume: 32, Issue:4

    Topics: Adenine; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes;

2018
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
    American journal of hematology, 2018, Volume: 93, Issue:2

    Topics: Adenine; Drug Substitution; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pro

2018
Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:8

    Topics: Adenine; Animals; Antigens, CD; Cell Adhesion; Coculture Techniques; Fibroblasts; Humans; Immunophen

2018
Survival adjusting for crossover: phase 3 study of ibrutinib
    Haematologica, 2018, Volume: 103, Issue:6

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambucil; Clin

2018
Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2018, Volume: 120, Issue:3

    Topics: Adenine; Agammaglobulinemia; Aged; Bacterial Infections; Humans; Immunoglobulins; Leukemia, Lymphocy

2018
    Haematologica, 2018, Volume: 103, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; CD79 Antigens; Clonal Anergy; Endocytosis;

2018
Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.
    Haematologica, 2018, Volume: 103, Issue:3

    Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd

2018
Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
    European journal of haematology, 2018, Volume: 100, Issue:4

    Topics: Adenine; Adult; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-C

2018
Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Future oncology (London, England), 2018, Volume: 14, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecu

2018
Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.
    The Lancet. Oncology, 2018, Volume: 19, Issue:1

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2018
Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Clinical chemistry and laboratory medicine, 2018, 04-25, Volume: 56, Issue:5

    Topics: Adenine; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Co

2018
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
    Cancer biology & therapy, 2018, 01-02, Volume: 19, Issue:1

    Topics: Adenine; Aged; Antineoplastic Agents; Atrial Fibrillation; Case-Control Studies; Electrocardiography

2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
    The Journal of experimental medicine, 2018, 02-05, Volume: 215, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Adhesion; Humans; Immunoglobulin M; Integrin alph

2018
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.
    Blood, 2018, 03-15, Volume: 131, Issue:11

    Topics: Adenine; Animals; Casein Kinase 1 epsilon; Casein Kinase Idelta; Cell Line, Tumor; Drug Delivery Sys

2018
Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:3

    Topics: Adenine; Aged; Cryptococcosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pi

2019
Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer discovery, 2018, Volume: 8, Issue:3

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother

2018
Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2018, May-25, Volume: 35, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Central Nervous System; Central Nervous System N

2018
Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:2

    Topics: Adenine; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chlorambucil; Comor

2018
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
    Medecine et maladies infectieuses, 2018, Volume: 48, Issue:4

    Topics: Adenine; Aged; Brain Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neuroaspergillo

2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
    Haematologica, 2018, Volume: 103, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Drug-Related Side Effects and Adverse

2018
CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.
    Immunotherapy, 2018, 02-01, Volume: 10, Issue:4

    Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyri

2018
Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018, Volume: 24, Issue:7

    Topics: Adenine; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Culture; C

2018
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adenine; Adult; Aged; Fatty Acids, Nonesterified; Female; Humans; Leukemia, Lymphocytic, Chronic, B-

2018
Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adenine; Aged; Antiviral Agents; Fatal Outcome; Feasibility Studies; Female; Hepatitis B; Hepatitis

2018
Ibrutinib-Induced Neutrophilic Dermatosis.
    The American Journal of dermatopathology, 2018, Volume: 40, Issue:3

    Topics: Adenine; Antineoplastic Agents; Chromosomes, Human, Pair 17; Drug Eruptions; Female; Humans; Leukemi

2018
Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib.
    British journal of haematology, 2018, Volume: 181, Issue:4

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Piperidines; Pyraz

2018
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 08-16, Volume: 67, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Bacterial Infections; Electronic Health Records; Female; Hu

2018
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
    Internal medicine (Tokyo, Japan), 2018, Aug-15, Volume: 57, Issue:16

    Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2018
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
    Cancer biology & therapy, 2018, 07-03, Volume: 19, Issue:7

    Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Drug Subs

2018
Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach.
    Internal medicine journal, 2018, Volume: 48, Issue:4

    Topics: Adenine; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukem

2018
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
    Haematologica, 2018, Volume: 103, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin

2018
Ibrutinib: coming of age?
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Pyraz

2018
Ibrutinib and fungus: an invasive concern.
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Adult; Fungi; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrim

2018
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
    Anticancer research, 2018, Volume: 38, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Disease-Free S

2018
Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Arthritis; Humans; Leukemia, Lymphocytic, Chroni

2019
Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
    JACC. Clinical electrophysiology, 2016, Volume: 2, Issue:7

    Topics: Adenine; Aged; Electrocardiography; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidi

2016
Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
    European journal of haematology, 2018, Volume: 101, Issue:3

    Topics: Adenine; Clinical Trials, Phase III as Topic; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-

2018
Five years of ibrutinib in CLL.
    Blood, 2018, 05-24, Volume: 131, Issue:21

    Topics: Adenine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles;

2018
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
    Cancer, 2018, 08-01, Volume: 124, Issue:15

    Topics: Adenine; Aged; Aged, 80 and over; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Elec

2018
Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
    Annals of hematology, 2019, Volume: 98, Issue:1

    Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aut

2019
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Biochemistry, 2018, 07-03, Volume: 57, Issue:26

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Cell Line, Tumor; Drug Design

2018
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
    Journal of hematology & oncology, 2018, 06-11, Volume: 11, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Atrial Fibrillation; Echocard

2018
Counterpoint: Does Chemoimmunotherapy Still Have a Role in CLL? Chemotherapy Can Be Eliminated in the Management of CLL.
    Oncology (Williston Park, N.Y.), 2018, Volume: 32, Issue:6

    Topics: Adenine; Antineoplastic Agents, Immunological; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immu

2018
Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?
    Haematologica, 2018, Volume: 103, Issue:7

    Topics: Adenine; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Py

2018
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
    British journal of haematology, 2019, Volume: 185, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C

2019
Resolution of eosinophilia and elevated immunoglobulin E with ibrutinib for chronic lymphocytic leukemia.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2018, Volume: 121, Issue:5

    Topics: Adenine; Eosinophilia; Humans; Immunoglobulin E; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middl

2018
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
    Journal of clinical and experimental hematopathology : JCEH, 2018, Sep-19, Volume: 58, Issue:3

    Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Humans; Leukemia, Lymphocytic, Chronic

2018
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
    Blood, 2018, 09-06, Volume: 132, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Cell Line, Tumor; Drug Resist

2018
Unusual cause of sinusitis and cough.
    BMJ case reports, 2018, Jul-19, Volume: 2018

    Topics: Adenine; Biopsy; Cough; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Midd

2018
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:6

    Topics: Adenine; Aged; Antifungal Agents; Aspergillus fumigatus; B-Lymphocytes; Humans; Leukemia, Lymphocyti

2019
No longer too exhausted to run.
    Blood, 2018, 08-02, Volume: 132, Issue:5

    Topics: Adenine; Antibodies, Bispecific; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Pipe

2018
Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.
    Blood advances, 2018, 08-14, Volume: 2, Issue:15

    Topics: Adenine; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Costs and Cost Analysis; Female; Hu

2018
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.
    British journal of haematology, 2018, Volume: 183, Issue:3

    Topics: Academic Medical Centers; Adenine; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Disease-Free

2018
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
    British journal of haematology, 2018, Volume: 183, Issue:2

    Topics: Adenine; Aged; Antineoplastic Agents; B-Lymphocytes; Down-Regulation; Female; Gene Expression Profil

2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
    American journal of hematology, 2018, Volume: 93, Issue:11

    Topics: Adenine; Age Factors; Aged; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Female; Humans; L

2018
Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
    Leukemia research, 2018, Volume: 72

    Topics: Adenine; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Gene Expression Regul

2018
Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
    American journal of hematology, 2018, Volume: 93, Issue:12

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocyti

2018
Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia.
    EBioMedicine, 2018, Volume: 35

    Topics: Adenine; beta 2-Microglobulin; Cell Death; Disease Progression; Humans; Immunoglobulin G; Injections

2018
Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:3

    Topics: Adenine; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macular Edema;

2019
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
    Blood, 2018, 11-22, Volume: 132, Issue:21

    Topics: Adenine; Aged; Aged, 80 and over; Cells, Cultured; Coculture Techniques; Cytokines; Dendritic Cells;

2018
Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.
    Haematologica, 2019, Volume: 104, Issue:1

    Topics: Adenine; Base Sequence; Disease Progression; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyti

2019
A new triple threat to CLL.
    Blood, 2018, 10-11, Volume: 132, Issue:15

    Topics: Adenine; Adult; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Humans;

2018
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
    British journal of haematology, 2019, Volume: 184, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Pr

2019
Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, Apr-15, Volume: 25, Issue:8

    Topics: Adenine; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein-Tyro

2019
Superior vena cava syndrome with concomitant upper extremity deep vein thrombosis.
    Internal and emergency medicine, 2019, Volume: 14, Issue:2

    Topics: Adenine; Aged; Female; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyr

2019
Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
    British journal of haematology, 2019, Volume: 185, Issue:4

    Topics: Adenine; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Ly

2019
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
    Blood advances, 2018, 11-13, Volume: 2, Issue:21

    Topics: Adenine; Animals; Antigens, CD19; Apoptosis; B-Lymphocytes; Cell Proliferation; Disease Models, Anim

2018
Is less equal with ibrutinib dose?
    Blood, 2018, 11-22, Volume: 132, Issue:21

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pilot Projects; Piperidines; Pyrazoles; Pyr

2018
γδ T cells for immunotherapy.
    Blood, 2018, 11-22, Volume: 132, Issue:21

    Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyri

2018
A rare colonic manifestation of chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:1

    Topics: Adenine; Aged; Colon, Sigmoid; Colonic Polyps; Female; Humans; Intestinal Mucosa; Leukemia, Lymphocy

2019
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Cancer research, 2019, 01-15, Volume: 79, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Proliferation; Cell Survival; Humans; Leukemia, L

2019
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Cancer, 2019, 02-15, Volume: 125, Issue:4

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combine

2019
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
    Haematologica, 2019, Volume: 104, Issue:5

    Topics: Adenine; Aged; Compassionate Use Trials; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human

2019
Cryopreservation of primary B cells minimally influences their signaling responses.
    Scientific reports, 2018, 12-05, Volume: 8, Issue:1

    Topics: Adenine; B-Lymphocytes; CD40 Ligand; Cells, Cultured; Cryopreservation; Flow Cytometry; Humans; Leuk

2018
Ibrutinib: searching for a partner drug.
    The Lancet. Oncology, 2019, Volume: 20, Issue:1

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother

2019
Concurrent treatment with two B-cell receptor pathway inhibitors.
    The Lancet. Haematology, 2019, Volume: 6, Issue:1

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein

2019
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
    Leukemia, 2019, Volume: 33, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2019
IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.
    American journal of hematology, 2019, Volume: 94, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Agen

2019
Alliance to iLLUMINATE the chemo-free sign.
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:2

    Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth

2019
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
    Bulletin du cancer, 2019, Volume: 106, Issue:1

    Topics: Adenine; Aged; Alemtuzumab; Antineoplastic Agents, Immunological; Antiviral Agents; Chronic Disease;

2019
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).
    Leukemia & lymphoma, 2019, Volume: 60, Issue:7

    Topics: Adenine; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Human

2019
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
    Leukemia, 2019, Volume: 33, Issue:4

    Topics: Adenine; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pip

2019
Ibrutinib-associated T-cell pseudolymphoma.
    Clinical and experimental dermatology, 2019, Volume: 44, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Diagnosis, Differential; Humans; Leukemia, Lymph

2019
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:6

    Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; My

2019
Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2019, Volume: 25, Issue:2

    Topics: Abdomen; Adenine; Aged; Fatal Outcome; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Ch

2019
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
    Nature chemical biology, 2019, Volume: 15, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Cycle Proteins; Chromatin; Drug Combinations; Dru

2019
Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
    Leukemia, 2019, Volume: 33, Issue:7

    Topics: Adenine; Biomarkers, Tumor; Circadian Rhythm; Drug Therapy, Combination; Gene Expression Regulation,

2019
Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2019, Volume: 25, Issue:6

    Topics: Adenine; Adult; Aspergillosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucormycosis; Neoplas

2019
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
    Cancer cell, 2019, 02-11, Volume: 35, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alternative Splicing; Animals; Antineoplastic Agents;

2019
Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:7

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines

2019
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 04-15, Volume: 25, Issue:8

    Topics: Adenine; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; P

2019
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:5

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; He

2019
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
    Blood advances, 2019, 02-12, Volume: 3, Issue:3

    Topics: Adenine; Animals; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphocytic, Chronic, B-Cell;

2019
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.
    British journal of haematology, 2019, Volume: 186, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Comorbidity; Female; Humans; Leukemia, Lymphocytic, Chronic

2019
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
    British journal of haematology, 2019, Volume: 186, Issue:1

    Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2019
Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.
    The American Journal of dermatopathology, 2020, Volume: 42, Issue:2

    Topics: Adenine; Antineoplastic Agents; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male

2020
Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.
    The oncologist, 2019, Volume: 24, Issue:9

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C

2019
Targeting CD20 takes the backseat in CLL.
    Blood, 2019, 03-07, Volume: 133, Issue:10

    Topics: Adenine; Antigens, CD20; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyr

2019
Fever and Rash in an Adult: Varicella Re-infection in Conjunction with Newly Diagnosed Chronic Lymphocytic Leukemia.
    The American journal of medicine, 2019, Volume: 132, Issue:6

    Topics: Acyclovir; Adenine; Adult; Antiviral Agents; Chickenpox; Dermatitis; Fever; Humans; Leukemia, Lympho

2019
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 07-01, Volume: 25, Issue:13

    Topics: Adenine; ADP-ribosyl Cyclase 1; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplast

2019
Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.
    British journal of haematology, 2019, Volume: 186, Issue:2

    Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neopl

2019
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
    Heart rhythm, 2019, Volume: 16, Issue:9

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Atrial Fibrillation; A

2019
Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
    Cancer medicine, 2019, Volume: 8, Issue:5

    Topics: Adenine; Aged; Anticoagulants; Antineoplastic Agents; Drug Approval; Female; Hemorrhage; Humans; Inc

2019
Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:9

    Topics: Adenine; Female; Foot Dermatoses; Hand Dermatoses; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; M

2019
Ibrutinib Regimens in Older Patients with Untreated CLL.
    The New England journal of medicine, 2019, 04-25, Volume: 380, Issue:17

    Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles

2019
Ibrutinib Regimens in Older Patients with Untreated CLL.
    The New England journal of medicine, 2019, 04-25, Volume: 380, Issue:17

    Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles

2019
Ibrutinib Regimens in Older Patients with Untreated CLL.
    The New England journal of medicine, 2019, 04-25, Volume: 380, Issue:17

    Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles

2019
Ibrutinib Regimens in Older Patients with Untreated CLL. Reply.
    The New England journal of medicine, 2019, 04-25, Volume: 380, Issue:17

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines

2019
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
    International journal of cancer, 2019, 12-01, Volume: 145, Issue:11

    Topics: Adenine; Case-Control Studies; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relation

2019
Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
    Haematologica, 2020, Volume: 105, Issue:1

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytokine

2020
Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib.
    Mayo Clinic proceedings, 2019, Volume: 94, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cryptococcosis; Fatal Outcome; Humans; Leukemia, Lymph

2019
Ibrutinib: the home run for cure in CLL?
    Blood, 2019, 05-09, Volume: 133, Issue:19

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chroni

2019
Ibrutinib is safer than we think.
    Blood, 2019, 05-09, Volume: 133, Issue:19

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines

2019
Managing patients with ibrutinib-resistant CLL: don't stop ibrutinib until you are ready with the next therapy.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:11

    Topics: Adenine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles

2019
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    The Lancet. Haematology, 2019, Volume: 6, Issue:7

    Topics: Adenine; Antineoplastic Agents; beta 2-Microglobulin; Bridged Bicyclo Compounds, Heterocyclic; Datab

2019
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:12

    Topics: Adenine; Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Re

2019
Ibrutinib and Venetoclax - Doubling Down on CLL.
    The New England journal of medicine, 2019, 05-30, Volume: 380, Issue:22

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2019
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cardiomyopathies; Female; Humans; Late Onset Dis

2020
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
    International journal of cancer, 2020, 01-01, Volume: 146, Issue:1

    Topics: Adenine; Cohort Studies; Female; Gene Expression Profiling; High-Throughput Nucleotide Sequencing; H

2020
Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:12

    Topics: Adenine; Antineoplastic Agents; Comorbidity; Disease Progression; Drug Resistance, Neoplasm; Female;

2019
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cl

2019
Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2019, Volume: 28, Issue:8

    Topics: Adenine; Adult; Antineoplastic Agents; Compassionate Use Trials; Humans; Leukemia, Lymphocytic, Chro

2019
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
    The American journal of cardiology, 2019, 08-15, Volume: 124, Issue:4

    Topics: Adenine; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito

2019
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs.
    The Lancet. Haematology, 2019, Volume: 6, Issue:8

    Topics: Adenine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; P

2019
New first-line options in CLL.
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:9

    Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi

2019
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphoc

2019
Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
    The Lancet. Haematology, 2019, Volume: 6, Issue:9

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm

2019
Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
    Scientific reports, 2019, 07-30, Volume: 9, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Survival; Drug Resistance, Neoplasm; Energy Metab

2019
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
    British journal of haematology, 2019, Volume: 187, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Di

2019
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    British journal of pharmacology, 2019, Volume: 176, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Ce

2019
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.
    Leukemia, 2013, Volume: 27, Issue:12

    Topics: Adenine; Aged; Animals; Female; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping

2013
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Cell death & disease, 2013, May-16, Volume: 4

    Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Prote

2013
A mechanism-driven treatment for chronic lymphocytic leukemia?
    The New England journal of medicine, 2013, Jul-04, Volume: 369, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Female; Humans; Leukemia, Lymph

2013
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
    Leukemia, 2013, Volume: 27, Issue:10

    Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Imm

2013
Targeting the B-cell signalling pathway in CLL and MCL.
    The Lancet. Oncology, 2013, Volume: 14, Issue:9

    Topics: Adenine; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piper

2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Blood, 2014, Feb-20, Volume: 123, Issue:8

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Survival; Disease Mode

2014
A new era of treatment for chronic lymphocytic leukaemia?
    The Lancet. Oncology, 2014, Volume: 15, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell

2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
    Blood, 2014, Mar-20, Volume: 123, Issue:12

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; CD40 Ligand; Disease-F

2014
Imbruvica--next big drug in B-cell cancer--approved by FDA.
    Nature biotechnology, 2014, Volume: 32, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Drug

2014
Boldly Targeting Kinases without mutations.
    Blood, 2014, Feb-20, Volume: 123, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Female; Humans; Leukemia, Lymphocytic, Chroni

2014
Idelalisib, ibrutinib show benefits in CLL.
    Cancer discovery, 2014, Volume: 4, Issue:4

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T

2014
Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:6

    Topics: Adenine; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Endoplasmic Reti

2014
Ibrutinib: targeting the hidden CLL.
    Blood, 2014, May-22, Volume: 123, Issue:21

    Topics: Adenine; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Piperidines

2014
New approved indication for ibrutinib.
    The American journal of nursing, 2014, Volume: 114, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Approval; Humans; Leukemia, Lymphocytic, Chronic,

2014
Ibrutinib resistance in chronic lymphocytic leukemia.
    The New England journal of medicine, 2014, Jun-12, Volume: 370, Issue:24

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, L

2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
    The New England journal of medicine, 2014, Jun-12, Volume: 370, Issue:24

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Binding Sites; Drug Resistance, Neoplasm; Exome;

2014
Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
    American journal of hematology, 2015, Volume: 90, Issue:2

    Topics: Adenine; Aged; Allopurinol; Antimetabolites; Antineoplastic Agents; Chromosome Deletion; Chromosomes

2015
Changes in the treatment landscape for chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Female; Humans; Leukemia, Lympho

2014
Ibrutinib treatment of CLL: the cancer fights back.
    Cancer cell, 2014, Jul-14, Volume: 26, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Progression; Drug Resis

2014
The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center.
    European journal of internal medicine, 2014, Volume: 25, Issue:8

    Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Female;

2014
[Chronic Lymphocytic Leukemia. New targeted therapy option Ibrutinib].
    Medizinische Monatsschrift fur Pharmazeuten, 2014, Volume: 37, Issue:7

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines

2014
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
    Leukemia, 2015, Volume: 29, Issue:4

    Topics: Adenine; Adenosine Diphosphate; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Platelets; Cel

2015
Ibrutinib: better combined with other drugs?
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fem

2014
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
    Leukemia, 2015, Volume: 29, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor

2015
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Sep-23, Volume: 111, Issue:38

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Evolution, Molecular; Human

2014
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
    Haematologica, 2015, Volume: 100, Issue:1

    Topics: Adenine; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplasti

2015
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
    Leukemia, 2015, Volume: 29, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2015
Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia.
    Blood, 2014, Nov-27, Volume: 124, Issue:23

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles;

2014
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
    Leukemia, 2015, Volume: 29, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibo

2015
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
    Blood, 2014, Dec-11, Volume: 124, Issue:25

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Animals, Newborn; Atrial Fibrillation; Gene E

2014
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
    Blood, 2014, Dec-11, Volume: 124, Issue:25

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alleles; Cohort Studies; DNA Mutational Analysis; Drug

2014
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
    British journal of haematology, 2015, Volume: 170, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosomes, Human, Pair 12; Female; Humans; Leukemia, Lymp

2015
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.
    Blood, 2015, Jan-08, Volume: 125, Issue:2

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Female;

2015
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
    Blood, 2015, Mar-26, Volume: 125, Issue:13

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Transformation, Neoplastic; Cli

2015
FDA grants accelerated approval for ibrutinib for CLL.
    The American journal of managed care, 2014, Volume: 20, Issue:5 Spec No.

    Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Approval; Humans; Leukemia,

2014
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Mar-01, Volume: 194, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents; B-Lymphocytes;

2015
Ibrutinib has some activity in Richter's syndrome.
    Blood cancer journal, 2015, Jan-30, Volume: 5

    Topics: Adenine; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell

2015
Understanding cancer cell survival is key to patient survival.
    The Lancet. Oncology, 2015, Volume: 16, Issue:2

    Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mu

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    British journal of haematology, 2015, Volume: 170, Issue:5

    Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2015
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    British journal of haematology, 2015, Volume: 170, Issue:5

    Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2015
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    British journal of haematology, 2015, Volume: 170, Issue:5

    Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2015
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    British journal of haematology, 2015, Volume: 170, Issue:5

    Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2015
The efficacy of ibrutinib in the treatment of Richter syndrome.
    Blood, 2015, Mar-05, Volume: 125, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Murine-Derived; Antineop

2015
Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
    Expert review of hematology, 2015, Volume: 8, Issue:3

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamust

2015
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
    Journal of oncology practice, 2015, Volume: 11, Issue:3

    Topics: Adenine; Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Health Expenditures; Humans; Leuk

2015
Life after ibrutinib? A new unmet need in CLL.
    Blood, 2015, Mar-26, Volume: 125, Issue:13

    Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazol

2015
[Chronic lymphatic leukemia].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:7

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-D

2015
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Aug-15, Volume: 21, Issue:16

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols;

2015
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
    Blood, 2015, Apr-02, Volume: 125, Issue:14

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting,

2015
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
    Blood, 2015, May-14, Volume: 125, Issue:20

    Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dr

2015
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-10, Volume: 33, Issue:14

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Chronic Disease; Disease Progression; Factor Analysis,

2015
Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.
    Annals of hematology, 2015, Volume: 94, Issue:8

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles;

2015
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Leukemia, 2015, Volume: 29, Issue:9

    Topics: Adenine; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Case-Control Studies; Cell Prolifera

2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Blood, 2015, Jul-02, Volume: 126, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol

2015
Combo Therapy Effective for Relapsed CLL.
    Cancer discovery, 2015, Volume: 5, Issue:7

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials

2015
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
    Oncotarget, 2015, Sep-08, Volume: 6, Issue:26

    Topics: Adenine; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclohexylamines; Dru

2015
Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Oct-15, Volume: 21, Issue:20

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Adhesion; Female; Fibronectins; Humans; Int

2015
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
    Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:6

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Pr

2015
IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:5

    Topics: Adenine; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cytogenetic Analysis; DNA Mutational Analys

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    JAMA oncology, 2015, Volume: 1, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli

2015
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
    Cancer, 2015, Oct-15, Volume: 121, Issue:20

    Topics: Abnormal Karyotype; Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Delet

2015
Extramedullary haematopoiesis in chronic lymphocytic leukaemia.
    British journal of haematology, 2015, Volume: 171, Issue:4

    Topics: Adenine; Aged; B-Lymphocytes; Bone Marrow; Clone Cells; Exons; Genes, p53; Hematopoiesis, Extramedul

2015
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Aug-15, Volume: 21, Issue:16

    Topics: Adenine; Aged; Clinical Trials as Topic; Drug Approval; Female; Humans; Leukemia, Lymphocytic, Chron

2015
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-01, Volume: 22, Issue:1

    Topics: Adenine; Antigens, CD20; Antineoplastic Agents; Biopsy; Bone Marrow; CD55 Antigens; Clinical Trials,

2016
Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer.
    JAMA oncology, 2016, Volume: 2, Issue:1

    Topics: Adenine; Antineoplastic Agents; Biomarkers, Tumor; CARD Signaling Adaptor Proteins; DNA Mutational A

2016
Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.
    Blood cancer journal, 2015, Oct-02, Volume: 5

    Topics: Adenine; Antineoplastic Agents; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, L

2015
Optic Neuropathy Due to Chronic Lymphocytic Leukemia Proven With Optic Nerve Sheath Biopsy.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2016, Volume: 36, Issue:1

    Topics: Adenine; Antimetabolites, Antineoplastic; Biopsy; Drug Therapy, Combination; Humans; Leukemia, Lymph

2016
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:6

    Topics: Adenine; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Caspases; Dose-Response Relationship,

2016
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
    Leukemia, 2016, Volume: 30, Issue:2

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Aut

2016
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
    Leukemia, 2016, Volume: 30, Issue:2

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Aut

2016
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
    Leukemia, 2016, Volume: 30, Issue:2

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Aut

2016
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
    Leukemia, 2016, Volume: 30, Issue:2

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Aut

2016
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
    Blood, 2016, Jan-28, Volume: 127, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Anti-Idiotypic; B-Lymphocytes; Cell Line,

2016
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
    Oncotarget, 2015, Dec-08, Volume: 6, Issue:39

    Topics: Adenine; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Surviva

2015
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Blood, 2016, Feb-04, Volume: 127, Issue:5

    Topics: Adenine; Animals; Ataxia Telangiectasia Mutated Proteins; DNA Damage; Drug Resistance, Neoplasm; Hum

2016
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
    Cancer, 2016, Feb-15, Volume: 122, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin

2016
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
    The Journal of biological chemistry, 2016, Feb-05, Volume: 291, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Calcium Signaling; Humans; Interferon-gamma;

2016
Targeted Therapies Improve Outlook for Chronic Lymphocytic Leukemia.
    Journal of the National Cancer Institute, 2015, Volume: 107, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Isoquinolines; Leukemia

2015
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
    Oncotarget, 2016, Feb-02, Volume: 7, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Anti

2016
Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
    Blood, 2016, Feb-25, Volume: 127, Issue:8

    Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung D

2016
Occult HBV reactivation induced by ibrutinib treatment: a case report.
    Acta gastro-enterologica Belgica, 2015, Volume: 78, Issue:4

    Topics: Adenine; Aged, 80 and over; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piper

2015
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Oncotarget, 2016, Jan-26, Volume: 7, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Blotting, Western; Case-

2016
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
    Bone marrow transplantation, 2016, Volume: 51, Issue:6

    Topics: Adenine; Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neu

2016
[Ibrutinib prescription in B-cell lymphoid neoplasms].
    Bulletin du cancer, 2016, Volume: 103, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Clinical Trials as Topic; Drug Resistan

2016
Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
    British journal of haematology, 2017, Volume: 176, Issue:5

    Topics: Adenine; Aged; Central Nervous System Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male

2017
Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:10

    Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Osteolysis, Essential; Piperid

2016
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
    Haematologica, 2016, Volume: 101, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Bri

2016
Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
    British journal of haematology, 2017, Volume: 176, Issue:6

    Topics: Adenine; Adult; Chimerism; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, C

2017
Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
    Blood, 2016, 05-12, Volume: 127, Issue:19

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic,

2016
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:11

    Topics: Adenine; Anemia, Hemolytic, Autoimmune; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Le

2016
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.
    Oncotarget, 2016, May-03, Volume: 7, Issue:18

    Topics: Adenine; Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combi

2016
Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal.
    The American Journal of dermatopathology, 2016, Volume: 38, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Bio

2016
The use of ibrutinib in chronic lymphocytic leukemia.
    Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:3

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2016
Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia.
    Molecular medicine reports, 2016, Volume: 13, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Adhesion Molecules; Cell L

2016
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
    Blood, 2016, 06-23, Volume: 127, Issue:25

    Topics: Adenine; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor

2016
CLL: ibrutinib and transplantation ride together.
    Bone marrow transplantation, 2016, Volume: 51, Issue:6

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines

2016
Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
    British journal of haematology, 2017, Volume: 178, Issue:1

    Topics: Adenine; Aged; Antineoplastic Agents; Calcification, Physiologic; Combined Modality Therapy; Female;

2017
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17;

2016
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Leukemia, 2016, Volume: 30, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic,

2016
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Haematologica, 2016, Volume: 101, Issue:12

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Compassionate Use T

2016
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
    Nature communications, 2016, 05-20, Volume: 7

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Apoptosis; Cell Transdiffere

2016
Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.
    Leukemia, 2016, Volume: 30, Issue:11

    Topics: Adenine; Aged; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Age

2016
The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
    Leukemia research, 2016, Volume: 47

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Apoptosis; B-Lymphocytes; Cell Cy

2016
p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
    Blood cancer journal, 2016, 06-10, Volume: 6

    Topics: Adenine; Angiopoietin-1; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cluster Analysis;

2016
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
    Blood, 2016, 08-18, Volume: 128, Issue:7

    Topics: Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cellular Microenvironment; Dose-Res

2016
Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:1

    Topics: Adenine; Cell Transformation, Neoplastic; Central Nervous System; Humans; Immune Reconstitution Infl

2017
Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 07-01, Volume: 22, Issue:13

    Topics: Adenine; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazole

2016
Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 07-01, Volume: 22, Issue:13

    Topics: Adenine; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazole

2016
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
    Leukemia, 2017, Volume: 31, Issue:2

    Topics: Adenine; Adult; Aged; Antigens, CD19; B-Lymphocytes; Biomarkers; Cell Proliferation; Cluster Analysi

2017
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
    Cancer research and treatment, 2017, Volume: 49, Issue:2

    Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Disease

2017
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
    Blood, 2016, 09-22, Volume: 128, Issue:12

    Topics: Adenine; Antigens, CD20; Chemokine CXCL12; Gene Expression Regulation, Neoplastic; Humans; Leukemia,

2016
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
    The Journal of biological chemistry, 2016, Oct-14, Volume: 291, Issue:42

    Topics: Adenine; Amino Acid Substitution; Animals; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplas

2016
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
    ACS chemical biology, 2016, 10-21, Volume: 11, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cysteine; Humans; Kinetics; Leu

2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
    Blood, 2016, 11-03, Volume: 128, Issue:18

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression;

2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
    Blood, 2016, 11-03, Volume: 128, Issue:18

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression;

2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
    Blood, 2016, 11-03, Volume: 128, Issue:18

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression;

2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
    Blood, 2016, 11-03, Volume: 128, Issue:18

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression;

2016
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
    Oncotarget, 2016, Oct-04, Volume: 7, Issue:40

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Huma

2016
Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders.
    British journal of haematology, 2016, Volume: 175, Issue:3

    Topics: Adenine; Anticoagulants; Atrial Fibrillation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi

2016
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
    British journal of haematology, 2016, Volume: 175, Issue:3

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Atrial Fibrillation; Disease Management; Fe

2016
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
    Oncotarget, 2016, Oct-18, Volume: 7, Issue:42

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Transformation, Neoplastic

2016
Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report.
    Anticancer research, 2016, Volume: 36, Issue:9

    Topics: Adenine; Agammaglobulinemia; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Humans;

2016
Ibrutinib holds promise for patients with 17p deletion CLL.
    The Lancet. Oncology, 2016, Volume: 17, Issue:10

    Topics: Adenine; Chromosome Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles

2016
Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    British journal of haematology, 2018, Volume: 180, Issue:2

    Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoe

2018
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
    Oncotarget, 2016, Oct-25, Volume: 7, Issue:43

    Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell

2016
Ibrutinib-induced pyoderma gangrenosum.
    Polskie Archiwum Medycyny Wewnetrznej, 2016, Sep-28, Volume: 126, Issue:9

    Topics: Adenine; Cyclosporine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Ma

2016
Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:5

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Chromosome Aberrations; Dr

2017
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:2

    Topics: Adenine; Aged; Antineoplastic Agents; Biomarkers; Biopsy; Blood Cell Count; Female; Humans; Leukemia

2017
Targeting BTK through microRNA in chronic lymphocytic leukemia.
    Blood, 2016, 12-29, Volume: 128, Issue:26

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzofurans; Cell Survival; Clone Cells; Drug

2016
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:6

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Cytochrome P-450 CYP3A; Drug In

2017
EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:7

    Topics: Adenine; Antineoplastic Agents; Bone Marrow; Burkitt Lymphoma; Diagnosis, Differential; Disease Prog

2017
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    British journal of haematology, 2017, Volume: 176, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Ner

2017
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
    Leukemia & lymphoma, 2017, Volume: 58, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Comorbidity; Female; Humans; Incidence

2017
Ibrutinib in the real world patient: many lights and some shades.
    Haematologica, 2016, Volume: 101, Issue:12

    Topics: Adenine; Age Factors; Clinical Studies as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pip

2016
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
    Leukemia, 2017, Volume: 31, Issue:6

    Topics: Adenine; Animals; Antibodies, Monoclonal; Apoptosis; Cell Proliferation; Humans; Leukemia, Lymphocyt

2017
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
    Leukemia, 2017, Volume: 31, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Monitoring; Female; Hemorrhage; Humans; Leukemia, Lymp

2017
Ibrutinib-Induced Lymphocytosis: Cytological Features.
    Acta haematologica, 2017, Volume: 137, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Chromo

2017
Severe hepatitis B virus reactivation related to ibrutinib monotherapy.
    Annals of hematology, 2017, Volume: 96, Issue:4

    Topics: Adenine; Aged; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2017
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
    Journal of immunology (Baltimore, Md. : 1950), 2017, 02-15, Volume: 198, Issue:4

    Topics: Adenine; Aged; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Hig

2017
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
    Oncotarget, 2017, Feb-21, Volume: 8, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Cell Proliferation;

2017
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Leukemia, 2017, Volume: 31, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apopto

2017
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
    The Lancet. Oncology, 2017, Volume: 18, Issue:3

    Topics: Adenine; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B

2017
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
    JCI insight, 2017, 01-26, Volume: 2, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Death; Cell Proliferation; Deuterium Oxide;

2017
Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
    Hematological oncology, 2018, Volume: 36, Issue:1

    Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines

2018
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
    Blood cancer journal, 2017, 02-03, Volume: 7, Issue:2

    Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A

2017
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Cancer, 2017, Jun-15, Volume: 123, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Deprescriptions; Disease Progression; Drug-Related Side Eff

2017
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
    Annals of hematology, 2017, Volume: 96, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth

2017
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
    Nature, 2017, 02-23, Volume: 542, Issue:7642

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Li

2017
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
    Oncotarget, 2017, Mar-14, Volume: 8, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; DNA; Drug Resistance, Neoplasm;

2017
Ventricular arrhythmias and sudden death in patients taking ibrutinib.
    Blood, 2017, 05-04, Volume: 129, Issue:18

    Topics: Adenine; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Humans; Leukemia, Lymphocytic, Chronic, B-Cel

2017
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
    Medicina clinica, 2017, Apr-21, Volume: 148, Issue:8

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl

2017
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
    Leukemia & lymphoma, 2017, Volume: 58, Issue:10

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hemat

2017
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:10

    Topics: Adenine; Antineoplastic Agents; CD52 Antigen; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi

2017
Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
    The Australasian journal of dermatology, 2017, Volume: 58, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic,

2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
    American journal of hematology, 2017, Volume: 92, Issue:6

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Dose-Response Rela

2017
The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.
    Cancer medicine, 2017, Volume: 6, Issue:4

    Topics: Adenine; Calcium-Binding Proteins; Cell Line, Tumor; Down-Regulation; EGF Family of Proteins; Endoth

2017
Ibrutinib-resistant CLL: unwanted and unwonted!
    Blood, 2017, 03-16, Volume: 129, Issue:11

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines

2017
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.
    Nature communications, 2017, 03-17, Volume: 8

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Bac

2017
Caspase-independent type III PCD: a new means to modulate cell death in chronic lymphocytic leukemia.
    Leukemia, 2009, Volume: 23, Issue:5

    Topics: Adenine; Caspases; CD47 Antigen; Cell Death; Dynamins; GTP Phosphohydrolases; Humans; Leukemia, Lymp

2009
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho

2011
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia

2011
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
    Blood, 2012, Mar-15, Volume: 119, Issue:11

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Blotting, Western; Cell Adhesion; Cell Move

2012
G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression.
    Oncogene, 2005, Mar-17, Volume: 24, Issue:12

    Topics: Adenine; Algorithms; Base Sequence; bcl-2-Associated X Protein; Cell Line, Tumor; Gene Expression Re

2005
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006, Volume: 35, Issue:4

    Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplas

2006